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1 GENERAL INTRODUCTION 
Proteins that bind DNA to form eukaryotic chromosome are divided in two general 
classes : histones and non-histone proteins. The structural complex created between 
these two classes and nuclear DNA is known as chromatin, that is a dynamic entity 
that change its shape in each phase of cellular cycle.  
Half of chromatin weight is constituted by proteins that in mayor part are histones. 
There are five main classes of histones: H1, H2a, H2b, H3, H4 containing residues 
positively charged (Arg, Lys) that allow to interact with DNA phosphoric groups 
negatively charged.
1
 The aminoacid sequences of histones H2a, 2b, 3, and 4 are 
highly conserved and this evolutionary stability let understand that these proteins 
have a well-adapted structure that is become intolerant to each variation. The 
histones are subjected to post-translational modifications and most of them are 
reversible and tend to decrease the histones positive charge that result in an alteration 
to their ability to bind DNA. The histones are responsible of the first level in the 
chromosome organization, the nucleosome. The structural organization has been 
determined by Roger Kornberg in 1974, by suggesting that nucleosome, were formed 
by histone octamer (H2a)2(H2b)2(H3)2(H4)2 associated with DNA in which H1 
played a not well defined role
1
 (Figure 1).  
 
Figure 1. Crystal structure of nucleosome PDB: 3AFA.
2
  UCSF Chimera 1.7 
 
The histone covalent modifications such as acetylation, methylation, phosphorylation 
and ubiquitination are responsible for the compartmentalization of the genome as 
transcriptionally silent heterochromatin or active euchromatin. These modifications 
allow the regulation of nuclear processes such as replication, transcription and 
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chromosome condensation.
3
 Alterations and dysfunctions of the normal operations of 
these processes can be at the basis of different pathologies.
4,5
 
The most studied epigenetic marks are histone acetylation
6
 and methylation that are 
coupled to various cellular functions such as DNA recognitions by proteins, DNA-
protein interactions, protein stability etc.
7,8
 The DNA transcriptional silencing is 
associated to histone hypoacetylation mediated by HDAC, while genomic 
transcriptional activation involves histone acetylation HAT catalysed.  
In eukaryotes the deacetylases are grouped in four classes I-IV according to their 
homology to yeast prototypes. The sirtuin family constitutes class III (SIRT1-7) and 
have no similarity to other HDACs; Class I members are Rpd3-like, include 
HDAC1-3 and 8. HDAC4, 5, 7, 9 being to class IIa while HDAC6 and 10 to IIb; 
finally the class IV is made by HDAC11.
9
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2 SIRTUINS 
2.1 Discovery and identification 
In 1979 the first sirtuin Sir2 from S. cerevisae originally known as MARI (mating-
type regulator 1) has been discovered by Klar and co-workers.
10
 Ten years later 
Gottlieb and Esposito
11
 proved that SIR2’s (silent information regulator) function is 
not restricted to controlling mating type expression but also may function in 
excluding the rDNA region from the general recombination system.
11
 In 1991 
Gottschling and co-workers
12
 showed that SIR genes are involved in a general 
mechanism for silencing chromosomal domains in S. cerevisae by providing a 
complete silencing at HML (Hidden MAT Left) and HMR (Hidden MAT Right) 
preventing switching from the silent to the active transcriptional state. After two 
years in 1993 Braunstein
13
 demonstrate that the silencing of silent mating-type 
cassettes and telomeres is strictly associated with acetylation of the epsilon-amino 
groups of lysine in the amino-terminal domains of three of the four core histones. 
The SIR2 overexpression induced a substantial histone deacetylation, an additional 
characteristic that distinguished SIR2 from other SIR genes. In 1995 Brachman
14
 and 
Derbyshire
15
 discovered four Saccharomyces cerevisae homologs of the SIR2 
silencing gene (HSTs), as well as conservation of this gene family from bacteria to 
mammals. They found that HST1 was closely related to SIR2, showing 71% 
sequence identity over 84% of its length. Polymerase chain reaction with degenerate 
primers on S. cerevisae DNA, identified three additional SIR2-related genes 
designated HST2, HST3 and HST4. In addition, HST3 and HST4 together were able 
to influence cell cycle progression and genomic stability, establishing new 
connections between silencing and these fundamental cellular processes. In 1999 and 
2000 Frye
16,17
 discovered seven human sirtuins (SIRT1-7) of which SIRT1 showed 
the closest homology to the S. cerevisae Sir2p. Furthermore Frye
17
 carried out a 
molecular phylogenetic analysis of 60 sirtuin conserved core domain sequences from 
a diverse array of organisms (including Achaeans, bacteria, yeasts, plants, 
protozoans, and metazoans) that allowed their classification into four main branches 
classes I-IV. Prokaryotic sirtuins are included in classes II and III. Gram positive 
bacteria and Thermotoga maritime sirtuins being to class V. Saccharomyces 
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cerevisae has class I sirtuins. Caenorhabditis elegans and Drosophila melanogaster 
have sirtuin genes from classes I, II, and IV. Finally the seven human sirtuin genes 
include all four classes: SIRT1, SIRT2, and SIRT3 are class I, SIRT4 is class II, 
SIRT5 is class III, and SIRT6 and SIRT7 are class IV. Close to the end of 2000 
Landry
18
 and Smith
19
 described the importance of NAD
+
 in the deacetylation 
reaction catalyzed by the SIR2 family of enzymes.
20
 They showed that the products 
of the reaction detected by HPLC analysis were ADP-ribose, nicotinamide, and a 
deacetylated peptide substrate, indicating that deacetylation involves the hydrolysis 
of one NAD
+
 to ADP-ribose and nicotinamide for each acetyl group removed. 
Subsequent crystallographic (will be discussed in details in a separate paragraph) 
studies have allowed to precisely define the catalytic core domain. After 34 years 
more than three thousand publications that touch the sirtuins from pharmacology, 
biology, biochemistry to medicinal chemistry have been written, but still a lot have to 
be discovered. 
 
2.2 Mechanism of Sirtuin deacetylation 
Sirtuins as introduced previously being to the III class of histone deacetylases and are 
NAD+ dependent enzymes. From yeast to humans they contain an highly conserved 
catalytic core domain formed by 275 amino acid (Figure 2) and N, C-terminal 
extension, that are variable in length and sequence that can affect the binding with 
interacting partners, mediate interactions with other sirtuin forms, and direct cellular 
localization. In mammals there are seven sirtuin isoforms (SIRT1-7) that are able to 
catalyze substrate specific deacetylation.
18,21
 SIRT4
22
 and SIRT6 possess mainly 
NAD
+
-dependent mono-ADP-ribosyltransferase activity. Recently has been reported 
that SIRT5 has potent demalonylase/ desuccinylase activity
23
 and deacylation 
reaction can be catalyzed by SIRT6.
24,25
  The poor deacetylases activity showed by 
SIRT6 in vitro seems depends on specific conditions, in which SIRT6 activity is 
nucleosome dependent and its binding to the nucleosome might convert it into an 
active structure.
24
 The accepted deacetylation mechanism (Figure 3) begins with 
Michaelis complex formation (when both NAD
+
 and substrate are bound) and start 
with a nucleophilic attack of  1′ nicotinamide ribose moiety by the carbonyl oxygen 
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of the lysine substrate through SN2 mechanism that led the nicotinamide cleavage 
and the 1′-O-alkylamidate intermediate formation. 
 
 
 
  SIRT1 
  Hst2  Sir2-Af1  Sir2-Af2 
Sir2Tm 
SIRT2 SIRT3 
A B C
  A 
D
  A 
E
  A 
F
  A 
G
  A 
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Figure 2. Crystal structure of sirtuins. The small domain is colored in green, the 
Rossman-fold domain in cornflower blue, the connection loops in yellow, the 
cofactor binding loop in black, the N-terminal in red and the C-terminal in magenta. 
(A) S.cerevisae Hst2 (PDB: 1Q14). (B) A. fulgidus Sir2-Af1 (PDB: 1ICI). (C) A. 
fulgidus Sir2-Af2 (PDB: 1MA3). (D) T.maritima Sir2Tm (PDB: 2H4J). (E) H. 
sapiens SIRT1 (PDB: 4IF6). (F) H. sapiens SIRT2 (PDB: 3ZGV). (G) H. sapiens 
SIRT3 (PDB: 3GLR). (H) H. sapiens SIRT5 (PDB: 4F4U). (I) H. sapiens SIRT6 
(PDB: 3ZG6). UCSF Chimera 1.7. 
 
Once the nicotinamide has been released it can rebinds in the C-pocket and react 
with the intermediate to reform NAD
+
.  In this step Phe33 (Sir2Tm numbering) 
appears to play a role as gatekeeper in the nicotinamide exchange reaction in which it 
helps to shield the O-alkylamidate intermediate from free nicotinamide. After the 
formation of 1′-O-alkylamidate intermediate, the 2′-hydroxyl group of the ribose is 
activated by a conserved His116 (Sir2Tm numbering) to afford 1′, 2′-cyclic 
intermediate (Figure 3). Then a protonated histidine can act as acid, protonates the 
amino-acetal and led the deacetylated substrate release. Finally an activated water 
molecule attacks the cyclic intermediate to furnish 2′-O-acetyl-ADP ribose (might be 
in equilibrium with its corresponding 3′ isomer).26,27 
 
SIRT5 SIRT6 
H
  A 
I
  A 
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Figure 3. Mechanism of sirtuin deacetylation. 
 
2.3 Sirtuins catalytic core domain 
The sirtuins catalytic region (Figure 2) consists of a Rossman-fold (light blue) a zinc-
binding domain (green) and connecting loops (yellow). The loops between the two 
domains form a cleft where NAD
+
 and Ac-Lys substrate can bind the enzyme. For 
instance the human SIRT1 catalytic core domain is composed of a central six-
stranded β-parallel sheet (β1- β3 and β7- β9) and height α helices (αA, α , α , αH 
and αJ- αM), the Zn2+ binding domain (also called small domain) is composed of 
three  β strands (β4- β6) and five α helices (α -αF and αI) in which the Zn2+ ion is 
tetrahedrally coordinated by four cysteine residues Cys371, Cys374, Cys395 and 
Cys398.
28
 The Zn ion is located far from the active site, it does not participate 
directly to the catalytic mechanism  like for class I/II but its presence is essential for 
deacetylase activity in fact seems to be required in order to holding together the β 
strand in the small domain. The small domains of the eukaryotic enzymes show 
variability among three-dimensional topology. Differently to SIRT2 and SIRT3, 
SIRT5 has an insertion loop that blocks a groove between the zinc binding motif and 
the helical bundle region. One explanation is probably that the small domains play a 
role in the needs to discriminate the substrates or in the protein-protein interactions.  
2.4 NAD
+
 binding site 
The connection loops together with large and small domain form a cleft in which 
substrate and the cofactor (NAD
+
) can bind. This region is highly conserved and has 
the highest homology sequence among the protein sequence; indeed mutations of its 
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residues can drastically reduce the enzymatic activity. The NAD
+
 binds in a cleft 
adjacent to the acetyl lysine side chain that is formed by three pockets: A, B, C 
(Figure 4).  The adenine-ribose binding site (pocket A) is an exposed surface area in 
which adenine has, van der Waals interaction with Leu215, Val232, Gly23 (Sirt2Tm 
numbering PDB code: 2H4F), H bonds with backbone amides Leu215, Val232 and 
side chains Asp231 and Thr26. The ribose moiety has H bond with Gly216 and van 
der Waals contact with Ser189.
26
 The phosphate groups binds between A and B 
pockets and show several H bonds with Ala22, Phe33, Arg34, Ser189, Ser190 and 
with a conserved water molecule.
26
 Conserved residues His116 and Phe33 located in 
the B pocket makes H bonds and van der Waals interactions with the nicotinamide 
ribose ring. Finally the nicotinamide moiety is positioned in hydrophobic cavity the 
so called C pocked and forms H bonds interactions with Ile100, Asp101 and a 
conserved water molecule.
26
 The NAD
+
 binding conformation object of 
crystallographic studies has been found be influenced by the occupancy of the lysine 
binding tunnel. The substrate binding, promotes the burial of the nicotinamide ring in 
the C pocket that seems destabilize the glycosidic bond between nicotinamide and 
ribose with a potential disruption of the electronic resonance and promotes NAD
+
 to 
adopt a strained conformation required for deacetylation activity. One of the 
connection loops is called cofactor binding loop (in black) that form part of NAD
+
 
binding site, may play also a role during the catalytic reaction steps. It shows an 
interesting dynamism and its conformation depends on what is bound in the 
substrate/cofactor binding site. The cofactor binding loop is disordered when NAD
+
 
is not bound and becomes ordered when both substrate and cofactor are bound. 
Recently Steegborn and co-workers
29
 have reported a well defined SIRT2 crystal 
structures in which the cofactor binding loop is perfectly defined in both the apo- and 
the ligand-bound state, confirming that the binding of NAD
+
 and the substrate induce 
its structural rearrangements.  
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Figure 4. NAD
+
 binding site overview (PDB: 2H4F). The peptidic substrate is 
colored in green and NAD
+
 is colored in yellow. UCSF Chimera 1.7. 
 
2.5 Substrate binding site 
The peptide substrate binds to the cleft between the small and the large domains with 
the acetyl-lysine placed into a hydrophobic tunnel located within the cleft. Main 
chain atoms of the peptide substrate for instance AceCS2 peptide in SIRT3 (Figure 
5) make several hydrogen bonds with main chain atoms of one connection loop 
(Val292, Gly295, Glu296) and another loop from the large domain (Glu323, Glu325) 
of the protein (SIRT3 numbering PDB code : 3GLR).
30
 
 
 
Figure 5. AceCS2-Kac peptide in complex with SIRT3 (PDB: 3GLR). Residues 
belonging to small domain are colored in green, connection loops in yellow , large 
A B 
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domain in cornflower blue and acetylated substrate in default color. (A) Substrate 
binding site around the acetylated lysine. (B) Substrate binding site represented in 
ribbon, and main H-bonds are represented by black lines. UCSF Chimera 1.7. 
 
The lysine acetyl group is sandwiched between His248 and Phe180 (SIRT3 
numbering). His248 has been found be critical for the deacetylation activity of 
sirtuins and is conserved in all the SIRT isoforms SIRT1-7. A comparison of sirtuins 
crystal structures has suggested that both peptide and NAD
+
 binding induce a 
significant shift in the position of the cofactor loop but also of the small domain, 
indeed not significant shift can be seen for the large domain (Figure 6). A direct 
overlay between SIRT3 crystal structure in apo-form and bound with a trapped 
intermediate, confirm that the protein bioactive conformation is characterized by a 
close conformation, in which the two domains result more closer to each other and 
this led the residue organization in the binding site for the deacetylation reaction 
(Figure 6). 
 
 
Figure 6. A superimposition between SIRT3 apoform (cornflower blue PDB: 3GLS) 
and SIRT3 bound with trapped AceCS2-KSAc-ADPR (green PDB: 3GLT) are 
represented in ribbon (left). Superimposition that evidence the shift of cofactor 
binding loop from SIRT3 apoform (yellow) to SIRT3 bound with trapped AceCS2-
KSAc-ADPR (red) are represented on the right window. UCSF Chimera 1.7. 
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3 THE SEVEN HUMAN ISOFORMS SIRT1-7 AND THEIR BIOLOGICAL 
RELEVANCE IN DISEASE 
The seven isoforms SIRT1-7 are differently located within the cellular compartments 
(Table 1) and it depends upon cell type, stress conditions and interaction with other 
proteins.
31
 SIRT1, SIRT6 and SIRT7 being nuclear.
31
 SIRT1 can be also found in 
cytoplasm in which SIRT2
32
 is predominantly located. SIRT3,
33
 4,
22
 5
31
 are localized 
to the mitochondria but SIRT3 localization is still debated because of its potential 
translocation to the nucleus under cellular stress conditions. As reviewed by Chen
34
 
sirtuins show histone and several non-histone substrates and it can explain the wide 
range of biological processes in which this enzymes are involved (Table 2-5).  
 
Table 1. Cellular localization and activity of Sirtuins 
Sirtuin 
Molecular 
mass 
Cellular 
localization 
Activity 
SIRT1 82 kDa 
Nucleus and 
Cytoplasm 
Deacetylase 
SIRT2 43 kDa 
Cytoplasm and 
Nucleus 
Deacetylase 
SIRT3 
45 kDa  
(nuclear encoded with N terminal 
mitochondrial targeting sequence) 
28 kDa 
(after mitochondrial cleavage) 
Mitochondria and 
Nucleus ? 
Deacerylase 
SIRT4 35 kDa Mitochondria 
ADP-ribosyl-
transferase 
Weak Deacetylase 
SIRT5 34 kDa Mitochondria 
Deacetylase  
Demalonylase 
Desuccinylase 
SIRT6 39 kDa Nucleus 
Deacetylase  
Deacylase 
ADP-ribosyl-
transferase 
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SIRT7 
45 kDa 
47.5 kDa  
(Cytoplasmic SIRT7) 
Nucleolus and 
Cytoplasm 
Deacetylase 
 
 
Table 2. SIRT1 substrates an overview 
SIRT1 substrates SIRT1 functions 
AceCS1 (K661)  (acetyl-CoA sinthetase1) Promotes AceCS1 activity and metabolism 
Akt, PDK1 (protein kinase B, 
phosphoinositide-dependent protein kinase 1) 
Enanches their binding with PIP3 and 
membrane localization during tumorigenesis 
and cardiac hypertrophy 
Androgen receptor 
Represses dihydrotestosterone-induced 
androgen receptor signaling 
APE1 (apuric/apyrimidinic andonuclease-1) Promotes base excision repair activity 
ATG (autophagy genes Atg5, 7 and Atg8) Promotes autophagy 
β-catenin 
Suppress its ability to activate transcription 
and to drive cell proliferation 
BMAL1 (heterodimeric basic helix-loop-helix 
transcription factor) 
Modulates CLOCK-mediated chromatin 
remodeling and circadian control 
CIITA (class two transactivator of 
histocompatibility complex II (MHC II)) 
Augments MHC II transcription by protecting 
CIITAfrom proteasomal degradation and 
promoting nuclear accumulation 
c-MYC (transcription factor that activates 
expression of many genes through binding on 
consensus sequences) 
Stabilizes or destabilizes C-MYC oncoprotein 
Cortactin (monomeric protein located in the 
cytoplasm when activated  promote 
polymerization and rearrangement of the actin 
cytoskeleton) 
Promotes cell migration 
 
CRTC1 (CREB-regulated transcription 
coactivator 1) 
 
Activates TORC1 by promoting its 
dephosphorylation and its interaction with 
CREB for neuroprotection 
CRTC2 
Attenuates CRTC2 activity and glucose 
output during fasting 
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DNMT1 (DNA methyltransferase 1) Deacetylation of lysines on DNMT1 
EVI1 (ecotropic viral integration site 1) Triggers EVI1 degradation 
eNOS (endothelial nitric oxide synthetase) 
Stimulates eNOS activity, increases 
endothelial nitric oxide, promotes 
endothelium-dependent vascular relaxation 
ERα (estrogen receptor alpha) ? 
Represses its DNA binding and transcriptional 
activity 
FOXO1 (forkhead box protein O1) 
Potentiates FOXO1-mediated transcription 
through its deacetylase activity 
FOXO3a (forkhead box protein O3) 
Increases FOXO3’s ability to induce cell 
cycle arrest and resistance to oxidative stress 
but inhibits FOXO3’s ability to induce cell 
death 
FOXO4 (forkhead box protein O4) Cell survival upon oxidative stress 
FOXp3 (forkhead box P3) Promotes its degradation 
FXR (nuclear bile acid receptor) 
Decreases its stability but enhances 
transactivation activity in lipid and glucose 
metabolism regulation 
HIF1α (hypoxia inducible factor 1-alpha) Inactivates HIF-1 alpha under hypoxia 
HIF2α (hypoxia inducible factor 2-alpha) Promotes HIF-2 signaling during hypoxia 
Histone H1 (K26), H3 (K9, K56), H4 (K16) 
Transcription regulation and chromatin 
function 
HSF1 (heat shock protein 1) 
Prolongs HSF1 binding to the heat shock 
promoter Hsp70 
Ku70 (protein that together with Ku80 make up 
the Ku heterodimer, which binds to DNA) 
Promotes DNA repair activity 
 
LXR (K432)  (Liver X receptor) 
 
Positively regulates its function for 
cholesterol and lipid homeostasis 
MeCP2 (Methyl-CpG binding protein 2) Promotes MeCP2-mediated BDNF expression 
MMP2 (matrix metalloproteinase 2) Enhances MMP2 protein stability 
MyoD (protein that regulates muscle 
differentiation. MyoD belongs to myogenic 
regulatory factors (MRFs)) 
Inhibits myogenesis 
NBS1 (nijimegen breakage syndrome protein Maintains NBS1 in a hypoacetylated state, 
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1) which is required for ionizing radiation-
induced NBS1 Ser343 phosphorylation 
NF-kB p65 (nuclear factor kappa-light chain 
enhancer of activated B cells)  
Reduces NF-κ  transcriptional activity, 
augments apoptosis in response to TNFα 
NHLH2 (nescient helix loop helix 2) Activates MAO-A to mediate anxiety 
N-MYC (proto-oncogene protein) Promotes protein stability 
NICD (notch 1 intracellular domain) 
Acts as a negative modulator of Notch 
signaling in endothelial cells 
NoRC (nitric oxide reductase) 
Leads to enhanced promoter-associated RNA 
binding and an increase in heterochromatic 
histone marks 
p300 (K1020/K2014) (play an essential role in 
regulating cell growth and division) 
Represses its transactivation activity 
p53 (K382) (tumor suppressor) Promotes cell survival under stress 
p73 
Suppression of transcriptional activity and 
apoptosis p73 mediated 
PARP1 (poly(adenosine diphosphate ribose) 
polymerase 1) 
Promotes cell survival under stress 
PER2  
Promotes PER2 degradation to regulate 
circadian clock gene expression 
PGC1α (peroxisome proliferator-activated 
receptor gamma coactivator 1-alpha) 
Positively and negatively controls gene 
expression for glucose homeostasis 
PIP5 Kγ (phosphatidylinositol 4-phosphate 5-
kinase) 
Regulates thyroid-stimulating hormone 
release by enhancing PIP5 Kgamma activity 
PTEN (phosphatase and tensin homolog) 
Modulates PTEN interaction with PDZ 
domain-containing proteins 
RARβ (retinoic acid receptor beta) 
Activates alpha-secretase gene ADAM10, 
suppresses beta-amyloid production 
 
Rb (retinoblastoma tumor suppressor protein) 
 
Inactivates retinoblastoma tumor suppressor 
protein 
Smad7 (mothers against decapentaplegic 
homolog 7) 
Inhibits transforming growth factor beta-
induced apoptosis in glomerular mesangial 
cells 
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SREBP-1C (sterol regulatory element-binding 
protein) 
Inhibits SREBP-1C activity in regulation of 
hepatic lipid metabolism 
STAT3 (signal transducer and activator of 
transcription 3) 
Suppresses the inhibitory effect of STAT3 on 
gluconeogenesis 
Survivin (inhibitor of apoptosis) Suppresses survivin thus inhibits cell survival 
SUV39H1 (Histone-lysine N-
methyltransferase) 
Increases SUV39H1 activity during 
heterochromatin formation 
Tat (trans-activating proteins) Facilitates the recycling of Tat 
Tip60, hMOF (histone acetyl transferase) 
Inhibits their acetyltransferase activity and 
promotes their degradation in DNA damage 
response 
WRN (Werner syndrome) 
Increases its helicase and exonuclease 
activities, promotes its translocation from 
nucleoplasm to nucleoli after DNA damage 
XBPIs (X-box binding protein) Inhibits its transcriptional activity 
Xpa, Xpc (xeroderma pigmentosum group A, 
B) 
Promotes nucleotide excision repair activity 
 
 
Table 3. SIRT2 substrates an overview 
SIRT2 substrates SIRT2 functions 
α-tubulin Abrogates resistance to axonal degeneration 
CDH1, CDC20 (cadherin protein , cell-
division cycle protein 20) 
Promotes their degradation and cell cycle exit 
FOXO1 Inhibits adipocyte differentiation 
FOXO3a Mediated its degradation 
Histone H3K56 Inhibits its assembly into chromatin in 
response to DNA damage 
Histone H4K16 Promotes cell cycle G2/M transition 
Keratin 8 (K207) (cytoskeletal keratin protein) Increases its solubility 
NF-kB p65 (K310) Suppresses NF-kB dependent gene 
expression 
p53 (K382) Increase its instability 
p300 Promotes its transcription 
PAR-3 (protease activated receptor 3) Regulates myelin formation 
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PEPCK1 (phosphoenolpyruvate carboxykinase 
1) 
Stabilizes PEPCK1 for gluconeogenesis 
PR-Set7 (histone-lysine N-methyltransferase) Increases its chromatin localization 
RIP1 (receptor interaction protein 1) Required for programmed necrosis 
 
 
Table 4. SIRT3-5 substrates 
Sirtuins Substrate Sirtuin function 
SIRT3 AceCS2 (K642) Promotes AceCS2 activity 
 Cyclophilin D Induces dissociation of hexokinase II from 
the mitochondria and suppress age related 
cardiac hypertrophy 
 FOXO3a Promotes its nuclear localization and 
mitochondrial biogenesis 
 GDH (glutamate dehydrogenase) Increases its activity 
 Histone H4K16 Gene transcription 
 IDH2 (K413) (isocitrate 
dehydrogenase 2) 
Activates its activity and protects the cells 
from oxidative stress, prevents age-related 
hearing loss under caloric restriction 
 Ku70 Protects cells from stress mediated cell death 
 LCAD (K318/K322) (long chain 
Acyl CoA dehydrogenase) 
Increases its enzymatic activity 
 LKB1 (liver kinase B1) Activates LKB1 and increase the activity of 
the LKB1-AMPK pathway 
 HMGCS2 (mitochondrial 3-
hydroxy-3-methylglutaril coenzyme 
A synthase 2) 
Enhances its enzymatic activity 
 MnSOD (manganese superoxide 
dismutase) 
Enhances its enzymatic activity 
  
MRPL10 (mitochondrial ribosomal 
protein) 
 
Suppress translational activity of 
mitochondrial ribosomes 
 NDUFA9 (NADH dehydrogenase 
(ubiquinone)) 
Augments complex I activity of the electron 
transport chain 
 OTC (ornithine transcarbamoylase) Stimulates its activity 
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 SDH (succinate dehydrogenase) Promotes its enzyme activity 
SIRT4 GDH (glutamate dehydrogenase) Mono-ADP-ribosylates it, reduces GDH 
activity 
 MCD (K741) (malonyl coenzyme 
A decarboxylase) 
Deacetylase and inhibits the activity of MCD 
SIRT5 CPS1 (carbamoyl phosphate 
synthetase 1)  
Deacetylase and upregulates its activity to 
regulate the urea cycle 
 Pyruvate and Succinate 
dehydrogenase 
Desuccinylates and represses their 
biochemical activity and thus cellular 
respiration 
 
 
Table 5. SIRT6 and SIRT7 substrates 
Sirtuins Substrate Sirtuins function 
SIRT6 
CtlP (C-terminal binding protein 
interaction protein) 
Deacetylates it promote DNA end resection 
 DNA-PK (DNA dependent 
protein kinase) 
Deacetylates and stabilizes it at chromatin for 
DNA double-strand break repair 
 GCN5 (histone 
acetyltransferase) 
Enhances   N5vactivity to acetylate P  1α 
and suppresses hepatic glucose production 
 Histone H3K56 Deacetylates to promote genomic stability 
 Histone H3K9 Deacetylates to maintain telomeric chromatin  
 PARP1 Mono-ADP-ribosylates it and stimulates its ply-
ADP-ribosylase activity 
 TNF-α Remove the fatty Acyl modifications  on K19 
and K20 to promote TNF-α secretion 
SIRT7 Histone H3K18 Maintains the transformation phenotype of 
cancer cells 
 
3.1 Sirtuins and metabolic functions 
SIRT1 exert profound effects on metabolic pathways such as lipogenesis, stimulation 
of fatty acid β-oxidation and gluconeogenesis. Overexpression of SIRT1 by knock-in 
generates phenotypes in mice similar to calorie restriction conditions, on contrary 
SIRT1
-/-
 mice die shortly after birth. SIRT1 is involved in the regulation of the food 
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intake and has been show to affect lipogenesis through the regulation of acetyl CoA 
synthetase and PPARγ. An interesting study by Xu et al.35 carried out by using 129 
SIRT1
+/-
 mice, shows that a reduction of SIRT1 activity increased a risk of fatty liver  
by increase in lipogenesis, reduction in fat export and inflammation of epididymal 
adipose tissue. SIRT1 deficiency increased PPARγ and NF-kB activity in the livery 
in response to dietary fat. SIRT1 inhibit lipid accumulation and promote lipid 
mobilization in adipocytes through inhibition of PPARγ activity. Another mechanism 
that connect SIRT1 with fatty acid oxidation involve the deacetylation of P  1α that 
increase the expression of PPARα gene targets promoting catabolism of fatty acids. 
On the contrary an opposite role seems played by   N5 that acetylates P  1α with 
a resulting inhibitory effect on this system. A balance between SIRT1 and GCN5 
activity might be fundamental for induction of PPARα gene targets.36  In pancreatic β 
cells, SIRT1 is implicated in control of metabolic glucose by repression of UCP2 
(uncopling protein 2) that has a role in regulating  insulin secretion and glucose 
tolerance, moreover has been proposed the role of SIRT1 in protecting β cells against 
oxidative stress with a mechanism that involve FOXO proteins.
37
 SIRT1 play a role 
in cholesterol homeostasis by a positive regulation of LXR (nuclear receptor that 
function as cholesterol sensors) through deacetylation at lysine 432 in a loop adjacent 
to the ligand dependent activation domain with a resulting up regulation and 
promotion of cholesterol efflux from cells.
38
   
All major mitochondrial processes, such as Krebs cycle, fatty acid metabolism, 
antioxidant response, aminoacid catabolism etc. are regulated by the balance of N
ε
-
lysine acetylation/deacetylation. SIRT3 the most well characterized mitochondrial 
sirtuin, shows a robust deacetylase activity.
39
 SIRT3 exist as a nuclear full length 
form FLSIRT3 that is processed as a result of cellular stress to the short 
mitochondrial form. Nuclear FLSIRT3
40
 exhibit deacetylase activity coherently with 
the fact that SIRT3 regulates the expression and activity of nuclear genes such as 
P  1α and MnSOD and modulates  FOXO3a by direct deacetylation. SIRT3 may 
regulate cellular energy status both at transcriptional level in the nucleus and by 
posttranscriptional mechanism in mitochondria. SIRT3 expression is highest in 
metabolically active tissues including the brain, liver, heart brown adipose tissue and 
skeletal muscle.
41
 The levels of SIRT3 are responsive to the nutrient availability of 
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the cell including fasting and calorie restriction and in response to low intake SIRT3 
activates a large array of proteins associated with metabolism.
42
 SIRT3 knock out 
mice show a reduced capacity of fatty acid oxidation in different tissues such as 
heart, muscle, liver and brown adipose tissue.
43
 This may be due to LCAD (long 
chain acyl-CoA dehydrogenase) hyperacetylation a key fatty acid oxidation enzyme 
target of SIRT3. LCAD deacetylation of lysine K318 and K322 by SIRT3 has been 
found positively modulate its enzymatic activity by coordination of FAD (LCAD 
cofactor) in the active site.
44
 SIRT3 has antioxidant effects mediated by deacetylation 
of MnSOD and isocitrate dehydrogenase 2. MnSOD the primary mitochondrial 
antioxidant enzyme, converts O2
·-
 to H2O2 that is further converted in H2O by 
catalase. IDH2 is an enzyme of the tricarboxylic acid cycle associated with  the 
Krebs cycle which produces NADPH a molecule implicate in the regeneration of 
antioxidant. IDH2 deacetylation mediated by SIRT3 increase its activity. SIRT3 
deacetylates OTC an enzyme involved in the urea cycle that might improve 
aminoacid catabolism during fasting. SIRT3 is involved also in energy production by 
deacetylation/activation of AceCS2 that catalyse the ligation of acetate with CoA to 
produce Acetyl-CoA, an essential molecule utilized in various metabolic pathways 
including fatty acid and cholesterol synthesis and the tricarboxylic acid cycle.
22
 
SIRT4 is located in the mitochondrial matrix and its first 28 amino acids are removed 
after import into mitochondria. SIRT4 exhibit prevalently ADP-ribosylase and a 
weak deacetylase activity. Little is known about the physiological relevance of 
SIRT4 and its role in metabolism. SIRT4 in pancreatic beta cells is involved in GDH 
regulation by  ADP-ribosylation  that cause the decrease of GHD activity and 
repression of amino acid-stimulated insulin secretion. Recently Haigis and co-
workers
45
 showed that SIRT4 promoted lipid synthesis and inhibition of fatty acid 
oxidation by  deacetylation of MCD (malonyl CoA decarboxylase) an enzyme that 
produces acetyl CoA from malonyl CoA.  
The enzymatic role of SIRT5 in metabolism in still unclear. SIRT5 has weak 
deacetylase activity, one of the substrate reported to be deacetylated is carbamoyl 
phosphatase 1 (CPS1) a key enzyme of the urea cycle. Deacetylation of CPS1 by 
SIRT5 was found improve the ammonia detoxification. Recently by Lin and co-
workers
23
 showed that SIRT5 has potent demalonylation and desuccinylation 
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enzymatic activity and that CPS1, IDH2, GHD and HMGCS2 are subjected to this 
post-translational modification. The involvement of SIRT5 in metabolic pathways 
need to further investigation.  
The first indication of the connection between SIRT6 and metabolism was provided 
by Mostoslavsky et al. 
46
 (2006) who showed that SIRT6 deficient mice had loss of 
subcutaneous fat, lymphopenia and acute hypoglycaemia. SIRT6 regulates glucose 
homeostasis via inhibition of glycolytic genes such as Glut1 a glucose transporter.
46
 
SIRT6 corepresses HIF-1α by deacetylating H3 9 at the promoters of several 
glycolytic genes, it has been linked with the potential tumor suppression activity of 
SIRT6.
47  
 
3.2 Sirtuins and cancer 
Of the sirtuin family, the involvement of SIRT1 function in cancer is the most 
studied and is decisively controversial and contradictory. SIRT1 is overexpressed in 
different kind of tumors such as prostate, breast, lung, hepatocellular, ovarian, 
epithelial, colorectal and melanoma, instead is reduced in bladder, colon carcinoma, 
glioblastoma, ovary an prostate cancer. This divergence has been explained  by 
considering that SIRT1 normally protects cells from oncogenic trasformation, but 
after, its enzymatic activity can promote cancer growth by deacetylation /inactivation 
of proapoptotic factors.
48,49
  
During tumorigenesis, SIRT2 can function as both tumor promoter and suppressor, 
this behaviour seems depend on the cellular context. The expression of SIRT2 has 
been found downregulated in several cancers such as gliomas,
50
 breast cancer,
51
 head 
and neck squamous cell carcinoma
52
 and esophageal adenocarcinoma
53
. Also SIRT2 
seems have tumor promoter properties, indeed its expression is elevated in different 
cancers such as neuroblastoma,
54
 pancreatic cancer and acute myeloid leukemia
55
. 
Several studies highlight a prosurvival role for SIRT3 in both normal and cancer 
cells in which seems control proliferative and survival pathways. Recently Alhazzazi 
et al.
56
 reviewed that SIRT3 is overexpressed in head and neck squamous cell 
carcinoma in which reduce ROS levels and maintain   a proliferative and aggressive 
phenotype by preventing apoptosis. Guo and co-workers
57
 reported that 
 21 
 
overexpression of SIRT3 in esophageal cancer tissue was associated with a poor 
outcome. A proapoptotic role has also been proposed but this dualism tumor 
promote/suppressor showed by SIRT3 needs to further investigations.  
Growing evidences show that SIRT6 is a tumor suppressor.
58
 SIRT6 involvements in 
cancer progression regards mainly its ability to regulates metabolic functions. Tumor 
cells needs to readjust their energy metabolism to fuel cell growth and division, and 
glucose metabolism is the best known example of metabolic reprogramming in 
cancer cells. SIRT6 regulates aerobic glycolysis in cancer cells and its inhibition in 
SIRT6 deficient cells rescue their tumorigenic potential.
46
 Furthermore SIRT6 
regulates cell proliferation by co-repressing c-MYC.
47
 Decreased SIRT6 expression 
and the consequent deregulation of related genes was found posses oncogenic effect 
in hepatocarcinogenesis.
59
 
The nucleolar sirtuin SIRT7 recently found exist also as cytoplasmic form, has been 
supported play a crucial role in oxidative and genotoxic stress response.
60
 
Homozygous knockout of SIRT7 in mice causes diminished lifespan and leads to 
hearth hypertrophy and inflammatory cardiopathy. SIRT7 is more abundant in highly 
proliferative tissues than in lowly proliferative and a role for SIRT7 as a activator of 
proliferation has been proposed. Barber et al.
21
 in 2012 reported that SIRT7 was 
responsible in the maintenance of cancer phenotype and transformation. They found 
that SIRT7 directly deacetylates histone H3K18 as a single histone mark. SIRT7 is 
reported to be upregulated in breast and thyroid cancers and the consequent H3K18 
hypoacetylation was considered a marker of malignancy. SIRT7 is responsible for 
maintaining some features of human cancers  such as anchorage independent growth, 
growth in low serum  and loss of contact inhibition. Depletion of SIRT7 inhibited 
growth of human cancer cells and in tumor xenografts in mice.
61,62
 Kim et al. 
63
 in 
2013  noted that SIRT7 expression was increased from precancer to overt cancer and 
it was upregulated in a subset of human HCCs. SIRT7 inactivation induced 
p21
WAF1/Cip1
 expression and suppressed cyclin D1 in HCC cells. The cyclin D1 
expression SIRT7 mediated can be a potent mitotic stimulation that causing 
uncontrolled cell growth during HCC progression.  
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3.2.1 SIRT1 and breast cancer 
The expression of SIRT1 was seen in most human breast cancer specimens, and its 
expression was associated with metastasis and poor prognosis. SIRT1 upregulation in 
breast cancer is associated with inactivation of tumor suppressor hypermetylated in 
cancer 1 (HIC1) by DNA hypermetylation. HIC1 binds to the SIRT1 promoter, 
represses its transcription and promotes p53 expression.
64
 When HIC1 is silenced in 
breast cancer, this results in SIRT1 upregulation and tumorigenesis promotion. 
Another well established pathway involves the association of estrogen receptor ERα 
and SIRT1 in development and progression of breast cancer, in which SIRT1 is 
essential for oncogenic signaling. SIRT1 is the binding partner of  Rα and this 
complex functions as transcriptional activator of SOD and Gpx (antioxidant activity 
and decrease of ROS production) and a repressor of p53 and cyclin G2 with 
inhibition of senescence, apoptosis and increase of cell survival both in normal that 
tumor cells.  Rα binds to p53 promoter and suppress its expression with a process 
SIRT1 dependent.
64
 Thus  Rα-SIRT1 complex function as suppressor of p53 in 
breast cancer. SIRT1 inactivation suppresses ERα induced cell growth and tumor 
development, and induced apoptosis.
64
 SIRT1 positively regulates the expression of 
aromatase that is responsable for the biosynthesis of estrogen in breast cancer. 
Furthermore SIRT1 can promote cell migration by deacetylation cortactin.
64
 More 
controversial is the case of connection between DBC1-SIRT1 in breast cancer.
65
 
Initially DBC1 has been proposed to function as negative regulator of SIRT1 with 
pro-apoptotic effects, then was found overexpressed in several breast cancer tissues 
and high levels of DBC1 were associated with short survival. D  1 stabilizes  Rα 
by SIRT1 inhibition and the consequent  Rα acetylation enhance its DNA binding 
and transcriptional activity. On the other hand  Rα signalling is oncogenic to the 
breast and D  1 upregulation could enhance  Rα function that can lead to 
development and progression of breast cancer.
66
 The data reported suggest that 
DBC1 and SIRT1 levels are critical for determining the fate of cancer, moreover this 
indicate that both these proteins have potential tumor promoter or tumor suppression 
functions.  
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3.2.2 SIRT1 and prostate cancer 
SIRT1 is overexpressed in human prostate cancer (PCa) cell lines compared with 
normal prostate epithelial cells. SIRT1 has been found also highly expressed in 
advanced prostate cancer tissues in which it can promotes metastasis and cell 
invasion through metalloproteinase-2 and cortactin. In transgenic mouse model, 
SIRT1 expression promotes prostate carcinogenesis. Ahmad and co-workers
67
 in 
2009 showed that mRNA level of SIRT1 and SIRT1 were high in a panel of prostate 
cancer cells. LNCaP and 22Rv1 that possess mutant but functional androgen receptor 
and wild type p53, DU145 cells (androgen receptor negative and mutant p53), and 
PC3 cells (androgen receptor and p53 null when compared to normal prostate 
epithelial cell PrEC). They found that SIRT1 was localized to the nucleus and also 
showed cytoplasmic localization. When the PCa cell lines were treated with 
nicotinamide the physiological SIRTs inhibitor there was a reduction in growth and 
viability of the cancer lines without any effect on the normal prostate cells. 
Furthermore Ahmad and co-workers evaluated the effect of SIRT1 knockdown on  
PCa cells, found that there was a marked decrease on the growth and viability of PCa 
cells when compare with nonsense shRNA control.
67
 In 2012 Ito and co-workers
68
 
showed the effect of cortactin in invasion and migration of prostate cancer. 
Cytoplasmic SIRT1 interact and deacetylates cortactin improving its ability to 
promote cancer cell migration. On the contrary knockdown of cortactin and SIRT1 
were found reduce and inhibit migration ability of DU145 cell line. The acetylation 
level of cortactin were found higher in SIRT1 knockdown cells than control, and 
SIRT1 knockdown inhibited cell migration and invasion more effectively than 
cortactin knockdown. They found that SIRT1 promote DU145 proliferation and 
migration by cortactin deacetylation but also it might depends on interaction with 
other molecular pathways.
68
 
 
3.2.3 SIRT1 and lung cancer 
SIRT1 and cortactin were found significantly overexpressed in 144 patients with 
invasive non-small cell lung cancers (NSCLC), their expression was observed in 
67% and 58% of patients with invasive NSCLC.
69
 SIRT1 and cortactin expression 
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was significantly associated with unfavorable clinicopathological factors, including 
high pathological T stage, lymphonode metastasis, and advanced tumor invasion. 
Furthermore cytoplasmic SIRT1 was associated with high pathological T stage and 
large tumor size compared to nuclear SIRT1. SIRT1 expression was correlated with a 
deregulation of HIC1-SIRT1-p53 loop in 118 lung cancer patients resulting in a low 
expression of HIC1 and reduced p53 acetylation.
70
 High expression of SIRT1 and 
low of DBC1 induced a p53 deacetylation and low HIC1 expression that may be 
correlated with the pathogenesis of lung SCC (squamous cell carcinoma). High 
expression of SIRT1 was found also in A549 lung AD (adenocarcinoma) cells but 
differently to SCC,  an epigenetic alteration by hypermethylation of HIC1 promoter 
region associated with DNMT (DNA methyltransferase) overexpression attenuated 
its transcription. Acetylated p53 resulted from DBC1 positive expression in A549 
cells, but it cannot bind to the epigenetically inactivated HIC1 at the promoter region 
to restore HIC1 expression. Another interesting pathway in which SIRT1 results 
involved is the modulation of DLL4/Notch signalling, essential for vascular 
development in lung cancer.
71
 SIRT1, was associated with the downregulation of 
DDL4/Notch signalling through Notch 1 deacetylation, and the inhibition of 
endothelial cell growth by DLL4/Notch that was enhanced in SIRT1-silenced lung 
cancer-derived cells ECs (vascular endothelial cells lung cancer-derived). 
 
3.2.4 SIRT1 and liver cancer 
HCC (hepatocellular carcinoma) is the third most common cause of cancer related 
death worldwide and nowadays only the early stage of HCC is curable. In the work 
reported by Portmann et al.
72
 SIRT1 expression was examined in a panel of 20 
human HCC tumors and non tumor tissue. A strong overexpression of SIRT1 was 
observed and its inhibition by knockdown or with cambinol reduced the tumor cell 
growth by removing its promoting growth signals. Furthermore they found that of the 
sirtuin family only SIRT1 mRNA  and SIRT1 protein levels were consistently 
expressed. SIRT1 silencing was associated with FOXO1 acetylation and cellular 
senescence in SK-Hep1 and HepG2 (transduced HCC p53 wild type) that showed an 
enhanced p53 acetylation and induction of p21.
73
 
 25 
 
3.2.5 SIRT1 in lymphoma and leukemia 
In 104 diffuse large B-cell lymphoma patients, the expression of SIRT1 was seen in 
74% of cases and associated with short overall survival.
74
 Furthermore a recent study 
proposed a direct correlation between SIRT1 and DBC1 in DLBCL (diffuse large B 
cell lymphoma) in which DBC1 activates AR (androgen receptor) by inhibiting 
SIRT1 that may be involved in the progression of DLBCL.
75
 SIRT1 is also 
overexpressed in chronic myelogenous leukemia (CML) in which plays a crucial role 
in development and chemoresistence.
76
 CML results from a malignant transformation 
of a hematopoietic stem cell (HSC) by the BCR-ABL oncogene targets of imatinib a 
tyrosine kinase inhibitor. CML has a chronic phase (CP) that progress to an 
accelerated phase (AP) and a terminal blast crisis (BC); unfortunately the disease 
recurrence happen because of cessation of drug treatment even in patients with 
undetectable BCR-ABL expression.
76
 Bhatia and co-workers
76
 in 2012 have found 
that both SIRT1 mRNA and SIRT1 protein levels were elevated in CO and BC CML 
CD34
+
 cells compared to CD34
+
 cells from cord blood and normal peripheral blood 
stem cell. SIRT1 knockdown inhibited CML progenitor, CB CD34
+ 
and CML CD34
+
 
proliferation. Furthermore the combination of imatinib and SIRT1 inhibition 
enhanced apoptosis of quiescent CML progenitors via p53 activation.  SIRT1 
inhibition in combination with BCR-ABL tyrosine kinase inhibitors can be explored 
as a novel approach to eradicate leukemic stem cells and residual disease in chronic 
phase CML.
77
 SIRT1 is highly expressed in adult T-cell leukemia lymphoma (ATL) 
an aggressive peripheral T-cell neoplasm characterized by poor prognosis with 
overall survival at 3 years only 24%. SIRT1 inhibition by Sirtinol has an apoptotic 
effect on primary ATL  cells and HTLV-1 infected T cells.
78
 
 
3.2.6 SIRT1 and neuroblastoma 
Neuroblastoma is a tumour derived from primitive cells of the sympathetic nervous 
system and is the most common solid tumour in childhood in which N-Myc and c-
Myc are seen in a quarter of tumour and found correlated with poor prognosis. Myc 
oncoproteins induce malignant transformation by modulating gene transcription with 
a consequent cell proliferation. Their stabilization is controlled by phosphorylation  
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at S62 regulated by ERK (protein kinase) signalling, while T58 phosphorylation 
induces ubiquitylation and degradation.
79,80
 The neuroblastoma cell proliferation is 
induced by a positive feedback loop in which N-Myc oncoprotein upregulates SIRT1 
transcription by binding to its gene promoter and SIRT1 binds N-Myc to form a 
transcriptional repressor complex that block MKP3 (mitogen protein kinase 
phosphatase 3) transcription. The repression of MPK3 that normally dephosphorylate 
and inactivates ERK led the N-Myc stabilization. The suppression of SIRT1 catalytic 
activity by Cambinol and Tenovin-6 reactivated MPK3 gene expression and induced 
neuroblastoma cell growth arrest.
81
 
 
3.2.7 SIRT1 and pancreatic cancer  
Pancreatic carcinoma is characterized by poor prognosis and fast progression and 
nowadays, gemcitabine is still the standard chemotherapeutic and first line drug for 
patients suffering from pancreatic cancer. SIRT1 overexpression was observed in 
pancreatic ductal adenocarcinoma (PDAC) and has been associated with increased 
cell viability and poorly differentiated tumor.
82
 Recently Gong et al.
83
 have found 
that the combination treatment of gemcitabine and sirtinol inhibits growth of 
pancreatic cancer in vitro in cell cultures as well as in vivo in xenogeneic athymic 
nude mice improving efficacy and survival time compared to treatment with single 
agent. Inhibition of SIRT1 is effective in suppression of ADM (acinar ductal 
metaplasia) and in reducing cell viability in established PDAC tumors in which the 
regulator of acinar differentiation such as transcription factor-1a and β-catenin can be 
deacetylated by SIRT1.
84
 
 
3.2.8 SIRT1 and colorectal cancer 
Colorectal cancer (CRC) is the third most common cancer in the world and is  is the 
second commonest cause of cancer deaths in the United States and United 
Kingdom.
85
 Malignant transformation is associated with the activation of Wnt/beta-
catenin signaling pathway which leads to the transcriptional induction of the c-MYC 
oncogene. Most lesions with high grade intraepithelial neoplasia and invasive 
carcinomas were characterized by high c-MYC and SIRT1 expression.
86
 Recently 
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Takano and co-workers
87
 measured the expression levels of SIRT1 and DBC1 by 
Western blot analysis of proteins extracted from fresh normal and cancerous tissues 
of 96 colorectal cancer patients. While expressions of SIRT1 and its inhibitor DBC1 
are concomitantly increased in cancers, high SIRT1 expression appears to be related 
to poor patients prognosis while high DBC1 expression was correlated only with 
poor differentiation. Another interesting pathway in the connection between SIRT1 
and colorectal cancer involve the downregulation of miR-34a a known post-
transcriptional inhibitor of SIRT1. A positive feedback loop was proposed in which 
p53 induced expression of miR-34a which suppresses SIRT1, increasing p53 
activity.
88 Overexpression of miR-34a decreased SIRT1 expression, leading to an 
increase in acetylated p53 levels and also an increase in p53 targets such as p21 and 
PUMA. MiR-34a was found induce apoptosis in HCT116 cells (HCT116 WT), but 
not HCT116 cells which do not have p53 (HCT116 p53 KO). 
 
3.2.9 SIRT1 and gastric cancer 
Gastric cancer is the second cause of death from malignant disease worldwide, with 
especially high mortality rates in East, South, and Central Asia; Central and Eastern 
Europe; and South America. In 2008, there were approximately 989 000 new cases 
of gastric cancer and 738 000 deaths worldwide. The prognosis of advanced gastric 
cancer remains poor, and curative surgery is regarded as the only option for cure.
89
 
Jang and co-workers
90
 in order to understand the impact of SIRT1 and DBC1 on 
gastric carcinoma reported a study conducted  on six hundred forty-three cases of 
patients. The expression of DBC1 and SIRT1 was found associated with unfavorable 
clinicopathologic variables and a significantly shorter survival in gastric carcinoma 
patients. It is known that DBC1 binds SIRT1 and inhibits its deacetylation activity 
promoting p53 mediated apoptosis. Therefore considering SIRT1 as potential 
oncogene DBC1 should play an antioncogenic role, but  DBC1  and SIRT1 
expression was found high and correlated with advanced clinicopathologic factors. 
The role of DBC1 in cancer is still controversial in which it can acts as tumor 
suppressor or tumor promoter.  May be that DBC1 expression, results increased to 
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compensate SIRT1 activity but another explanation could be that DBC1 is tumor 
promoter.
90
 
 
3.3 SIRT1 and polycystic kidney disease 
Polycystic kidney disease an autosomal dominant pathology is one of the most 
common genetic disorders in humans caused by mutations of PKD1 and PKD2. The 
disease is characterized by the development of multiple bilateral renal cysts with a 
consequent renal failure.
91
 The cyst formation and expansion involve 
hyperproliferation, dedifferentiation and liquid secretion. SIRT1 and c-MYC 
expression was found increased in PDK1 mutant renal epithelial cells and genetic 
deletion of SIRT1 by knockout mice or inhibition by nicotinamide delayed renal cyst 
formation in postnatal kidneys. The cystic cellular proliferation was found regulated 
by Rb in which its inactivation by SIRT1 deacetylation induced cellular proliferation. 
Knockdown of SIRT1 or its inhibition by nicotinamide increased Rb acetylation and 
decreases Rb phosphorylation. The treatment with nicotinamide induced apoptosis 
and p53 acetylation in cystic cells  that also may depend on the involment of other 
SIRT1 mediated pathways such as FOXO3α and  2F1.92 
 
3.4 Sirtuins and neurodegenerative disease 
3.4.1 SIRT1 and Alzheimer’s disease 
Alzheimer disease (AD) in one of the most common and devastating age related 
neurodegenerative disease. The typical neuropathological hallmarks are, extracellular 
lesions  (protein aggregates formed by a peptide derived from enzymatic proteolysis 
of amyloid precursor protein the β-amyloid), loss of neurons (progressive neuronal 
death due to apoptosis) and reactive inflammation or gliosis (chronic inflammation 
that contributes to neuronal death). In mixed cortical cultures, microglia-dependent 
Aβ toxicity was associated with strong activation of NF-kB signaling in both 
microglia and astrocytes. In in vitro model the expression of SIRT1 protects 
microglia cells through inhibition of NF-kB signalling by deacetylation at Lys310 of 
RelA/p65.
93
 The AD in mouse model APPswe/PS1d 9 (Aβ plaque formation and 
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learning and memory deficits) was mitigated by SIRT1 overexpression and 
exacerbated in mice with SIRT1 knocked out in the brain. Overexpression of SIRT1 
reduced Aβ plaque formation by α-secretase stimulation through activation  of 
ADAM10. The mechanism of activation of ADAM10 by SIRT1 appears to be 
deacetylation of the RARβ, which is known to activate ADAM10 transcription 
resulting in a reduced production of Aβ.94 In another mechanism SIRT1 
expression/activity is involved in the regulation of the serine/threonine Rho kinase 
ROCK1, known in part for its role in the inhibition of the non-amyloidogenic-α-
secretase. The expression of exogenous human (h) SIRT1 in the brain of hSIRT1 
transgenics, resulted in decreased ROCK1 expression and elevated α-secretase 
activity in vivo.
95
 
 
3.4.2 SIRT1, SIRT2 and Huntington’s disease 
Huntington’s disease (HD) is a neurodegenerative genetic polyglutamine (polyQ)  
disorder. Classical HD is characterized by personality changes, weight loss, 
cognitive disorders and motor impairment, including the hallmark feature of chorea. 
The disease is caused by an autosomal dominant mutation of two copies of a gene 
called Huntingtin, which gradually damages cells in the brain.  Life expectancy in 
HD is generally around 20 years. The largest risk of death are pneumonia, heart 
disease, suicide, physical injury from falls, and malnutrition.
96,97
 In a C. elegans 
model for HD suggest the promotion of Sir2 activity was found protective against the 
early phases of polyQ cytotoxicity through activation of daf-16 (member of FOXO 
family).
98 These observations raised the possibility that caloric restriction and a Sir2 
activator that promotes cell survival by inhibiting stress induced apoptotic cell death 
and functions in a FOXO3-dependent manner, may be protective to neurons 
expressing alleles associated with Huntington disease. Krainc and co-workers
99
 in 
2012 found that SIRT1 knockout mouse model of Huntington’s disease resulted in 
exacerbation of brain pathology, instead its expression improved survival. SIRT1 had 
neuroprotective effects through activation of TORC1 by promoting its 
dephosphorylation and its interaction with CREB with a resulting positive 
modulation of BDNF (brain-derived neurotrophic factor) activity. In contrast with 
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the findings above mentioned a potent SIRT1 inhibitor EX527 (Selisistat) is in phase 
II for HD (clinical trials.gov identifier: NCT01521585) and only the outcome from 
the clinical trials will reveals the beneficial effects of SIRT1 inhibition in 
Huntingotn’s disease. 
The major beneficial effects of SIRT2 on HD depends on its hypomodulation. 
Decreased level of SIRT2 increased the viability of photoreceptor neurons in fly 
model of Huntington’s disease100 and as showed by Luthi-Carther et al SIRT2 
inhibition reduced the sterols levels via SREBP-2 cytoplasmic retention with a 
consequent downregulation of cholesterol biosynthetic genes.
101
  
 
3.4.3 SIRT2 and Parkinson’s disease 
After Alzheimer’s disease Parkinson (PD) is the most common neurodegenerative 
disease. The pathology is due to degeneration and lost of nigrostriatal dopaminergic 
neurons characterized by the presence of evident symptoms such as bradykinesia, 
rigidity and tremor. The pathology of the disease is characterized by the 
accumulation of a protein alpha-synuclein into inclusions Lewy bodies.
102
 Inhibition 
of SIRT2 by small molecule such as AGK2 or by knockout models result in the 
rescue of α-synuclein mediated toxicity and promoted fewer and larger Lewy body-
like inclusions.
103
 Recently has been proposed that SIRT2 increase nigrostriatal 
damage after treatment with MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) 
via FOXO3a deacetylation and activation of proapoptotic factor Bim.
104
 
 
3.4.4 SIRT2 and Wallerian degeneration 
Wallerian degeneration also named anterograde degeneration is a process that occur  
when a nerve fiber is damaged or cut and involves the separation between the axon 
and neuron’s cell body.   In 2007 Suzuki and Koike105 found a connection between 
Wallerian degeneration and tubulin deacetylation SIRT2 mediated. They found that 
levels of SIRT2 in  Wld
S 
mice (mouse model with delayed Wallerian degeneration) 
granule cells were reduced and that SIRT2 overexpression abrogated microtubule 
hyperacetylation and resistance to axonal degeneration. Conversely, SIRT2 
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knockdown by using a lentiviral vector expressing small interfering RNA, enhanced 
microtubule acetylation and resistance to axonal degeneration. 
 
 
4 SIRTUIN INHIBITORS 
4.1 Adenosine mimetics 
 
 
Adenosine mimetic compounds have been proposed as SIRT1, 2 inhibitors by Jung 
and co-workers
106
 in 2006 starting from the consideration that a class of kinase 
inhibitors (CDK)  also inhibit NAD
+
 dependent mitochondrial malate dehydrogenase 
(mMDH). A library of commercial available kinase and phosphatase inhibitors 
formed by 84 compounds were tested toward SIRT2 and only selected compounds 
tested against SIRT1. In order to avoid false positive, the most active compound 
(showed above) was assayed using two different SIRT1/2  protocols.  Fluorescent 
deacetylase assay in which show IC50 value of 3.5 µM and 0.8 µM on SIRT1 and 
SIRT2 respectively (ZMAL substrate 10.5 µM, NAD
+
 500 µM),
107
 and a scintillation 
assay in which the same magnitude of inhibition  was observed (radioactive 
deacetylase assay has been performed as described by North et al.
108
 with acetylated 
H4 histone N-terminal peptide, residues 1-25). Competitions studies indicate that the 
scaffold proposed  was competitive with respect to NAD
+
 and not competition with 
substrate was observed. Furthermore SIRT2 was confirmed one of the cellular target 
by Western blot analysis. 
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4.2 AGK2 
 
 
During a screening carried out on 200 structural analogues of B2 a nitroquinoline 
compound, AGK2 a selective SIRT2 inhibitor was discovered. The fluorimetric in 
vitro screening performed using the commercially available BIOMOL assay reveals 
that AGK2 is a SIRT2 selective inhibitor with IC50  of 3.5 µM on SIRT2  with a poor 
SIRT1, 3 inhibition profile. A  2 was found able to inhibit the deacetylation of α 
tubulin via immunoblot and on overexpressed SIRT2 immunoprecipitated  from Hela 
cells. The compound has only minimal toxicity at 50 µM on after 72 h incubation in 
Hela cells, and in Parkinson disease model  AGK2 rescued dopamine neurons from 
α-synuclein toxicity.103 Furthermore AGK2 can exacerbate the H2O2-induced 
decrease in the level of intracellular ATP in PC12 cells (pheochromocytoma of the 
rat adrenal medulla cells).
109
 
 
4.3 Anilinobenzamides 
 
 
2-Anilinobenzamides were identified in 2006 by Suzuki et al.
110
 as potential 
nicotinamide mimetic compounds. The most potent compound of the serie 1 showed 
an IC50 value of 17 µM on SIRT1, 74 µM and 235 µM on SIRT2 and SIRT3 
respectively (BIOMOL drug discovery kit AK555-557 with 25 µM of both substrate 
and NAD
+
). The enzyme kinetic study (Lineweaver-Burk plot) proved that 1 was not 
competitive with NAD
+
 but with the acetylated lysine substrate. The ability of 
compound 1 to induce p53 acetylation  was confirmed by Western blot analysis on 
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HCT116 cell lines after etoposide induced DNA damage. In 2012 Suzuki et al.
111
 
improved the knowledge around this scaffold by designing and synthesizing several 
derivatives of compound 1 that led them indentify a series of potent, SIRT2 selective 
and cell permeable inhibitors.  Compound 2 represents the lead with an IC50 value of 
0.57 µM on SIRT2 and up to 300 µM on SIRT2, 3 respectively. Compound 2 was 
found able to induce α-tubulin hyperacetylation in HCY116 cell lines greater then 
AGK2 a known SIRT2 inhibitors.  
 
4.4 Cambinol and its derivatives  
 
Bedalov and co-workers
112
 in order to improve the stability of splitomicin a weak 
SIRTs inhibitor discovered Cambinol a SIRT1, 2 inhibitor with moderate potency 
with IC50 of 56 µM and 59 µM on SIRT1 and SIRT2 respectively (assayed with 
scintillation assay by using [
3
H]acetyl-H4 peptide). Cambinol was found be 
competitive with histone H4 peptide substrate and hyperacetylation of p53, α-tubulin, 
FOXO3a and Ku70 were observed after Cambinol treatment of NCI H460 lung 
cancer and Hela cells, moreover it shows to impair the growth of Burkitt lymphoma 
xenografts. A SAR investigation around Cambinol
113
 led the identification of 
compound 1 with an appreciable SIRT1 selectivity (SIRT1 IC50 of 12.7 µM and > 90 
µM on SIRT2) and a series of SIRT2 selective compounds when N-1 position was 
substituted, among which the most potent one was the N-tertbutyl derivative 2 with 
IC50 = 1 µM (BIOMOL drug discovery kit AK555, 556 with 15 µM of substrate, 1 
mM of NAD
+
 and 15 µL, 0.07 U/µL for SIRT1 and 0.03 U/µL for SIRT2). Western 
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blot analysis show that the treatment of H1299 cells with compound 2 increased the 
amount of acetylated α-tubulin. Cambinol inhibited the expression of cytokines 
(TNF, IL-1β, I -6, IL-12p40, and IFN-γ), NO and  D40 by macrophages, dendritic 
cells, splenocytes and whole blood stimulated with a broad range of microbial and 
inflammasome stimuli.
114
 Cambinol lead to a G1 arrest in p53wt-HepG2 cells 
(hepatocellular carcinoma cells) without impair the regenerative capacity of normal 
liver. Furthermore tumor growth was reduced in animals treated with cambinol 
without change the normal physiological growth response in non-malignant liver 
cells.
72
 Preventative treatment with Cambinol reduced tumorigenesis in TH-MYCN 
transgenic mice.
81
 
  
4.5 Chroman-4-one derivatives 
 
Chroman-4-one constitute one of the most recent scaffold with SIRT2 selective 
properties. The structural investigation proposed by Luthman and co-workers
115
 
allowed the identification of an hit series of potent and highly selective SIRT2 
inhibitors, of which compound 1 with n-butyl alkyl chain in position 2 and the intact 
carbonyl function in position 4 was found the most active. The reported  SIRT2 IC50 
is 4.3 µM and no relevant inhibition against SIRT1 and SIRT3 at concentration of 
200 µM was observed. In order to confirm that the activity of 1 was not only an 
artefact caused by the fluorophore, a SIRT2 assay based on the release of 
14
C-
nicotinamide, and western blot analysis of the SIRT2 mediated deacetylation of 
acetylated α-tubulin were carried out. Compound 1 is clearly a SIRT2 selective 
inhibitor of which S enantiomer was a more potent inhibitor with IC50 value of 1.5 
µM.  The enzymatic assay has been performed using a BIOMOL like protocol, with  
homemade GST-SIRT1/2 enzyme, recombinant His-SIRT3 and substrates 
commercially available. Km values were experimentally found be 58 µM for SIRT1, 
198 µM for SIRT2 and 32 µM for SIRT3 (reported by BIOMOL). The assay was 
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carried out using 0.7 Km of substrate concentration and 0.9 Km of  NAD
+
 
concentration. 
 
4.6 EX-527 
 
EX-527 and its derivatives have been discovered in 2005 by Napper et al.
116
 through 
an high-throughput screening of 280.000 compounds using the commercially 
available fluorimetric assay (BIOMOL). Selected compounds were also assayed by 
radiochemical assay that monitors the enzymatic release of nicotinamide from 
NAD
+
. Among the hit series EX-527 is the most potent and selective compound with 
a SIRT1 IC50 of 0.098 µM as racemic mixture (in the manuscript the reported  IC50 
values of the separated enantiomers are e1 IC50 0.123 µM and e2 IC50 >100 µM) 
SIRT2 of 19.6 µM and SIRT3 48.7 µM. SAR studies reveal the importance of the 
primary amide as functional group, and the reduction of tetrahydrocarbazole to 
hexahydro drastically reduced the inhibition activity. Enzyme kinetic analysis and 
nicotinamide exchange assay have revealed that EX-527 is a mixed-type inhibitor 
with the ability to inhibit the nicotinamide exchange reaction, suggesting that the 
compound could occupy the nicotinamide binding site. Recently Steegborn and co-
workers
117
 described the molecular basis of sirtuin inhibition by EX-527. A kinetic 
analysis using a continuous assay, confirmed the previously reported NAD
+ 
dependent
 
non-competitive inhibition mechanism. Furthermore the SIRT3 crystal 
structure with bound 2′-O-acetyl-ADP ribose and EX-243 (the EX527 active 
enantiomer) show that the cofactor binding loop is trapped in a closed conformation 
instead of being open for product release. Zhao et al.
118
 in 2013 solved the crystal 
structure of the SIRT1 catalytic domain with bounded  NAD
+
 and an analogue of 
EX-527 (2). Interestingly the racemic mixture of 2 was added to the protein 
crystallization but only the (S)- enantiomer that is also the most active in vitro can be 
seen in the crystal structure. Thus confirming the stereoisomeric binding 
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discrimination. Crystal structures of EX-527 on SIRT3 (PDB code : 4BV3) and its 
analogue (2) on SIRT1 (PBD code : 4I5I) endorse the inhibition mechanism 
proposed by Napper et al. in which both the inhibitors are able to bind in the C 
pocket with a resulting displacement of NAD
+
 nicotinamide moiety that induces the 
cofactor to adopt a non-productive binding mode that might preclude on SIRT1 the 
substrate binding by steric interference.  
EX-527 is able to induce p53 acetylation in different cell lines such as NCI-H460, U-
2 OS, MCF7 and HMEC cells, without affect cell survival or cell proliferation.
119
 
The effectiveness of EX-527 as SIRT1 binders has also been confirmed by Sinclair 
and co-workers that reported the ability of this scaffold to inhibit the complex 
formation between DBC1 (a known SIRT1 inhibitor) -SIRT1, suggesting the idea to 
develop potential SIRT1 activators with the capacity to block DBC1 binding without 
affect the SIRT1 catalytic activity.
120
 EX-527 (also called Selisistat) is in phase II for 
HD (clinical trials.gov identifier: NCT01521585) and only the outcome from the 
clinical trials will reveals the beneficial effects of SIRT1 inhibition in Huntington’s 
disease. 
 
4.7 NAD
+
 analogues 
 
 
Non hydrolysable NAD
+
 analogue carba-NAD have represented one of the most 
important starting point in understanding the sirtuin catalysed deacetylation.
121
 Its 
chemical stability is due to the substitution of an oxygen atom with a carbon,  that 
stabilizes the bond between nicotinamide and C1 of the cyclopentyl ring. Carba-
NAD has been a useful tool in studying Sirtuin bioactive conformation because, 
crystallization of sirtuins ternary complex SIRTs-NAD
+
-substrate was challenging 
due to the short lived nature of the ternary complex. On the contrary carba-NAD 
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does not react with acetylated substrate and it has allowed the crystallization of its 
ternary complex on  HST2 , SIRT3 and SIRT5.
122,123
 Carba-NAD derivatives can 
serve also as sirtuin inhibitors thank to their ability to compete with NAD
+
, but the 
lack of cellular permeability due to their physiochemical properties, make them a 
non-suitable scaffold for further investigations. In 2011 Wagner and co-workers
124
 
developed a small series of NAD
+
 analogues of which 8-(4-chlorophenyl) derivative 
was a moderate SIRT2 inhibitor with an IC50 of  35 µM. The compounds were 
assayed using a BIOMOL like assay with GST-SIRT1 and His-SIRT2, 10.5 µM of 
ZMAL substrate and 500 µM of NAD
+
. 
 
4.8 Peptides and Pseudopeptides 
 
 
Fatkins et al.
125
 in 2006 discovered the first thioacetylated peptidic inhibitor (1) of 
SIRT1 simply starting from the consideration that residues 372-389 of human p53 
N
ε
-acetylated at Lys382 were an in vitro substrate of SIRT1. N
ε
-Thioacetyl group 
was incorporated into Lys382 as acetyl mimetic and was found increase the rate of 
nicotinamide formation, and potently inhibit SIRT1 with an IC50 of 2 µM (HPLC 
assay using 0.5 mM NAD
+
, 0.3 mM 372-389 of human p53 as substrate and 14 µM 
GST-SIRT1) with a retardation of 400 fold the de(thio)-acetylation SIRT1 mediated. 
In 2007 Smith and Denu
126
 determined the chemical mechanism of thioacetyl-lysine 
peptide inhibition through mass spectrometry, pre-steady state, steady state kinetics 
and mutagenesis. Starting from 11-mer peptide based on the human histone H3 a 
small array of  N
ε
 substituent at Lys-14 were explored (Figure 7). Thioacetyl 
derivative was found the best inhibitor with IC50  value of 2.0 µM, 5.6 µM, 2.3 µM 
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and 1.0 µM for SIRT1, SIRT2, SIRT3 and Hst2 respectively (scintillation assay with 
50 µM NAD
+
, 20 µM [
3
H]acetyl-lysine peptide, 0.1-0.2 µM enzyme).  
 
 
 
 
Figure 7. Nε modifications at Lys-14 of human histone H3 peptidic sequence. 
 
Differently to monofluoroacetyl-, difluoroacetyl-, and trifluoroacetyl peptides that 
would be inhibitor through competition with AcH3, Thioacetyl derivative inhibited 
by stalling a reaction step after Michaelis complex formation (Figure 8). 
  
 
Figure 8. Mechanism of sirtuin inhibition of thioacetylated paptides. 
 
After a fast nicotinamide cleavage, the thioacetyl inhibitor is readily converted to a 
stalled intermediate 1′-S-alkylamidate with a consequent  retardation of the overall 
turnover rate.
127
 In 2008 Fatkins et al.
128
 starting from the results previously obtained 
with thioacetylated SIRT1 substrate 1 (p53 372-389),  synthesized also α-tubulin 
sequence 36-44 (a known SIRT2 substrate) and Acetyl-coenzyme A synthetase 2 
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sequence 633-652 (as substrate of SIRT3), with the aim to obtain not only potent 
inhibitors, but informations in term of selectivity. From the results reported by the 
authors (Table 6) peptide 1 was found a potent SIRT1 and SIRT2 inhibitor, instead 2 
and differently to compound 3 that was a pan inhibitor, is the only one that showed a 
considerable selectivity. 
 
Table 6. IC50 Values for compounds 1-3
128
 
Peptide IC50 µM 
 SIRT1 SIRT2 SIRT3 
2HN-KKGQSTSRHKK(ThAc)LMFKTEG-COOH (1) 1.7 1.8 67.3 
2HN-MPSDK(ThAc)TIGG-COOH (2) 116.8 11.4 449.4 
2HN-KRLPKTRSGK(ThAc)VMRRLLRKH-COOH (3) 0.9 4.3 4.5 
 
These results opened the street to further structural investigations in which the most 
relevant SAR has been proposed by Kiviranta et al.
129
 in 2009.  Penta and tripeptides 
(Figure 9) were found good SIRT1 and SIRT2 inhibitors demonstrating that, 
additional C and N-terminal residues were not necessary for a tight binding.  
 
 
Figure 9. The most representative penta and tripeptides SIRT1/2 inhibitors. 
 
Compounds were designed considering p53 and α-tubulin based sequences and  
potent SIRT1, SIRT2 inhibitors were found (Table 7). The tripeptide 6 was the 
compound with the highest SIRT1 selectivity, opening the perspective that the 
correct selection of sidechains was important for obtain a good inhibitory activity 
and selectivity. Following this direction Kokkonen et al.
130
 in 2012 proved that a 
 40 
 
specific selection of a peptidic/pseudopeptidic compounds from an homemade 
library could be applied also for design inhibitors of SIRT6 deacetylase activity. 
 
 
Table 7.  IC50 Values for compounds 4-6
129
 
Peptide IC50 µM 
 SIRT1 SIRT2 
4 0.18 3.8 
5 0.18 6.9 
6 0.57 151 
 
In this scenario in which peptidic inhibitors gave potent inhibition but negligible 
druglike properties, Suzuki et al.
131,132
 reported  new substrate mimetic 
pseudopeptidic inhibitors with the aim to improve cell permeability (Figure 10). 
 
 
Figure 10. NAD
+
 conjugates generated by compounds 7, 8. 
 
Compound 7 was the best result (Figure 10, Table 8) of a SAR investigation to the 
N
ε
- Lys position, carried out with the aim to find a new functional groups able to 
keep a tight binding with the enzyme by reacting with NAD
+
. Instead compound 8 
(Figure 10) represents the first structural optimization of thioacetyl Lys substrate 
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based inhibitors, demonstrating that peptidic scaffold could be replaced with a 
pseudopeptidic backbone retaining a good SIRT1 inhibition profile. The mechanism 
of SIRT1 inhibition by compounds 7 and 8 was investigated by mass spectroscopic 
analysis, in which a stable adduct formation as result of SIRT1-catalyzed reaction 
was observed (Figure 10). 
 
Table 8. IC50 Values for N
ε
- Lys modified compounds
131
 
 
R    IC50 µM   
 SIRT1 
-CN 300 
-CF3 >300 
-SCH3 >300 
-SOCH3 >300 
-SO2CH3 N.D. 
2-CF3Ph >300 
4-CF3Ph >300 
2-NO2Ph >300 
4-NO2Ph N.D. 
-COOCH3 35 
-COOEt (7) 3.9 
-COOn-Pr 62 
-COOi-Pr 47 
-COOn-Bu 73 
-COOt-Bu >300 
-COOCH2-c-Pr 14 
-COOCH2CF3 15 
-COOCH2Ph 96 
-CONH2 >300 
-CONHCH3 >300 
-CON(CH3)2 >300 
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-COCH3 >300 
-COEt 88 
-COn-Pr 56 
-COCF3 >300 
-COPh >300 
 
IC50 values were experimentally calculated using SIRT fluorimetric BIOMOL assay 
AK555, AK556 and AK557 (25 µM NAD
+
 and 25 µM of substrate) showed that 
both compounds 7 and 8 were good SIRT1 inhibitors with IC50 of 3.9 µM and 2.7 
µM respectively and weak SIRT2 inhibitors (IC50 > 65 µM  and 23 µM respectively) 
without show activity against SIRT3.  Unlike peptidic inhibitors, 7 and 8 were found 
cell permeable with the ability to induce p53 hyperacetylation after DNA damage in 
HCT116 cells. 
In 2010 Huhtiniemi et al.
133
 proposed, one of the last SAR investigation to the N
ε
- 
Lys position of a peptidic scaffold. Thioacetyl moiety was confirmed the most 
promising N
ε
- substituent of the series. In 2011 Lahtela-Kakkonen and co-workers
134
 
created the first binding hypothesis in designing new pseudopeptidic inhibitor of 
SIRT1 and SIRT2. The authors designed  a small array of pseudopeptidic inhibitors 
(Table 9) of SIRT1/2 considering the potential interactions in the substrate binding 
area by docking simulations. The enzymatic assay performed using a BIOMOL like 
protocol (homemade GST-SIRT1/2 enzymes 40 µM of SIRT1 substrate, 138 µM for 
SIRT2 and NAD
+ 
 500 µM) shows that most of the compounds were potent SIRT1 
inhibitors with a considerable inhibition profile also on SIRT2. 
 
Table 9. .  IC50 Values for pseudopeptidic inhibitors
134
 
R IC50 µM 
 SIRT1 SIRT2 
 
 
0.77 6.5 
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18 ND 
 
13 17 
 
0.99 56 
 
1.3 27 
 
1.0 53 
 
0.97 13 
 
 
9.9 15 
 
23 ND 
 
7.4 16 
 
5.1 7.4 
 
1.6 4.3 
 
Furthermore selected compounds were found able to induce p53 hyperacetylation 
after etoposide induced DNA damage in different cellular lines such as NHA, SH-
SY5Y and ARPE cell lines. Zheng and co-workers
135
 in 2010 investigated on the 
possibility to make structural changes on the substrate acetyl lysine moiety. Starting 
from sequence 380-384 of p53 a known SIRT1 substrate in vitro, a series of peptides 
containing acetyl lysine analogues were synthesized (Figure 11). Each compound of 
the series doesn’t show substrate property and neither significant inhibitory activity 
even when L-Acetyl lysine was replaced with non-natural D isomer. 
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Figure 11. Modification proposed at acetyl lysine moiety. 
 
The structural investigation proposed reveals that substrate binding site has stringent 
requirements and poor plasticity in which the distance between lysine α-carbon and 
its acetoamido group is critical for the correct substrate placements. This let 
understand the difficulty in designing acetyl lysine mimetic compounds as potential 
sirtuin inhibitors. Furthermore the full inactivity showed by p53 380-384 containing 
D-isomer of AcLys evidences also the stereospecificity of deacetylation SIRT1 
catalyzed. The versatility of peptidic scaffold has been applied by Lin and co-
workers after the discovery of demalonylase and desuccinylase activity of SIRT5.
23
 
The specificity of this enzymatic reaction was evidenced designing histone H3 lysine 
9 (H3K9) thiosuccinyl peptide (H3K9TSu) (Figure 12) and the corresponding H3K9 
thioacetyl derivative as control.
136
 H3K9TSu differently to H3K9 thioacetyl 
derivative, (active in low micromolar concentration on SIRT1-3 but not on SIRT5) 
was found a selective and a competitive inhibitor of SIRT5 with an IC50 of 5 µM (by 
HPLC assay, 1 µM of Sirtuin 0.3 mM acetyl/succinyl peptide H3K9, Km 41 µM and 
0.5 mM NAD
+
) without show any significant activity on the other sirtuin isoforms.  
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Figure 12. Histone H3 lysine 9 thiosuccinyl peptide (H3K9TSu) 
 
4.9 Sirtinol/Salermide derivatives 
 
Sirtinol was discovered in 2001 by high throughput cell-based screening of 1600 
compounds
137
 in which cell-based URA3 reporter-based screen was used to identify 
the potential inhibitors. Sirtinol was able to inhibit yeast Sir2p and SIRT2 enzymatic 
activity with an IC50 of 68 µM and 38 µM respectively (scintillation assay). In 2005 
Mai et al.
138
 proposed a small SAR investigation in which the hydroxyl function of 
naphthyl group was found essential for the activity, moreover R and S sirtinol, meta-
sirtinol and para-sirtinol were prepared and assayed on human SIRT1 and SIRT2. 
The IC50 values experimentally calculated with fluorescent BIOMOL assay (1 µg of 
SIRT1 or SIRT2, 250 µM of substrate and 200 µM of NAD
+
) show that the switch 
from meta to para sirtinol improved the inhibition profile in which this latter  had 
IC50  of 13 µM and 26 µM on SIRT1 and SIRT2 respectively. Sirtinol has different 
biological activities; it reduces inflammation in human dermal microvascular 
endothelial cells by reduction of monocyte adhesion,
139
 induces apoptotic and 
autophagic cell death in MCF7 breast cancer cells,
140,141
 prostate cancer cells (PCa)
67
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and a significant growth inhibition and apoptosis in adult T-cell leukemia-lymphoma 
(ATL)
78
. 
In 2009 Fraga
142
 and few years later Mai
143
 and co-workers focused their effort to 
rationally modify the sirtinol structure in order to create stronger sirtuin inhibitors. 
The founder of this series so called Salermide with a medium SIRT1/2 inhibition 
profile (IC50 43 µM and 25 µM on SIRT1 and SIRT2 respectively) shows specific 
proapoptotic effect in several cancer cell lines such as leukemia (MOLT4, KG1A, 
K532, U937), lymphoma (Raji), colon (SW481, RKO), breast (MDA-MB-231, 
MCF7) and cancer stem cells (CSCs) colorectal carcinoma (CRC), glioblastoma 
multiforme (GBM), without affect the viability of non-tumorigenic MRC5 cells. The 
effect of Salermide was dependent on SIRT1 by reactivation of proapoptotic genes 
(CASP8, TNF, TNFRSF10B and PUMA) through SIRT1 mediated K16H4 
deacetylation.
142,143
 JGB1741
144
 instead was discovered by docking simulations of 
sirtinol analogues, in which JGB1741 resulted the best scored compound. JGB1741 
was found a SIRT1 selective inhibitor with an IC50 value of 15 µM on SIRT1 and 
>100 µM on SIRT2 and SIRT3 (using BIOMOL assay, other information are not 
reported). JGB1741 inhibits cell proliferation of K562 (myelogenous leukemia), 
HepG2 (hepatocellular carcinoma) and MDA-MB231 (breast cancer) cell lines 
without show any cytotoxicity on HEK293 (Human Embryonic Kidney 293 cells). 
Furthermore on MDA-MB231, JGB1741 was able to induce apoptosis by increasing 
cytochrome c release and H3K9, p53 K382 hyperacetylation. MC2141
145
 is the 
founder compound of a series of benzodeazaoxaflavins proposed by Mai and co-
workers in 2010 as a result of cambinol’s chemical manipulation. M 2141 is a 
selective SIRT1 inhibitor, with IC50 values of 8.4 µM and 191.2 µM on SIRT1 and 
SIRT2 respectively (Fluor de Lys fluorescence based assay kit based on the method 
described in the BIOMOL product sheet AK-555, AK-556). MC2141 induces p53 
acetylation at Lys382 on MCF7 cell line and apoptosis in different cancer cell lines 
such as Raji (lymphoblastoid cells derived from  urkitt’s lymphoma), D D1 (colon 
carcinoma), Hela (cervical carcinoma), U937 (leukemia), two colorectal carcinoma 
(CSC-CRO, CSC 1.1) and two glioblastoma multiforme (CSC 30P, CSC 30PT) 
cancer stem cells.
146,147
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4.10 Splitomicin and its derivatives 
 
 
 
In a cell based screening on 6000 compounds from the National Cancer Institute, 
Splitomicin was identified a specific inhibitor of yeast Sir2p with a minimum growth 
stimulating concentration (MCG) of 0.49 µM and with  low and no inhibitory 
activity against Hst1p, Hst2p, Hst3p and Hst4p isoforms.
148
 After the identification 
of critical residues responsible of its inhibitory discrimination a library of 100 
analogues was synthesized and screened against Sir2p and Hst1p in which 
Dehydrosplitomicin was Hst1p specific inhibitor.
149,150
 This first approach on yeast 
isoforms gave the input to develop splitomicin derivatives active on human sirtuins. 
HR73 has been identified a potent SIRT1 inhibitor with IC50 < 5 µM.
151
 Compound 9 
and its hydrolytically stable derivative 10 were found SIRT2 inhibitors in low 
micromolar concentration with IC50 of 1.5 µM and 6.4 µM respectively 
(homogeneous fluorescent assay 10.5 µM of ZMAL substrate, 500 µM of NAD
+
).
152
 
Compound 11 the result of Splitomicin structural optimization in order to achieve a 
more stable and less hydrolysable derivative, is an equipotent SIRT1/SIRT2 inhibitor 
with an IC50 value of 9.6 µM and 10 µM (homogeneous fluorescent assay 10.5 µM 
of ZMAL substrate, 500 µM of NAD
+
) on SIRT1 and SIRT2 respectively.
153
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4.11 Suramin  
 
 
 
The inhibitory activity of Suramin against SIRT1 was discovered by Sinclair and co-
workers during a screening of potential Sirtuin activators.
154
 In 2007 Trapp et al.
155
 
performed a structure activity study of 30 Suramin analogues tested on SIRT1 and 
SIRT2. The replacement of the urea central moiety with isophthalic acid 12 led a 
potent SIRT1 inhibitor (Table 10).   
 
Table 10. IC50 Values for the most representative Suramin derivatives
155
 
Compound IC50 µM 
 SIRT1 SIRT2 
Suramin 0.29 1.1 
12 0.093 2.3 
13 0.23 7.9 
14 0.58 60% at 20 µM 
15 0.52 15.5 
   
Downsizing of the central core with 13 and 15 and a pronounced structural 
rearrangement 14  gave compounds with marked but also drastically reduced 
SIRT1/SIRT2 inhibition profile (homogeneous fluorescent assay 10.5 µM of ZMAL 
substrate, 500 µM of NAD
+
) on SIRT1 and SIRT2 respectively. 
 49 
 
4.12 Tenovin and its derivatives 
 
 
An high-throughput cell-based screening of 30 000 drug-like small molecule, carried 
out to detect compounds that activate p53 led the identification of Tenovin.
156
 Due to 
Tenovin  poor water solubility Tenovin-6 was synthesized and found a SIRT1/2 
inhibitor with an IC50 of 21 µM and 10 µM on SIRT1 and SIRT2 respectively 
(BIOMOL assay AK555-557, 7 µM of substrate and 1mM of NAD
+
). Structural 
investigations around Tenovin-6
157,158
 (a schematic example in figure above) let 
understand the difficulties in order to gain more potent derivatives in which 
compounds 16 and 17 represent the most optimized structures with IC50 of 18.3, 21.5 
µM and 4.6, 0.8 µM on SIRT1 and SIRT2 respectively.
157,158
 Tenovin-6 rapidly 
increase the level of K382-Ac-p53 in MCF7 and H1299 cell lines and the treatment 
of aggressive melanoma cell line (ARN8) with Tenovin-6 decreases its growth. 
Tenovin-6 significantly increases apoptosis of CML (chronic myelogenous 
leukemia) CD34
+
CD38
-
 and CD34
+
CD38
+
 cells but not normal cells.
76
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4.13 Thienopyrimidine 
 
 
Thienopyrimidine are a new class of low nanomolar SIRT1-3 inhibitors discovered 
through an in vitro SIRT3 affinity selection through an encoded library technology 
(ELT).
159
 The screened library was generated using 16 bis acids, 134 diamines and 
570 heteroaryl building blocks that afford a library of 1.2 million compounds. An 
intensive SAR investigation was carried out, moreover the crystallization of 
compounds 18-20 with SIRT3 allowed to understand their binding mode.  
Compounds 18-20 were low nanomolar inhibitors with IC50 values that range from 
3.6-15 nM for SIRT1, 2.7-10 nM for SIRT2 and 4.0-33 nM for SIRT3.  IC50 were 
measured by a discontinuous OAADPr mass spectrometry assay with Ac-
RHKKAcW-NH2 as substrate  (used at Km value 2 µM SIRT1, 10 µM SIRT2 and 2.2 
µM for SIRT3). Test compounds were preincubated with  either SIRT1 (5 nM), 
SIRT2 (10 nM) and SIRT3 (5nM) then peptidic substrate was added along with 
NAD
+
 at Km value (80 µM SIRT1, 50 µM SIRT2 and 2.2 µM for SIRT3). As can be 
seen by SIRT3 crystal structures (PDB: 4JSR, 4JT8, 4JT9) the three inhibitors have 
the same binding mode in with thienopyrimidine scaffold occupy the C-pocket in 
which the carboxamide makes four hydrogen bonds with Asp231, Ile230 and a 
conserved water molecule (Figure 13), the thienopyrimidine ring has stack 
interaction with Phe157 and the ethylpiperidine moiety is placed in the hydrophobic 
cleft of the acetyl-lysine substrate channel.  
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Figure 13. Binding mode of compound 20 (PDB: 4JSR). Maestro 9.2 Schrödinger, 
LLC, New York, NY, 2011. 
 
4.14 Thiobarbiturates 
 
 
A virtual screening of 328 000 molecules followed by MM-PBSA approach allowed 
the identification of  thiobarbiturate scaffold as Sirtuin inhibitor.
160
 From Cambridge 
database containing 328 000 compounds, 390 that showed structural similarity to a 
Cambinol derivative were selected and docked into SIRT2, then 131 molecules  were 
successfully docked into C-pocket and 5 barbiturate and thiobarbiturate were 
purchased and tested. After this preliminary screening in which compound 21 was 
the best SIRT2 inhibitor with IC50 of 9.1 µM and 13.2 µM (Table 11, fluorescent 
assay ZMAL substrate 10.5 µM and NAD
+
 500 µM) on SIRT2 and SIRT1 
respectively, a small array of other derivatives were designed and synthesized. The 
most potent SIRT2 inhibitor was compound 22 with IC50 of 8.7 µM (Table 11), on 
the contrary 24 showed the greatest SIRT1 inhibition with IC50  of 5.9 µM (Table 
11). The versatility of thiobarbiturate scaffold was applied also on SIRT5 when Jung 
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and co-workers
161
 in 2012 assayed a small library of thiobarbiturates against SIRT5 
that were found inhibitors in micromolar range. Belong them compound 25 was the 
best inhibitor (Table 11, Fluorescent assay, ZK(s)A substrate 200 µM, Km 17.4 µM , 
NAD
+
 500 µM). 
 
Table 11. IC50 Values for derivatives 21-25
160,161
 
Compound IC50 µM 
 SIRT1 SIRT2 SIRT3 SIRT5 
21 13.2 9.1 unavailable unavailable 
22 50.5 8.7 40.3 30.0 
23 12.4 14.7 13% at 50 µM 39.4 
24 5.9 20.3 14% at 50 µM 46.5 
25 5.3 9.7 41% at 50 µM 2.3 
 
4.15 Miscellaneous Inhibitors 
 
 
 
Compound 26 also named AC-93253
162
 reported as potent agonist of the retinoic 
acid receptor (RAR) was found SIRT2 inhibitor with an IC50 of 6.0 µM (fluorescent 
assay) with lower potency on SIRT1 and SIRT3  (IC50 of 45.3 µM and 24.6 µM 
respectively). The treatment of Hela cells with 26 induced hyperacetylation of p53 
K382, H4  16 and α-tubulin K40 showing also cytotoxic effect on DU-145 (PC3 
human prostate cancer cell lines). 
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From a screening of an homemade library, very recently J.Wu et al.
163
 reported a 
series of benzofuran SIRT1 inhibitors of which compound 27 was the most active 
with IC50 of 2.8 µM on SIRT1 (NAD
+
 quantification assay with Ac-RHKKAc-NH2 
substrate)
164
 showing the ability to induce p53 hyperacetylation on treated MCF7 cell 
line.  
With the aim to move from pseudopeptides to small molecules Salo et al.
165
 
approached a virtual screening  on 50 000 compounds from Cambridge database that 
were docked on SIRT3. Selected compounds that showed favourable interactions in 
the substrate binding area were purchased and assayed on SIRT1-3. Compound 28 
that showed 71% and 72% inhibition on SIRT3 and SIRT1 respectively, is the most 
promising scaffold of the serie that can be used for further investagations. 
Starting from nicotinamide the physiological SIRTs inhibitor, a small array of 
nicotinamide derivatives were synthesized and screened on SIRT1-3.
166
 From the 
series only compound 29 showed an interesting inhibition profile as SIRT3 selective 
inhibitor with IC50 value of 23 µM (fluorescent assay BIOMOL drug discovery kit).  
Inauhzin was discovered through a computational screening of 500 000 compounds 
in which 50 top candidates were purchased and tested in a cell based assay for their 
ability to increase p53 level in human lung carcinoma (H460).
167
 Inauhzin was the 
most effective compound of the library showing the ability to reduce cancer cell 
growth by p53 dependent fashion with the ability to prevent p53 ubiquitylation from 
MDM2. Inauhzin induced p53 level and apoptosis in several cancer cell lines such as 
HCT116 (colon cancer), H460, A549 (lung cancer), A2780 (ovarian cancer), U87 
(glioma), U2OS and SJSA (osteosarcoma) cells. Interestingly Inauhzin did not 
induce apoptosis in p53 deficent H1299 and HCT116 cells. An extensive study that 
ranged from cellular (SIRT1 knockdown, Western blot etc.) to enzymatic assays 
proven that  Inauhzin was a non-competitive and selective SIRT1 inhibitor with an 
IC50 in enzymatic assay of 0.7-2 µM (Fluor de Lys BML AK555, AK556, AK518). 
Administration of Inauhzin 30mg/Kg via intraperitoneal significantly reduced the 
tumour weight nearly 40% in xenograft tumor derived from H460 cells without 
change body weight, behaviour and appetite of treated animals. Interestingly in p53 
null HCT116 xenografts no significant difference in apoptosis were observed 
between Inauhzin and vehicle treatments. All this findings let understand that 
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Inauhzin is a promising SIRT1 inhibitor and an optimal candidate for further 
structural investigations. 
167
 
A series of chalcone, flavone, flavanone and stilbene derivatives were synthesized 
and screened on SIRT1 by Setou and co-workers
168
 with the aim to find new SIRT1 
activators.
168
 Among the series in which none of proposed compounds showed 
activators properties, on the contrary compound 30 was found a SIRT1/3 inhibitor 
with IC50 of 40.3 µM and 48.0 µM respectively. 
From a panel of compounds previously characterized as polyglutamine aggregate 
inhibitors, AK-7 was found SIRT2 specific inhibitor.
169,170
 Pharmacokinetic studies 
demonstrates that AK-7 has brain permeable properties but limited metabolic 
stability. Furthermore AK-7 stimulated the cytoplasmic retention of SREBP-2 (sterol 
regulatory element binding protein-2) with a resulting reduction of cholesterol in 
primary striatal neurons. In 2012 Kazantsev and co-workers
171
 reported also the 
neuroprotective effect of AK-7 in Huntington’s disease mouse model in which 
improved motor function, extended survival and reduced brain a atrophy. 
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5 SIRTUIN ACTIVATORS  
 
 
In 2003, resveratrol a polyphenol found in the red wine has been proposed by 
Sinclair and co-workers as the first SIRT1 activator, after a screening conducted 
using the BIOMOL fluorescent assay.
154
 In 2004, Sinclair co-founded Sirtris 
Pharmaceuticals with Christoph Westphal which has been acquired in 2008 for $720 
million by GlaxoSmithKline. In 2005 Borra et al.
172
 investigated SIRT1 activation 
mediated by resveratrol using three different assays such as coumarin and rhodamine 
fluorescent assay, charcoal binding assay and HLPC based assay. They found that 
SIRT1 activation was independent of the peptide sequence but dependent on the 
presence of fluorophore. In 2006 Stünkel and co-workers
173
 in a HTS of 147 000 
commercially available compounds using fluorescent BIOMOL assay identified a 
small hit of potential SIRT1 activators that showed at 10 µM a % activation > 216% 
of which compound 36 was the best one. Compound 36 in a cell based adipogenesis 
differentiation assay reduced the size of intracellular cytosolic and fat deposit, 
moreover in human leukemia cell line THP-1, differently to resveratrol compound 36 
suppressed TNF-α release. 
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In search for more potent compounds in 2007 Westphal, Sinclair and co-workers
174
 
performed an HTS using a 20 aminoacid peptide substrate (Ac-Glu-Glu-Lys(biotin)-
Gly-Gln-Ser-Thr-Ser-Ser-His-Ser-Lys(Ac)-Nle-Ser-Thr-Glu-Gly–Lys(MR121 or 
Tamra)-Glu-Glu-NH2) "derived from p53" that was N-terminal linked with biotin 
and C-terminal to a fluorescent TAMRA or MR121.   
 
 
In this screening three selective SIRT1 activators more potent than resveratrol (EC1.5 
46.2 µM) named SRT1720, 2183, 1460 were identified and showed EC1.5 of 0.16 µM 
(781% activation), 0.36 µM (296 % activation), and 2.9 µM (447% activation) 
respectively (EC1.5 is the concentration required to increase enzyme activity of 
50%).
174
 The proposed mechanism of activation depended on decreasing of Km of 
SIRT1 acetylated substrate (with fluorescent tag) by promoting a more productive 
conformation that enhance catalytic activity. Isothermal titration calorimetry studies 
of SRT1460 against SIRT1 showed that binding occurred only in presence of 
acetylated substrate (with fluorescent tag). Furthermore the authors claimed that 
resveratrol, SRT1720 and related activators in diet-induced obese (DIO) and 
genetically obese mice (Lep
ob/ob
 ) improved insulin sensitivity, lowered plasma 
glucose and increased mitochondrial capacity, moreover in Zucker fa/fa rats 
(genetically obese rodents used for study insulin resistence) SRT1720 ameliorated 
gluconeogenic capacity and decreased gluconeogenesis. 
174
 In 2009 Perni
175
 (Sirtris) 
and later Toyooka
176
 and co-workers improved the medchem knowledge of "SIRT1 
activators" by developing a SAR around SRT1720 such as compound 31, moreover 
new oxazolo[4,5-b]pyridines series with related derivatives as 35
177
 were developed.  
In the same year Mai et al.
178
 prepared a small library of 1,4-dihydropyridine (DHP), 
they found that DHPs derivatives that bearing a benzyl moiety at the N1 position 
were potent SIRT1-3 activators (Fluor de Lys BIOMOL assay). Furthermore N-
benzyl-DHP compounds induced hypoacetylation on α-tubulin in U937 cells 
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(leukemia cell line), reduced the number of senescent cells in primary human 
mesenchimal stem cells (hMSC) up to 40%, and when tested in murine C2C12 
myoblast showed a dose dependent increase of mitochondrial function by a 
mechanism involving PGC-1α. 
In these years the growing interest around sirtuins captured the interest of Pfizer 
Global Research and Development, that in 2010 published an independent work
179
 in 
which the Sirtris’s compounds SRT1720, SRT2183, SRT1460 and resveratrol failed 
to activate SIRT1. In details, by using an HPLC method which separated 
deacetylated TAMRA-p53 peptide product from the acetylated substrate, Sirtris 
compounds activated SIRT1. When the same experiment was repeated using a native 
p53 substrate that lacking fluorophore or when native full length SIRT1 substrates 
such as p53 and AceCS1 were used, no activation of SIRT1 was detected. In order to 
confirm that SIRT1 activation was dependent only by flurophore tag, NMR chemical 
shift perturbation and isothermal calorimetry studies were carried out. NMR 
chemical shift perturbation detected a resonance shift of lysine acetyl (CH3) group 
only when SRT1460 was incubated with TAMRA containing substrate, moreover 
isothermal calorimetry (ITC) demonstrated that SRT1460 bound to the SIRT1-
TAMRA-peptide substrate complex but not to the SIRT1-native peptide substrate 
complex. In the same report Pacholec et al.
179
 reported that SRT1720 neither lowers 
plasma glucose nor improved mitochondrial capacity in mice fed a high fat diet. 
Furthermore the concentration used in the Sirtris experiments of 100mg/Kg for 
SRT1720 was not tolerated and resulted in the death of three of the eight mice used 
in the study. After the demonstration that resveratrol and Sirtris series were not direct 
SIRT1 activators, an in vitro selectivity profile was carried out. The compounds were 
tested at 10 µM against over 100 targets that included receptors, enzymes, kinases, 
ion channels and transporters. SRT1720, SRT2183 and SRT1460 did not activate 
SIRT1 and moreover were found highly promiscuous compounds able to exhibit > 
50% inhibition of 38 (Table 12), 14 and 20 targets on 100, while resveratrol 7 on 100 
targets. 
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Table 12. Inhibition profile of SRT1720
179
 
Target 
SRT1720  
% inhibition at 10 µM 
5-HT1B 88 
5-HT1D 99 
5-HT2A 77 
5-HT2A (agonist site) 72 
5-HT2B (agonist site) 55 
5-HT6 54 
A3 101 
alpha 2A 60 
alpha 2C 91 
D2S (agonist site) 72 
D3 56 
delta 2 (DOP) 82 
H2 69 
H4 69 
kappa (KOP) 51 
M1 100 
M2 88 
M3 90 
M4 91 
M5 81 
MC3 67 
MCH1 85 
Motilin 73 
NK1 59 
NK2 90 
sst4 75 
UT1(GPR14) 88 
Carbonic anhydrase II 58 
PDE11 66 
PDE2 81 
PDE3 59 
PDE4 54 
PDE6 51 
Ca
2+
 channel (N-type) 76 
Na
+
 channel (site 2) 63 
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Choline transporter (CHT1) 94 
DA transporter 85 
NE transporter 86 
 
Later Huber et al.
180
 (Elixir Pharmaceuticals, Inc.) reported that SRT1720 and 
SRT2183 when tested in different enzymatic assays did not activate SIRT1, and  
were effectively able to decrease the acetylation of p53 in cells but do so in cells that 
lack SIRT1, and this was attributed to inhibition of histone methyltransferase p300. 
The scientist of Sirtris in response to the Pacholec work published a paper that 
suggested a direct interaction of SRT compounds with SIRT1 and that the activation 
followed an allosteric mechanism.
181
 In order to clarify the molecular mechanism of 
Sirtuin activation by resveratrol Steegborn and co-workers
182
 solved SIRT3 and 
SIRT5 crystal structure in complex with fluorogenic substrate (FdL1) and 
piacetannol/resveratrol. In this study 0.2 mM of resveratrol and piacetannol could 
stimulate SIRT5 deacetylase activity when fluorophore modified peptide substrate 
was used, but on contrary inhibited SIRT3 dependent deacetylation. In the SIRT5 
complex resveratrol (Figure 14 A) is positioned next to the substrate in direct contact 
to the coumarin fluorophore moiety. A similar binding mode was observed also by 
piacetannol (resveratrol metabolite) in complex with SIRT3  where the scaffold 
shows direct interaction with coumarin moiety (Figure 14 B). 
 
 
Figure 14. Binding mode of Resveratrol in SIRT5 (PDB: 4HDA) and Piacetannol in 
SIRT3 (PDB: 4HD8). Substrates are colored in green. UCSF Chimera 1.7. 
 
A B 
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In the two complexes both acetylated substrates are bound in the substrate binding 
site but differently to SIRT3 complex in which substrate seems not optimal 
positioned for a productive binding, in SIRT5 complex with resveratrol the acetyl 
lysine moiety is positioned deeper in the hydrophobic binding tunnel, resulting in a 
more productive binding conformation. The direct interaction between resveratrol 
and fluorescent substrate reveals the importance of this latter in the resveratrol 
SIRT1 mediated activation. Interestingly the authors found that resveratrol activates 
SIRT5 dependent deacetylation of FdL1-peptide, Prx1-Lys197 peptidic sequence 
(SKEYFSK(Ac)QK without fluorescent tag) and full length substrate and 
Cytochrome c full length but had no effect on deacetylation of p53-Lys382 
(RHKK(Ac)LMFK. These interesting findings indicate the possibility develop sirtuin 
modulators targeting only specific substrates.
182
 
In 2013 Wu et al.
183
 proposed a new library of SIRT1 activators bearing to hydrazone 
scaffold after a screening of an in-house library using fluorescent assay with 
coumarin-labeled substrate. Compound 38 was the most promising SIRT1 activator 
of the series with EC1.5 of 0.9 µM and 624 % of activation but as well as SRT series 
when the compounds were assayed with fluorescent unlabeled substrate the 
deacetylation was not observed. 
To address the controversy of Sirtris activators, Sinclair and co-workers
184
 tested an 
alternative hypothesis in which the failure of STACs to deacetylate native substrates 
could be explained by the fact that fluorophore mimicking the characteristic of 
specific SIRT1 substrates containing bulky groups. SRT derivatives such as 
SRT1460 and compound 32 that activated SIRT1 only with AMC-tagged substrate 
were able to activate SIRT1 when PGC-1α  778 (PASTKSK(Ac)YDSLDF) and 
FOXO3a K290 (Ac-DSPSQLSK(Ac)WPGSPTS-NH2) were used as substrates. 
Kinetic analysis revealed that activation was primarily through a lowering of peptide 
Km. PGC-1α  778 and FOXO3a  290 in position +1 contain hydrophobic bulky 
residues tryptophan and tyrosine respectively and their substitution with alanine 
blocked the activation mediated by SRT1460 and 32. The finding that the ability of 
SIRT1 to be activated by resveratrol was attenuated in one mutant that substituted a 
lysine for a glutamate at position 230 whether an AMC-tagged substrate was used, 
led postulate an allosteric mechanism of SIRT1 activation. Furthermore the 
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substitution of Glu230 with a Lys or Ala attenuated the SIRT1 activation also by 117 
structural diverse activators such as compounds 33 and 34 by using Ac-
RHKK(Ac)W-NH2 as substrate.
184
 Beside the controversial SIRT1 activation 
mechanism resveratrol and STR1720 has been shown to mitigate negative effects of 
obesity and high-fat diets in both rats and mice as reviewed by Baur et al.
185
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6 AIMS OF THE STUDY  
 
1. To develop new SIRT1-3 inhibitors by designing diverse structural scaffolds. 
2. To study the structure activity relationship from a simple medicinal chemistry 
functionalization to a fragment based approach. 
3. To gain information of putative binding mode of the inhibitors by docking 
simulations. 
4. To focus the attention on SIRT1/2 inhibition in understanding the proved 
connection with cancer, thanks to collaboration with biochemists and 
biologist. 
5. To design specific molecular probes as useful tools to study the cellular 
localization of the SIRT1-3 inhibitors.  
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7 CARPROFEN ANALOGUES AS SIRTUIN INIHBITORS: ENZYME AND 
CELLULAR STUDIES 
 
Abstract: SIRT1/2 inhibitors were developed by combining chemical features of 
selisistat (EX527) and carprofen (anti-inflammatory drug). The most potent 
compound increased acetyl-p53 and acetyl-α-tubulin levels, and induced slight 
apoptosis at 50 μm in U937 cells, differently from selisistat and carprofen. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Adapted with the permission from Mellini, P.; Carafa, V.; Di Rienzo, B.; Rotili, D.; De Vita, D.; 
Cirilli, R.; Gallinella, B.; Provvisiero, D.P.; Di Maro, S.; Novellino, E.; Altucci, L.; Mai A. Chem Med 
Chem 2012, 7: 1905-1908. Copyright 2012 Wiley-VCH Verlag GmbH& Co. KGaA, Weinheim. 
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6.1 Introduction 
The nonsteroidal anti-inflammatory drug (NSAID) carprofen (Figure 1) was shown 
to activate the p38 mitogen-activated protein kinase (MAPK) pathway leading to 
increased level of p75
NTR
 protein and induction of apoptosis in prostate (PC-3 and 
DU-145) and bladder (T24) cancer cells.
186
 In this assay, carprofen was one order of 
magnitude more potent than a series of related profens. Due to the structure 
similarity between carprofen and EX-527, we prepared a small library of carprofen-
related derivatives (compounds 1-11) by retaining the carbazole core and replacing 
the carboxylic acid function with an ester, (substituted)amide, or 
(substituted)hydroxamate group (Figure 1). Compounds 1-11 were then tested 
against SIRT1 and SIRT2, and among them compound 2 was selected for evaluation 
of p53 and α–tubulin acetylation levels in the p53 wild-type breast cancer MCF-7 
cells. Moreover, the effects of the 6-chloro-9H-carbazol-2-ylamides 2, 4, 6, 9, and 11 
on cell cycle, apoptosis, and granulocytic differentiation in U937 cells have been 
explored. 
 
Figure 1. Carprofen analogues described in this study. 
 
6.2 Chemistry 
The synthetic pathway followed for preparation of 1-11 is depicted in Scheme 1. The 
methylester 1 was prepared by heating carprofen, methanol, and 96% sulphuric acid 
at reflux temperature for 5 h according to literature  (US patent: 3,896, 1451 1975). 
Reaction of carprofen with thionyl chloride led to the formation of the corresponding 
acyl chloride, which was treated with the appropriate amines to afford the 
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carboxamides 2-10. Finally, the use of iodomethane in the presence of potassium 
carbonate in dry N,N-dimethylformamide (DMF) converted 2 into the related N-
methylcarbazole derivative 11. 
 
Scheme 1
a 
 
a
(a) CH3OH, H2SO4, reflux, 5 h; (b) 1) SOCl2, reflux, 4 h, 2) amine or amine 
hydrochloride/triethylamine, CH3CN (CH3CN/CH3OH for 6-8), rt, 3 h to overnight; 
(c) CH3I, K2CO3, DMF, rt, 24 h. 
 
6.3 Results and discussion 
Carprofen and its analogues 1-11 were tested in vitro against hSIRT1 and hSIRT2 at 
the concentration of 50 µM using a fluorescent biochemical assay. Since the 
carprofen-based compounds possess a chiral center, the enantiomers of 2-(6-chloro-
9H-carbazol-2-yl)propanamide 2 and its N-methylpropanamide derivative 3 were 
isolated on a semipreparative scale by enantioselective HPLC (Figure 2) and 
submitted to individual biological investigations. As shown in Table 1, carprofen as 
well as its methyl ester 1 showed low SIRT1 inhibitory effects. Among the 6-chloro-
9H-carbazol-2-ylamides 2-11, the highest SIRT1 inhibition activities were observed 
with the primary propanamide 2 (with no differences between the two enantiomers) 
and its 9-methyl analogue 11, with 78.3 and 59.5% of inhibition at the tested dose, 
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respectively. The IC50 (inhibitory concentration 50, compound dose required to 
inhibit the enzyme activity of 50%) values for 2 and 11 against SIRT1 were 7.1 ± 0.4 
and 38.0 ± 1.9 µM, respectively. The hydroxamic acid derivative 6 is still active 
(50% of SIRT1 inhibition at 50 µM), but lost its inhibitory action when it was 
substituted at the O atom (7 and 8, O-methyl and O-benzyl hydroxamates). 
 
               
Figure 2. Typical analytical HPLC chromatogram illustrating the enantioseparation 
of 2 (top) and 3 (bottom). Column: Chiralpak AD (250 mm x 4.6 mm I.D.); eluent: 
n-hexane-ethanol 70/30 (v/v); flow rate: 1 mL/min; column temperature: 25 °C; 
detector: UV at 254 nm.  
 
The introduction of other than hydrogen substituents at the primary amide function 
of 2 induced moderate to null SIRT1 inhibition (4, bearing a 2-hydroxyethyl group, 
displayed 36% of inhibition at 50 µM, while the N-methylpropanamide 3 was totally 
inactive). The insertion of cyclic amines (morpholine (9), N-ethylsulfonylpiperazine 
(10) at the carprofen scaffold gave rise to appreciable (9, >50%) or low (10, 14%) 
SIRT1 inhibition. Against SIRT2, 2 displayed the highest inhibitory activity (59.6 % 
of inhibition at 50 µM; IC50 = 64.9 ± 5.8 µM; no stereoselectivity), followed by O-
benzyl hydroxamate 8 (54.4 % inhibition). O-Methyl hydroxamate 7, N-methyl 
derivatives 3 and 11 (IC50 = 99.7 ± 8.8 µM), and N-glycinamide 5 all exhibited 
greater than 30% inhibition of SIRT2, while the remaining compounds displayed 
only very low SIRT2 inhibitory activities at 50 µM. The SIRT1 and -2 inhibition by 
2 was functionally confirmed by functional assays through Western blot analyses. 
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The acetylation levels of p53 (MCF7 cells) a well-known SIRT1 substrate, and α–
tubulin (U937 cells) as a substrate of SIRT2 were determined after treatment of the 
cells with 50 µM 2. 
 
Table 1. hrSIRT1 and hrSIRT2 inhibition assay performed on carprofen and 1-11.
a 
 
Compd 
% inhibiting activity @ 50 µM 
SIRT1 SIRT2 
1 37.2 ± 1.5 NI
b
 
2 78.3 ± 3.9 59.6 ± 2.4 
(+)-2 79.0 ± 2.8 61.7 ± 1.8 
(-)-2 77.5 ± 3.9 59.1 ± 1.5 
3 NI
b 
34.2 ± 1.7 
(+)-3 NI
b 
23.3 ± 1.2 
(-)-3 NI
b
 34.7 ± 1.7 
4 36.0 ± 1.8 9.8 ± 0.4 
5 21.5 ± 0.9 30.5 ± 1.5 
6 50.0 ± 2.6 21.0 ± 0.8 
7 19.2 ±  1.0 39.3 ± 2.0 
8 NI 54.4 ± 2.2 
9 56.4 ± 2.8 6.0 ± 0.3 
10 14.0 ± 0.7 21.2 ± 1.1 
11 59.5 ± 3.0 33.9 ± 1.7 
carprofen 20.2 ± 1.0 13.8 ± 0.4 
EX-527 83.6 ± 4.2 45.5 ± 2.8 
 a
Values are means  SD of at least two 
experiments. 
b
NI, no inhibition at the dose 
evaluated. 
 
Selisistat (10 µM), SAHA (5 µM) and AGK-2 (50 µM), a SIRT2 selective inhibitor 
were used as reference agents. In these assays, the level of Lys 373-382 acetylated 
p53 increased after the treatment with 2, correlating with p53 activation (Figure 3A), 
and also the acetyl-α-tubulin level showed an increase after 2 treatment (Figure 3B).  
Selected SIRT inhibitors 2, 4, 6, 9, and 11 were tested at 50 µM for 30 h in the 
human U937 leukemia cell line to detect their effects on cell cycle progression and 
apoptosis (Figure 4). Carprofen and EX-527 (both at 50 µM) were added as reference 
drugs. After the treatment with EX-527 and 6, an arrest at the G1 phase was 
observed, while with 4, 9, and 11 an increase of the S phase was obtained (Figure 
4A). 
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Figure 3. Western blot analyses performed with 2 (50 µM) to detect p53 or α–
tubulin acetylation in MCF-7 cells. EX-527 (10 µM), SAHA (5 µM) and AGK-2 (50 
µM) were used as reference. 
 
With regards to apoptosis, compounds 2, 4, and 9 gave a little but significant increase 
of the DNA fragmentation (pre-G1 pick), whereas EX-527 and carprofen did not 
display any detectable effect at the tested conditions (Figure 4B). 
 
 
Figure 4. Cell cycle effect (A) and death induction (B) of 2, 4, 6, 9, and 11 (50 µM, 
30 h) in U937 cells. 
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In addition, granulocytic differentiation was evaluated for 2, 4, 6, 9, and 11 (50 µM, 
24 h) in U937 cells by the increase of % CD11c positive/propidium iodide (PI) 
negative cells (Figure 5). At the tested conditions, a significant induction of 
granulocytic differentiation was not detected. 
 
 
 Figure 5. Granulocytic differentiation induced by 2, 4, 6, 9, and 11 in U937 cells at 
50 µM for 24 h. EX-527 and carprofen (both at 50 µM) were added as reference 
drugs. 
 
6.4 Conclusions 
In conclusion, we highlighted the usefulness of the carprofen’s carbazole scaffold for 
design and synthesis of novel SIRT1/2 inhibitors. Analogously to the related EX-
527, the 2-(6-chloro-9H-carbazol-2-yl)propanamide 2 was the most efficient against 
both SIRT1 and SIRT2, since further substitutions at the carboxamide function or at 
the carbazolyl nitrogen atom yielded less potent or inactive compounds. Differently 
from EX-527 and carprofen, 2 and some analogues (4 and 9) induced to some extent 
cell death in human leukemia U937 cells when tested at 50 µM for 30 h. Further 
studies have to be addressed to improve the potency and selectivity of the novel 
compounds against sirtuins, as well as their ability to induce anticancer effects. 
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6.5 Experimental Section 
Chemistry. Chemical reagents including carprofen and solvent used in this study 
were purchased from Sigma-Aldrich Chemical Co. (Milano, Italy) and were of 
analytical grade. Melting points were determined on a Tottoli apparatus (Buchi) and 
are uncorrected. Infrared spectra were recorded on a neat compounds on a Perkin-
Elmer Spectrum-One spectrophotometer equipped with an ATR detector; band 
frequencies are reported in wave number (cm
-1
). 
1
H NMR spectra were acquired on a 
Bruker Avance 400 spectrometer operating at 400 MHz. Chemical shift values, 
unless otherwise stated, are reported as δ (ppm) relatively to TMS (tetramethylsilane) 
as internal reference; coupling constant are given in Hz. Yields of all reactions refer 
to the purified products. Mass spectra were recorded on: API-TOF Mariner by 
Perspective Biosystem (Stratford, Texas, USA), samples were injected by an Harvard 
pump using a flow rate of 5-10 µl/min, infused in the Electrospray system. Elemental 
analyses were obtained by a PE 2400 (Perkin- Elmer) analyser and have been used to 
determine purity of the described compounds, that is >95%. Analytical results are 
within ± 0.40% of the theoretical values. Analytical and semipreparative HPLC 
resolutions were performed using the commercially available 250 mm × 4.6 mm I.D. 
and 250 mm × 10 mm I.D. Chiralpak AD columns (Chiral Technologies Europe, 
Illkirch, France). 
The analytical HPLC apparatus consisted on a Dionex P580 LPG pump, an ASI-100 
T autosampler, a STH 585 column oven, a PDA-100 UV detector; data were 
acquired and processed by a Chromeleon Datasystem (Dionex Corporation, 
Sunnyvale, CA). For semipreparative separation a Perkin-Elmer (Norwalk, CT, 
USA) 200 LC pump equipped with a Rheodyne (Cotati, CA, USA) injector, a 1 mL 
sample loop, a Perkin-Elmer LC 101 oven and Waters 484 detector (Waters 
Corporation, Milford, MA, USA) were used. The signal was acquired and processed 
by Clarity software (DataApex, Prague, The Czech Republic). Specific rotations 
were measured at 589 nm by a Perkin-Elmer polarimeter model 241 equipped with a 
Na/Hg lamp. The volume of the cell was 1 mL and the optical path was 10 cm. The 
system was set at a temperature of 20 °C. 
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Synthesis of 2-(6-Chloro-9H-carbazol-2-yl)propanamide (2). A mixture of 
carprofen (0.7 g, 2.5 mmol) and thionyl chloride (8.7 mL) was heated at 45 °C for 5 
h. After this time, the obtained yellow solution was carefully evaporated under 
reduced pressure, then dry acetonitrile (20 mL) was added, and NH3(g) was bubbled 
into the solution at room temperature for 3 h. Afterwards, the solvent was evaporated 
and the remaining solid was treated with aqueous saturated potassium carbonate (10 
mL), filtered-off, and washed with water (3 × 4 mL). Finally, the solid was dried 
under reduce pressure and crystallized by acetonitrile to give pure 2 (0.6 g, 2.2 
mmol, 88.0%). Mp: 204-206 °C (from acetonitrile). IR (neat): 3402 (NHcarbazole + 
NHamide), 3176 (NHamide) 2977-2899 (CH-CH3), 1655 (C=O) cm
-1
. 
1
H NMR 
(CD3 N): δ = 9.43 (s, 1H, NH), 8.06 (d, 1H, J = 2.2 Hz, H-5), 8.0 (d, 1H, J = 8.1 Hz, 
H-4), 7.51 (d, 1H, J = 1.47 Hz, H-1), 7.46 (d, 1H, J = 8.5 Hz, H-8), 7.35 (dd, 1H, J = 
2.2, 8.5 Hz H-7) 7.18 (dd, 1H, J = 1.47, 8.1 Hz, H-3), 6.1 (s br, 1H, CONH), 5.6 (s 
br, 1H, CONH), 3.72-3.77 (q, 1H, J = 7.1 Hz, -CH-CH3), 1.46 (d, 3H, J = 7.1 Hz -
CH-CH3). Anal. (C15H13ClN2O) C, H, N. MS, m/z : 273 [M+H]. 
 
2-(6-Chloro-9H-carbazol-2-yl)-N-methylpropanamide (3). A mixture of carprofen 
(0.2 g, 0.73 mmol) and thionyl chloride (2.5 mL, strong excess) was heated at 45 °C 
for 5 h. Then the obtained yellow solution was carefully evaporated under reduced 
pressure, diluted in dry acetonitrile (10 mL) and treated with methylamine(g) bubbled 
through the solution at room temperature for 3 h. Afterwards, the solvent was 
evaporated and the remaining thick oil was treated with aqueous saturated potassium 
carbonate (5 mL) and extracted with ethyl acetate (4 × 30 mL). The combined 
organic extracts were collected, dried (sodium sulphate), and evaporated under 
vacuum to give a yellow solid, that was purified on silica gel column 
chromatography by eluting with ethyl acetate/methanol 8/2 v/v to afford pure 3 (0.09 
g, 0.32 mmol, 44 %). Mp 164-166 °C. IR (neat): 3262 (NHcarbazole + NHamide), 2969-
2934 (CH-CH3), 1623 (C=O) cm
-1
. 
1
H NMR (DMSO-d6): δ = 11.34 (s, 1H, NH), 
8.15 (d, 1H, J = 2 Hz, H-5), 8.05 (d, 1H, J = 8.1 Hz, H-4), 7.9 (q, 1H, J = 4.6 Hz, 
CONH-CH3), 7.47 (d, 1H, J = 8.6 Hz, H-8), 7.43 (s, 1H, H-1), 7.35 (dd, 1H, J = 2, 
8.6 Hz, H-7), 7.13 (d, 1H, J = 8.1 Hz, H-3), 3.69-3.75 (q, 1H, J = 6.9 Hz, -CH-CH3), 
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2.56 (d, 3H, J = 4.6 Hz, CONH-CH3), 1.40 (d, 3H, J = 6.9 Hz, -CH-CH3). Anal. 
(C16H15ClN2O) C, H, N. MS, m/z : 287 [M + H]
+
. 
 
Synthesis of 2-(6-Chloro-9H-carbazol-2-yl)-N-(2-hydroxyethyl)propanamide (4). 
A solution of 2-(6-chloro-9H-carbazol-2-yl)propanoyl chloride in dry acetonitrile (5 
mL) [prepared following the same procedure as described for 3 from carprofen (0.2 
g, 0.73 mmol) and thionyl chloride (2.5 mL, strong excess)] was added to a stirred 
solution of 2-aminoethanol (0.27 mL, 4.4 mmol) in dry acetonitrile (5 mL). After 
stirring at room temperature for 3 h the solvent was evaporated and the remaining 
solid was treated with aqueous saturated potassium carbonate (5 mL). The obtained 
suspension was extracted with ethyl acetate (3 × 35 mL), and the combined organic 
extracts were dried (sodium sulphate) and evaporated under reduced pressure. The 
solid residue was recrystallized by acetonitrile to give pure 4 (0.1 g, 0.31 mmol, 
42.5%). Mp 168-170 °C (from acetonitrile). IR (neat): 3402-3253 (NH carbazole, NH 
amide, OH), 2977-2877 (CH aliphatic), 1627 (C=O) cm
-1
. 
1
H NMR (DMSO-d6): δ = 
11.32 (s, 1H, NH), 8.15 (d, 1H, J = 1.7 Hz, H-5), 8.05 (d, 1H, J = 8.1 Hz, H-4), 7.94 
(t, 1H, J = 5.4 Hz, CONH), 7.47 (d, 1H, J = 8.6 Hz, H-8), 7.45 (s, 1H, H-1), 7.35 (dd, 
1H, J = 1.7, 8.6 Hz, H-7), 7.15 (d, 1H, J = 8.1 Hz, H-3), 4.62 (s br, 1H, -OH), 3.75-
3.81 (q, 1H, J = 6.9 Hz, CH-CH3), 3.38 (pseudo s br, 2H, -CH2-OH), 3.04-3.20 (m, 
2H, -CH2-NH), 1.41 (d, 3H, J = 6.9 Hz, -CH-CH3). Anal. (C17H17ClN2O2) C, H, N. 
MS m/z : 317 [M + H]
+
. 
 
N-(2-Amino-2-oxoethyl)-2-(6-chloro-9H-carbazol-2-yl)propanamide (5). A 
solution of 2-(6-chloro-9H-carbazol-2-yl)propanoyl chloride in dry acetonitrile (10 
mL) [prepared from carprofen (0.2 g, 0.73 mmol) and thionyl chloride (2.5 mL, 
strong excess)] was added to a suspension of glycinamide hydrochloride (0.243g, 2.2 
mmol) and triethylamine (1 mL, 7.3 mmol) in acetonitrile/methanol 8/2 v/v (25 mL), 
prepared 15 min before. The reaction was stirred at room temperature for 12 h, then 
the solvent was evaporated and the solid residue was treated with aqueous saturated 
potassium carbonate (5 mL). The obtained suspension was extracted with ethyl 
acetate (3 × 35 mL) and the combined organic extracts were dried (sodium sulphate) 
and evaporated under reduced pressure. The solid residue was recrystallized by 
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acetonitrile to give pure 5 (0.076 g, 0.23 mmol, 31.6 %). Mp 185-187°C (from 
acetonitrile). IR (neat): 3400-3193 (NH carbazole,NH I amide, NH II amide), 2977-2892 
(CH aliphatic), 1652 (C=O), 1625 (C=O)  cm
-1
. 
1
H NMR (DMSO-d6): δ = 11.32 (s, 1H, 
NH), 8.14 (d, 1H, J = 1.71 Hz, H-5), 8.07 (t, 1H, J = 5.87 Hz, -CONHCH2-) 8.05 (d, 
1H, J = 8.1 Hz, H-4), 7.47 (d, 1H, J = 8.46 Hz, H-8), 7.45 (s, 1H, H-1), 7.34 (dd, 1H, 
J = 1.71, 8.46 Hz, H-7), 7.18 (s br, 1H, -CONH2), 7.15 (d, 1H, J = 8.1 Hz, H-3), 6.97 
(s br, 1H, -CONH2), 3.88-3.83 (q, 1H, J = 7.34 Hz, -CHCH3), 3.72-3.66 (dd, 1H, J = 
5.87, 10.76 Hz, -CH2CONH2), 3.58-3.52 (dd, 1H, J = 5.87, 10.76 Hz, -CH2CONH2), 
1.41 (d, 3H, J = 7.34 Hz, -CHCH3). Anal. (C17H16ClN3O2) C, H, N. MS, m/z : 330 
[M + H]
+
. 
 
Synthesis of 2-(6-Chloro-9H-carbazol-2-yl)-N-hydroxypropanamide (6). 
Triethylamine (1 mL, 7.3 mmol) was added to a suspension of hydroxylamine 
hydrochloride (0.15 g, 2.2 mmol) in a mixture acetonitrile/methanol 9.5/0.5 v/v (10 
mL), and the resulting mixture was stirred for 20 min. Afterwards, the reaction was 
treated with a solution of 2-(6-chloro-9H-carbazol-2-yl)propanoyl chloride [from 
carprofen (0.2 g, 0.73 mmol) and thionyl chloride (2.5 mL, strong excess)] in dry 
acetonitrile (5 mL) and stirred at room temperature for 12 h. Then, the solvent was 
evaporated, the solid residue was treated with aqueous saturated potassium carbonate 
(5 mL), and the obtained suspension was extracted with ethyl acetate (3 × 35 mL). 
The combined organic extracts were dried (sodium sulphate) and evaporated under 
reduced pressure, and the solid residue was recrystallized by acetonitrile to give pure 
6 (0.13 g, 0.44 mmol, 60.2%). Mp 174-177 °C (from acetonitrile). IR (neat): 3479 
(NHcarbazole), 3334 (NHamide), 3147 (OH), 2971-2877 (CH-CH3), 1632 (C=O) cm
-1
. 
1
H 
NMR (DMSO-d6): δ = 11.33 (s, 1H, NH), 10.64 (s, 1H, CONH-OH), 8.76 (s, 1H, 
CONH-OH), 8.14 (d, 1H, J = 2 Hz, H-5), 8.04 (d, 1H, J = 8.1 Hz, H-4), 7.46 (d, 1H, 
J = 8.8 Hz, H-8), 7.44 (s, 1H, H-1), 7.33 (dd, 1H, J = 2, 8.8 Hz, H-7), 7.12 (d, 1H, J 
= 8.1 Hz, H-3), 3.55-3.60 (q, 1H, J = 7.1 Hz, -CH-CH3), 1.40 (d, 3H, J = 7.1 Hz, -
CH-CH3). Anal. (C15H13ClN2O2) C, H, N. MS, m/z : 289 [M + H]
+
. 
 
2-(6-chloro-9H-carbazol-2-yl)-N-methoxypropanamide (7). The same procedure 
reported for the synthesis of 6 was employed using carprofen and O-
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methylhydroxylamine hydrochloride. Yield, 38.5 %. Mp 219-220 °C (from 
acetonitrile). IR (neat): 3471 (NHcarbazole), 3329 (NHamide), 2970-2879 (CH-CH3), 
1638 (C=O) cm
-1
. 
1
H NMR (DMSO-d6): δ = 11.33 (s, 1H, NH), 11.22 (s, 1H, -
NHOCH3), 8.15 (d, 1H, J = 1.71 Hz, H-5), 8.06 (d, 1H, J = 8.07 Hz, H-4), 7.47 (d, 
1H, J = 8.56 Hz, H-8), 7.43 (s, 1H, H-1), 7.35 (dd, 1H, J = 1.71, 8.56 Hz, H-7), 7.12 
(d, 1H, J = 8.07 Hz, H-3) 3.55 (pseudo s, 4H, -CHCH3 + -OCH3), 1.41 (d, 3H, J = 
7.09 Hz, -CHCH3). Anal. (C16H15ClN2O2) C, H, N. MS, m/z : 303 [M + H]
+
. 
 
N-Benzyloxy-2-(6-chloro-9H-carbazol-2-yl)propanamide (8). The same procedure 
reported for the synthesis of 6 was employed using carprofen and O-
benzylhydroxylamine hydrochloride. Yield, 42.5 %. Mp 234-235 °C (from 
acetonitrile). IR (neat): 3467 (NHcarbazole), 3324 (NHamide), 2974-2883 (CH-CH3), 
1637 (C=O) cm
-1
. 
1
H NMR (DMSO-d6): δ = 11.35 (s, 1H, NH), 11.24 (s, 1H, -
NHOCH2), 8.17 (d, 1H, J = 1.96 Hz, H-5), 8.06 (d, 1H, J = 8.07 Hz, H-4), 7.48 (d, 
1H, J = 8.56 Hz, H-8), 7.44 (s, 1H, H-1), 7.36 (dd, 1H, J = 1.96, 8.56 Hz, H-7), 7.30 
(pseudo s, 5H, -Ar), 7.11 (d, 1H, J = 8.07 Hz, H-3), 4.74 (s, 2H, -OCH2), 3.61-3.55 
(q, 1H, J = 7.09 Hz, -CHCH3), 1.42 (d, 3H, J = 7.09 Hz, -CHCH3). Anal. 
(C22H19ClN2O2) C, H, N. MS, m/z : 379 [M + H]
+
. 
 
2-(6-Chloro-9H-carbazol-2-yl)-1-morpholinopropan-1-one (9). A solution of 2-
(6-chloro-9H-carbazol-2-yl)propanoyl chloride [from carprofen (0.2 g, 0.73 mmol) 
and thionyl chloride (2.5 mL, strong excess)] and triethylamine (0.20 mL, 1.46 
mmol) in dry acetonitrile (5 mL) was added to a stirred solution of morpholine (0.08 
mL, 0.87 mmol) in dry acetonitrile (5 mL). After stirring at room temperature for 12 
h the solvent was evaporated and the solid residue was treated with aqueous saturated 
potassium carbonate (5 mL). The obtained suspension was extracted with ethyl 
acetate (3 × 35 mL), dried (sodium sulphate), and evaporated under reduced pressure. 
The solid residue was purified on alumina column chromatography by eluting with 
dichloromethane/methanol 9/1 v/v and recrystallized by acetonitrile to give pure 9 
(0.11 g, 0.32 mmol, 43.8%). Mp 217-220 °C (from acetonitrile). IR (neat): 3254 
(NH), 2978-2842 (CH-CH3), 1613 (C=O) cm
-1
. 
1
H NMR (MeOD/DMSO-d6 9.5/0.5 
v/v): δ = 8.80 (d, 1H, J = 2 Hz, H-5), 8.77 (d, 1H, J = 8.1 Hz, H-4), 8.18 (d, 1H, J = 
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8.6 Hz, H-8), 8.10 (s, 1H, H-1), 8.08 (dd, 1H, J = 2, 8.6 Hz, H-7), 7.83 (d, 1H, J = 
8.1 Hz, H-3), 4.92-4.97 (q, 1H, J= 6.6 Hz, -CH-CH3), 4.06-4.39 (m, 7H, 
morpholine), 3.81 (m, 1H, morpholine), 2.17 (d, 3H, J = 6.6 Hz, -CH-CH3). Anal. 
(C19H19ClN2O2) C, H, N. MS, m/z 343 [M + H]
+
. 
 
2-(6-Chloro-9H-carbazol-2-yl)-1-[4-(ethylsulfonyl)piperazin-1-yl]propan-1-one 
(10). A solution of 2-(6-chloro-9H-carbazol-2-yl)propanoyl chloride [from carprofen 
(0.2 g, 0.73 mmol) and thionyl chloride (2.5 mL, strong excess)] in dry acetonitrile 
(10 mL) was added to a stirred solution of 1-(ethylsulfonyl)piperazine (0.65 g, 9.65 
mmol) in dry acetonitrile (10 mL). After stirring at room temperature for 12 h, the 
solvent was evaporated and the remaining solid was treated with aqueous saturated 
potassium carbonate (5 mL). The obtained suspension was extracted with ethyl 
acetate (3 × 30 mL), dried (sodium sulphate), and evaporated under reduced pressure. 
The obtained solid was washed with water (2 × 3 mL), dried and purified using PLC 
(Preparative Layer Plates) Silica gel 20 × 20 cm by eluting with ethyl 
acetate/cyclohexane/methanol 6/3/1 v/v/v to give pure 10 (0.135 g, 0.31 mmol, 
42.5%). Mp 123-125 °C (from cyclohexane). IR (neat): 3461 (NHcarbazole), 3329 
(NHamide), 2979-2889 (CH aliphatic), 1628 (C=O), 1338 (S=O) cm
-1
. 
1
H NMR 
(CD3 N): δ = 9.42 (s br, 1H, NH), 8.05 (d, 1H, J = 1.96 Hz, H-5), 8.02 (d, 1H, J = 
8.07 Hz, H-4), 7.47 (d, 1H, J = 8.56 Hz, H-8), 7.39 (s, 1H, H-1), 7.36 (dd, 1H, J = 
1.96, 8.56 Hz, H-7), 7.12 (d, 1H, J = 8.07 Hz, H-3), 4.18-4.13 (q, 1H, J = 6.85 Hz, -
CH-CH3), 3.77-3.71 (m, 1H, piperazine), 3.57-3.50 (m, 2H, piperazine), 3.44-3.39 
(m, 1H, piperazine), 3.25-3.17 (m, 1H, piperazine), 3.07-3.02 (m, 2H, piperazine), 
2.88-2.73 (q, 2H, J = 7.34 Hz, -CH2-CH3), 2.55-2.49 (m, 1H, piperazine), 1.41 (d, 
3H, J = 6.85 Hz, -CH-CH3), 1.12 (t, 3H, J = 7.34 Hz -CH2CH3). Anal. 
(C21H24ClN3O3S) C, H, N. MS, m/z : 434 [M + H]
+
. 
 
Synthesis of 2-(6-Chloro-9-methyl-9H-carbazol-2-yl)propanamide (11). Dry 
potassium carbonate (0.3 g, 2.1 mmol) was added to a solution of 2-(6-chloro-9H-
carbazol-2-yl)propanamide 2 (0.15 g, 0.55 mmol) in N,N-dimethylformamide (3 mL) 
and the suspension was stirred at room temperature for 20 min. Afterwards, methyl 
iodide (0.13 mL, 2.1 mmol) was added dropwise and the reaction was stirred at room 
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temperature for 24 h. Then water (20 mL) was added to the reaction, and the 
obtained suspension was extracted with ethyl acetate (3 × 50 mL), dried (Na2SO4), 
and evaporated under reduced pressure. The thick oil was washed with petroleum 
ether (4 × 3 mL), and the obtained yellow solid was purified on silica gel column 
chromatography eluting with a mixture of dichloromethane/methanol 9/1 to afford 
pure 3 (0.05 g, 0.17 mmol, 32.0 %). Mp 176-179 °C. IR (neat): 3403, 3191 (-NH2), 
2977-2929 (CH-CH3), 1651 (C=O) cm
-1
. 
1
H NMR (DMSO-d6): δ = 8.20 (d, 1H, J= 
1.7 Hz, H-5), 8.11 (d, 1H, J= 8.1 Hz, H-4), 7.62 (d, 1H, J= 8.6 Hz, H-8), 7.52 (s, 1H, 
H-1), 7.44 (dd, 1H, J= 1.7, 8.6 Hz, H-7), 7.37 (s br, 1H, CONH), 7.21 (d, 1H, J= 8.1 
Hz, H-3), 6.82 (s br, 1H, CONH), 3.86 (s, 3H, CH3), 3.75-3.80 (q, 1H, J= 6.8 Hz, -
CH-CH3), 1.44 (d, 3H, J= 6.8 Hz, -CH-CH3). Anal. (C16H15ClN2O) C, H, N. MS, m/z 
: 287 [M+H]. 
 
Enantioseparation of 2 and 3 pure enantiomers. The direct HPLC 
enantioseparation of the compounds 2 and 3 was achieved on the polysaccharide-
type Chiralpak AD chiral stationary phase (CSP) using the mixture n-hexane/ethanol 
70/30 (v/v) as eluent. The enantiomeric forms were isolated on a semipreparative 
scale with high yields (> 90%) and enantiomeric purity (enantiomeric excess > 99%). 
The specific rotations of the enantiomers of 2 and 3 in ethanol solution were: (+)-2: + 
11 (c = 0.1, EtOH), first eluted enantiomer; (-)-2: - 10 (c = 0.1, EtOH), second eluted 
enantiomer; (+)-3: + 28 (c = 0.1, EtOH) first eluted enantiomer; (-)-3: -27 (c = 0.1, 
EtOH), second eluted enantiomer. 
 
 
Elemental analyses for compounds 2-10. 
 
cpd MW 
calculated, % found, % 
C H N C H N 
2 272.73 66.06 4.80 10.27 66.12 4.86 9.96 
3 286.76 67.02 5.27 9.77 66.91 5.19 9.92 
4 316.78 64.46 5.41 8.84 64.77 5.52 8.68 
5 329.78 61.91 4.89 12.74 62.09 4.97 12.56 
6 288.73 62.40 4.54 9.70 62.63 4.49 9.46 
7 302.76 63.47 4.99 9.25 63.61 5.09 9.11 
8 378.85 69.75 5.05 7.39 69.94 5.17 7.13 
9 342.82 66.57 5.59 8.17 66.78 5.62 7.91 
10 433.95 58.12 5.57 9.68 57.96 5.49 9.84 
11 286.76 67.02 5.27 9.77 67.21 5.36 9.52 
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SIRT1/2 Inhibition Assay. The SIRT activity assay was performed using human 
recombinant SIRT1 and SIRT2 produced in E. coli. Compounds were tested using a 
modified Fluor de Lys fluorescence-based assay kit (AK-555, AK-556 Biomol). The 
assay procedure has two steps: in the first part the SIRT1/2 substrate, an acetylated 
Lys side chain comprising amino acids 379-382 (Arg-His-Lys-Lys(Ac)) (for SIRT1 
assay) or 317-320 (Gln-Pro-Lys-Lys(Ac)) (for SIRT2 assay) of human p53 
conjugated with aminomethylcoumarin is deacetylated during incubation at 37 °C for 
1 h by SIRT1 or SIRT2 in the presence of NAD
+
 and the tested compounds. The 
second stage is initiated by the addition of the Developer II, including nicotinamide 
(NAM), a sirtuin inhibitor that stops the SIRT1/2 activity, and the fluorescent signal 
is produced. The fluorescence was measured on a fluorometric reader (Inphinite 200 
TECAN) with excitation set at 360 nm and emission detection set at 460 nm. 
Experiments on the SIRT1 and 2 inhibition have been performed in triplicate. IC50 
data were analyzed using GraphPad Prism Software. 
 
Cell lines. Human leukemia cell lines (U937) was grown in RPMI 1640 medium 
(EuroClone) supplemented with 10% heat-inactivated FBS (Sigma Aldrich), 1% 
glutamine (EuroClone), 1% penicillin/streptomycin (EuroClone) and 0.1% 
gentamycin (EuroClone), and kept at 37°C in air and 5% CO2. Conversely, adherent 
MCF7 (human breast cancer) cells were grown in D-MEM medium (EuroClone) 
supplemented with the same components described above and in the same incubation 
settings. 
 
Western Blot analyses of p53 and α–tubulin acetylation. To detect acetylation of 
p53 (K373/382) and -tubulin, 50 and 20  of total protein extracts (MCF7 cells), 
respectively, were separated on a 10% polyacrylamide gels and blotted for 2 h at 
70V. Western blots were shown for acetylated p53 (K373/382) (Upstate, dilution 
1:500) and -tubulin (Sigma, dilution 1:1000). Total ERKs (Santa Cruz, 
dilution1:1000) represent equal loading. 
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Cell Cycle and Cell death Analysis on U937 cells. Cells were collected and 
resuspended in L of hypotonic buffer (0.1% Triton X-100, 0.1% sodium citrate, 
50 g/mL propidium iodide (PI)). Then the cells were incubated in the dark for 30 
min. Samples were acquired on a FACS-Calibur flow cytometer using the Cell Quest 
software (Becton Dickinson). Analyses were performed with standard procedures 
using ModFit LT version3 software (Verity). All experiment were performed in 
triplicate. 
 
Granulocytic differentiation on human leukemia U937 cells. Cells were 
resuspended in L phycoerythrine-conjugated CD11c (CD11c-PE). Control 
samples were incubated with L of PE conjugated mouse IgG1. The incubations 
were performed at 4 °C in dark for 30 min. After cells were collected, washed in 
phosphate buffered saline (PBS), and resuspended in L of PBS containing 
propidium iodide (PI) (0.25 g/mL). Samples were analyzed by FACS with Cell 
Quest technology (Becton Dikinson). PI positive cells have been excluded from the 
analysis. 
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7 DISCOVERY OF SALERMIDE-RELATED SIRTUIN INHIBITORS: 
BINDING MODE STUDIES AND ANTIPROLIFERATIVE EFFECTS IN 
CANCER CELLS INCLUDING CANCER STEM CELLS 
 
Abstract: Chemical manipulations performed on sirtinol (1a) led to a series of 
SIRT1/2 inhibitors (2-6) in some cases more potent than 1a mainly against SIRT1. 
The higher inhibitory activity showed by 4b with respect to 1a has been rationalized 
through docking studies. Most of the 2-6 derivatives were assayed against different 
cancer cell lines such as U937, MOLT4, MDA-MB-231, RKO cancer cell lines and 
on colorectal carcinoma and glioblastoma multiforme cancer stem cells (CSCs) in 
which showed antiproliferative effects.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* Adapted with the permission from: Rotili, D. Tarantino, D.  Nebbioso, A.  Paolini,  .  Huidobro,  .  
 ara,  .  Mellini, P.   enoci, A.  Pezzi, R.   otta,  .   ahtela- akkonen, M.  Poso, A.  Steink hler, 
C.; Gallinari, P.; De Maria, R.; Fraga, M.; Esteller, M.; Altucci, L.; Mai A. J Med Chem 2012, 55: 
10937-10947. Copyright 2012 American Chemical Society. 
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7.1 Introduction 
Among the SIRT1/2 inhibitors described so far, sirtinol (1a), cambinol, JGB1741 
and MC2141 sharing the same 2-hydroxy-1-naphtyl pharmacophore moiety (Figure 
1) were found active antiproliferative agents alone or in combination with other 
chemotherapeutics, in a variety of cancer cells.
67, 72,78,112,140,141,144,147
 
 
 
 
Figure 1. Known SIRT1/2 inhibitors sharing the 2-hydroxy-1-napthyl 
pharmacophore moiety. 
 
In 2005 we reported some sirtinol analogues and among them , only compounds 
bearing the N-(1-phenylethyl)amino side chain shifted from -ortho to -meta or -para 
position of the benzene ring showed improved activity against SIRT1 and SIRT2.
138
 
Pursuing our research on Sirtuin modulators we designed a small library of sirtinol 
derivatives by replacing the benzoyl amide linkage of the prototype with other 
bioisosteric groups such as retromide, sulphonamide, thiomethyl, sulfinylmethyl and 
sulfonylmethyl and bearing the 1-phenylethyl side chain with -ortho, -meta and -
para regiochemistry. The compounds 2-6 were tested in vitro and their potential 
binding mode on SIRT1 and SIRT2 was studied (for detailed results concerning 
anticancer activity of 2-6 see Rotili et al. 2012). 
 
7.2 Results and discussion 
The (2-hydroxy-1-naphthylmethylene)amino-N-phenyl derivatives 2-6 were tested in 
vitro against hrSIRT1 and hrSIRT2 using a fluorogenic substrate and NAD
+
 (Table 
1).  IC50 values of 1a, 1b, 1c against hrSIRT1 and hrSIRT2 were added for 
comparison. 
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Table 1. IC50 values of 1-6 against SIRT1 and SIRT2. 
  IC50 µM 
Compd  SIRT1 SIRT2 
1a 
(Sirtinol) 
 
 
123.3 ± 14.2 45.9 ± 6.4 
1b 
 
58.6 ± 8.1 34.5 ± 4.0 
1c 
 
48.1 ± 5.2 29.9 ± 4.1 
2a 
 
55.0 ± 5.3 75.5 ± 4.5 
2b 
 
42.8 ± 7.9 25.0 ± 3.8 
2c 
 
40.9 ± 6.1 37.3 ± 9.5 
3a 
 
90.8 ± 10.6 57.0 ± 0.4 
3b 
 
55.6 ± 8.1 61.6 ± 6.5 
3c 
 
 
44.1 ± 6.2 22.6 ± 4.2 
4a 
 
55.1 ± 5.0 48.0 ± 9.0 
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4b 
 
40.3 ± 8.1 19.2 ± 4.5 
4c 
 
 
45.5 ± 7.0 
 
   28.2 ± 3.0 
5a 
 
44.9 ± 5.6 33.0 ± 6.0 
5b 
 
67.3 ± 8.2 43.0 ± 8.1 
5c 
 
56.3 ± 4.6 48.2 ± 9.5 
6a 
 
64.0 ± 8.8 24.2 ± 7.7 
6b 
 
65.8 ± 6.2 48.9 ± 6.9 
6c 
 
74.9 ± 7.2 57.5 ± 5.4 
 
Against hrSIRT1, compounds 2-6 showed quite similar inhibiting activity with IC50 
values ranging from 40.3 to 67.3 µM, regardless to the nature or regiochemistry of 
the side chain. The only exceptions were 3a and 6c, which displayed lower potency, 
whereas the 4-phenylpropionamide derivative 2c and the (2-phenylpropyl)thio 
derivative 4b were the most efficient inhibitors, with IC50 values of 40.9 and 40.3 
µM, respectively. In comparison with the reference compounds, the majority of 2-6 
 83 
 
displayed higher inhibition than 1a and similar as 1b and 1c. In general terms, in the 
SIRT2 assay the tested compounds 2-6 exhibited similar or higher inhibiting 
activities respect to those against SIRT1, with some exceptions (2a and 3b). Among 
compounds substituted with 2-phenylpropionamide function, the meta analogue 2b 
(salermide) displayed the highest activity (IC50 = 25.0 µM), while in the 3 series the 
4-N-(1-phenylethyl)benzenesulphonamide 3c was the most efficient (IC50 = 22.6 
µM). In the (2-phenylpropyl)thio-substituted series, the highest hrSIRT2 inhibiting 
activity was shown by the meta (4b) and the para (4c) analogues, 4b being the most 
potent (IC50 = 19.2 µM) among all the tested derivatives. Similar potency against 
SIRT2 was also observed with the 2-(2-phenylpropyl)sulfonyl derivative 6a (IC50 = 
24.2 µM). 
The structural variability of the compounds with meta, orto, and para substituents 
offers the possibility of different interaction in the binding site, that could reflect in 
some cases in a divergence in the activity on SIRT1 and SIRT2. In order to study the 
effect of the substution of the (2-hydroxy-1-naphthylmethylene)amino-N-phenyl 
derivatives 2-6 on the binding in the NAD
+
 pocket, 2-6 were docked to SIRT1 and 
SIRT2 homology models.  The aim of the docking simulation was investigate about 
the hypothesis that the sirtinols derivatives were able to bind the SIRT1, 2 NAD
+
 
binding pockets (A, B, C) (Figure 2).  
 
 
Figure 2. NAD
+
 binding site overview. SIRT1 (left), SIRT2 (right) homology 
models. 
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Our docking simulations showed that in the most representative cases (1a, 1c, 2b, 4b, 
4c, 6a) in which there were a little but significant differences in the activity on 
SIRT1, 2 there is the same coherence in the binding mode (see pictures below).  
In details compound 1a in SIRT1 has H-bond between the carbonyl of the amide 
function with Arg274 and an CH-π interaction with Asp289, but is clearly evident 
that the β-naphthol ring is completely out of the binding site. While within SIRT2 
compound 1a has two H-bonds between -OH of the β-naphthol ring with Thr262 and 
Ser98 increasing the affinity of binding compared to SIRT1, moreover two favorable 
CH-π interaction with Asp95 and Ser263. The β-naphthol ring in this case is placed 
in the B-pocket (blue) and the phenyl ring was oriented towards the C-pocket 
(yellow). 
 
 
Figure 3. Docking poses for 1a and 1c in SIRT1 (left) and SIRT2 (right). 
 
Compound 1c in SIRT1 has H-bond between -OH of the β-naphthol ring with Ser249 
and an CH-π interaction with Ala70. The molecule adopt an elongated conformation 
from  B to A pocket with different solvent exposed areas. In SIRT2, 1c 
1a  1a  
1c  1c  
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has H-bond between –OH of the β-naphthol ring with His187 and two favorable CH-
π interaction with Asp95, Ser263. Also in this case an elongated conformation of the 
molecule can be seen but with a diverse orientation from A to C pocket in which the 
phenyl ring is placed near the Ac-Lys  binding site with a potential improvement of 
binding affinity. Compound 2b in SIRT1 has two H-bonds between -OH of the β-
naphthol ring with Ser249 and Ser250, with the naphthol ring placed in the B pocket 
(Figure 4, blue). Nevertheless in SIRT2 2b is well positioned in the NAD
+
 binding 
site in which resulted stabilized by H-bond between the carbonyl of the amide 
function with His187; the phenyl ring is placed in the B pocket (blue) but should be 
noteworthy that in this case the β-naphthol ring is close to the Ac-Lys binding site 
(Figure 4). 
 
 
Figure 4. Docking poses for 2b and 4b in SIRT1 (left) and SIRT2 (right). 
 
In SIRT1, 4b does not have a perfect fit in the binding pose because there are 
different exposed area (Figure 4). In SIRT2, 4b is binding from A to C pocket 
(Figure 4, right) and shows a correct fit in NAD
+
 binding site. This might be due to 
2b  2b  
4b  4b  
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openness of C-pocket in SIRT2 and to favorable interaction in the C-pocket between 
Phe96 and His187 established by 4b in SIRT2 (Figure 4). 
In SIRT1, compound 4c does not show an optimal binding mode because of clashed 
areas with protein surface but 4c has H-bonds between–OH of the β-naphthol ring 
with Ser249 and Ser250 and an additional H-π interaction with Ala70 that may help 
the binding stabilization (Figure 5). Nevertheless in SIRT2 4c has H-bond interaction 
with Asp95 in the B-pocket and H-π interaction, moreover H-bond between the 
sulfur of the thioether function and His187  could participate to stabilize the binding 
mode (Figure 5). 
 
Figure 5. Docking poses for 4c and 6a in SIRT1 (left) and SIRT2 (right). 
 
In SIRT1, compound 6a binds from B to A pocket (Figure 5 blue-green) and shows 
H-bond between the sulphonyl and Asn273 and H-π interaction with Arg274. The 
naphthol ring is placed in the B-pocket (blue) and the phenyl ring completely out of 
the binding site. In SIRT2, the binding mode showed by 6a seems well stabilized by 
H-bond between the sulphonyl and His 187 and an H-π interaction of the β-naphthol 
with Ala85. The β-naphthol is placed in the B-pocket and the rest of the molecular 
4c  4c  
6a  6a  
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moiety, fit inside of the C-pocket with the phenyl ring oriented towards the Ac-Lys 
binding site (Figure 5). 
  
7.3 Conclusions 
The conclusion from docking studies is that the most potent compounds show a 
common binding mode for SIRT2: the β-naphthol ring has enough space to fit in B-
pocket and the rest of the scaffold can enter into the C-pocket. On the contrary, in the 
case of SIRT1, there is a less space in B-pocket, the scaffold has not optimal fit in it, 
and the C-pocket is practically empty, so that only suboptimal complementary 
binding is achieved in SIRT1. 
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7.4 Experimental Section 
SIRT1/2 Inhibition Assay. The SIRT activity assay was performed using human 
recombinant SIRT1 and SIRT2 produced in E. coli. Compounds were tested using a 
modified Fluor de Lys fluorescence-based assay kit (AK-555, AK-556 BIOMOL). 
The assay procedure has two steps: in the first part the SIRT1/2 substrate, an 
acetylated Lys side chain comprising amino acids 379-382 (Arg-His-Lys-Lys(Ac)) 
(for SIRT1 assay) or 317-320 (Gln-Pro-Lys-Lys(Ac)) (for SIRT2 assay) of human 
p53 conjugated with aminomethylcoumarin is deacetylated during incubation at 37 
°C for 1 h by SIRT1 or SIRT2 in the presence of NAD
+
 and the tested compounds. 
The second stage is initiated by the addition of the Developer II, including 
nicotinamide (NAM), a sirtuin inhibitor that stops the SIRT1/2 activity, and the 
fluorescent signal is produced. The fluorescence was measured on a fluorometric 
reader (Inphinite 200 TECAN) with excitation set at 360 nm and emission detection 
set at 460 nm. Experiments on the SIRT1 and 2 inhibition have been performed in 
triplicate. IC50 data were analyzed using GraphPad Prism Software. 
 
Molecular Modelling. No crystal structure is available for SIRT1, and for SIRT2 
there is only apo structure available. Therefore, we were forced to build also 
homology model for SIRT2 in bioactive conformation. The template used for the 
homology model of SIRT1 and SIRT2 was the crystal structure of Sir2 homolog 
from Archeaoglobus fulgidus (Sir2-Af1) with NAD
+ 
(PDB code: 1ici). The 
homology models of SIRT1 and SIRT2 were built using FUGUE and ORCHESTRA 
in SYBYL 1.3 (SYBYL-X 1.3, Tripos International, 1699 South Hanley Rd., St. 
Louis, Missouri, 63144, USA) .The side chains were optimized by geometry 
optimization with Amber99 using MOE 2010.10 (Molecular Operating Environment 
(MOE) version 2010.10; Chemical Computing Group Inc.: Montreal, Canada). The 
ligand structures were built with MOE software and minimized using MMFF94 force 
field until a rmsd gradient of 0.05 kcal mol
-1
Å
-1
 was reached. The protein geometry 
was evaluated by Ramachandran plot and Verify 3D (Veryfy 3D Structure evaluation 
server: http://nihserver.mbi.ucla.edu/Verify_3D/). The docking simulations were 
performed in the NAD
+
 binding site of the homology models SIRT1 and -2 using 
MOE. Default values were used for all docking settings. The best ranked poses of 
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each docked ligand was included in the analysis. The docking results were visually 
inspected. The figures were prepared using MOE (version 2010.10). 
SIRT1 homology model. SIRT1 Homo Sapiens sequence 555aa, was downloaded 
from NCBI (National Center for Biotechnology Information) AAH12499.1, saved as 
FASTA file and used as input for run FUGUE (SYBYL  1.3.11283). Sir2 homolog, 
from Archeaoglobus fulgidus (Sir2-Af1, PDB :1ICI) complexed with NAD
+ 1
  
(resolution : 2.10 Å), was used as template for align the sequences
187
 (see below) and 
built the SIRT1 homology model in bioactive conformation. After the alignement 
with  FUGUE, the SIRT1 homology was built using ORCHESTRA with a schematic 
workflow described below : 
1. Building of the Conserved Regions (SCRs) 
2. Search and Remodel Loops,  in the model there are three missing loops: 
 Met1 : Pro40 ; Arg90 : Asp100 ; Tyr305 : Ser555 because the template area 
is missing. 
3. Add and modeling Side-chains : 
 Clashes and Side-chains with abnormal conformation were modeled manually 
considering the template’s Side-chains orientation. 
4. Structure analysis : 
 Fixed Termini Treatment 
 Hydrogen and Charges were added 
5. Geometry Optimization : 
 With Amber99 as Force Field, gradient 0.05 and Homo LP were 
adjusted.  
6. Examination of the Model : 
 266 Res, 289 Missing Res, 2 Gaps, 0 Missing Side-chains 
 Outlier (all are out of the NAD+ binding site) Ala89, Leu91, Pro96, Pro99, 
Pro121, Pro131, Cys134 see Ramachandran plot  (Figure 6). 
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Figure 6. SIRT1 homology model Ramachandran plot.
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Alignement SIRT1-Sir2Af1
187
template (ORCHESTRA, SYBYL)
 
1      11    21   31       41 
query    MIGTDPRTILKDLLPETIPPPELDDMTLWQIVINILSEPPKRKKRKDINT 
model_s9_1    ---------------------------------------PKRKKRKDINT 
hs1icia    --------------------------------------GSHHHHHHGSHM 
51      61    71        81        91 
query    IEDAVKLLQECKKIIVLTGAGVSVSCGIPDFRSRDGIYARLAVDFPDLPD 
model_s9_1    IEDAVKLLQECKKIIVLTGAGVSVSCGIPDFRSRDGIYARLAVDFPDLPD 
hs1icia    DEKLLKTIAESKYLVALTGAGVSAESGIPTFRGKDGLWNRY--------R 
 
101       111       121       131       141 
query    PQAMFDIEYFRKDPRPFFKFAKEIYPGQF--QPSLCHKFIALSDKEGKLL 
model_s9_1    PQAMFDIEYFRKDPRPFFKFAKEIYPGQF--QPSLCHKFIALSDKEGKLL 
hs1icia    PEELANPQAFAKDPEKVWKWYAWRMEKVFNAQPNKAHQAFAELERLGVLK 
 
151       161       171       181       191 
query    RNYTQNIDTLEQVAGIQRIIQCHGSFATASCLICKYKVDCEAVRGALFSQ 
model_s9_1    RNYTQNIDTLEQVAGIQRIIQCHGSFATASCLICKYKVDCEAVRGALFSQ 
hs1icia    CLITQNVDDLHERAGSRNVIHLHGSLRVVRCTSCNNSFEVESAPKI---P 
 
201       211       221       231       241 
query    VVPRCPRCPADEPLAIMKPEIVFFGENLPEQFHRAMKYDKDEVDLLIVIG 
model_s9_1    VVPRCPRCPADEPLAIMKPEIVFFGENLPEQFHRAMKYDKDEVDLLIVIG 
hs1icia    PLPKCDKCG-----SLLRPGVVWFGEMLPPDVLDRAMREVERADVIIVAG 
 
251      261       271       281       291 
query    SSLKVRPVALIPSSIP-HEVPQILINREPLPHLH-FDVELLGDCDVIINE 
model_s9_1    SSLKVRPVALIPSSIP-HEVPQILINREPLPHLH-FDVELLGDCDVIINE 
hs1icia    TSAVVQPAASLPLIVKQRGGAIIEINPDETPLTPIADYSLRGKAGEVMDE 
 
301       311       321      331       341 
query    LCHRLGGEYAKLCCNPVKLSEITEKPPRTQKELAYLSELPPTPLHVSEDS 
model_s9_1    LCHRLGGEY----------------------------------------- 
hs1icia    LVRHVRKALS---------------------------------------- 
 
351       361       371      381       391 
query    SSPERTSPPDSSVIVTLLDQAAKSNDDLDVSESKGCMEEKPQEVQTSRNV 
model_s9_1    -------------------------------------------------- 
hs1icia    -------------------------------------------------- 
 
401       411       421      431       441 
query    ESIAEQMENPDLKNVGSSTGEKNERTSVAGTVRKCWPNRVAKEQISRRLD 
model_s9_1    -------------------------------------------------- 
hs1icia    -------------------------------------------------- 
 
451       461       471      481       491 
query    GNQYLFLPPNRYIFHGAEVYSDSEDDVLSSSSCGSNSDSGTCQSPSLEEP 
model_s9_1    -------------------------------------------------- 
hs1icia    -------------------------------------------------- 
 
501       511       521      531       541 
query    MEDESEIEEFYNGLEDEPDVPERAGGAGFGTDGDDQEAINEAISVKQEVT 
model_s9_1    -------------------------------------------------- 
hs1icia    -------------------------------------------------- 
 
551 
query    DMNYPSNKS 
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model_s9_1    --------- 
hs1icia    --------- 
Joy Annotation: 
alpha helix red x 
beta strand blue x 
3 - 10 helix maroon x 
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SIRT2 homology model. SIRT2 Homo Sapiens sequence 352aa, was downloaded 
from NCBI (National Center for Biotechnology Information) AAK51133.1, saved as 
FASTA file and used as input for run FUGUE (SYBYL  1.3.11283). Sir2 homolog,  
from Archeaoglobus fulgidus (Sir2-Af1, PDB : 1iCi , %ID 26.5) complexed with 
NAD
+ 1
 (resolution : 2.10 Å), was used as template for align the sequences and built 
the SIRT2 homology model in bioactive conformation. After the alignement
188
 with  
FUGUE (see below), the SIRT2 homology was built using ORCHESTRA with a 
schematic workflow described below : 
It is the same described for SIRT1. 
Examination of the Model : 
• 263 Res, 89 Missing Res, 3 Gaps, 0 Missing Side-chains 
• Outlier (all are out of the NAD+ binding site) Thr64, Ala80, Ile81, Ile138, 
Thr243, Pro131, see Ramachandran plot  (Figure 7). 
 
 
Figure 7. SIRT2 homology model Ramachandran plot.
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Alignement SIRT2-model-Sir2Af1
188
 template (ORCHESTRA, SYBYL) 
 
1     11   21   31      41 
query   MDFLRNLFSQTLSLGSQKERLLDELTLEGVARYMQSERCRRVICLVGAGI  
model_s10_1  ---------------SQKERLLDELTLEGVARYMQSERCRRVICLVGAGI 
hs1icia   --------------GSHHHHHHGSHMDEKLLKTIA--ESKYLVALTGAGV 
 
51     61        71         81       91 
query   STSAGIPDFRSPSTGLYDNLEKYHLPYPEAIFEISYFKKHPEPFFALAKE  
model_s10_1  STSAGIPDFRSPSTGLYDNLEKYHLPYPEAIFEISYFKKHPEPFFALAKE 
hs1icia   SAESGIPTFRGK-DGLWNRYR------PEELANPQAFAKDPEKVWKWYAW 
 
101     111   121   131      141 
query   LYPGQF--KPTICHYFMRLLKDKGLLLRCYTQNIDTLERIAGLEQEDLVE  
model_s10_1  LYPGQF--KPTICHYFMRLLKDKGLLLRCYTQNIDTLERIAGLEQEDLVE 
hs1icia   RMEKVFNAQPNKAHQAFAELERLGVLKCLITQNVDDLHERAG--SRNVIH 
 
151     161   171   181      191 
query   AHGTFYTSHCVSASCRHEYPLSWMKEKIFSEVTPKCEDCQSLVKPDIVFF  
model_s10_1  AHGTFYTSHCVSASCRHEYPLSWMKEKIFSEVTPKCEDCQSLVKPDIVFF 
hs1icia   LHGSLRVVRCTSCNNSFEVE-----SAPKIPPLPKCDKCGSLLRPGVVWF 
 
201     211   221   231      241 
query   GESLPARFFSCMQSDFLKVDLLLVMGTSLQVQPFASLISKAPLSTPRLLI  
model_s10_1  GESLPARFFSCMQSDFLKVDLLLVMGTSLQVQPFASLISKAPLSTPRLLI 
hs1icia   GEMLPPDVLDRAMREVERADVIIVAGTSAVVQPAASLPLIVKQRGGAIIE 
 
251     261       271        281      291 
query   -NKEKAGQSDPFLGMIMGLGGGMDFDSKKAYRDVAWLGECDQGCLALAEL  
model_s10_1  -NKEKAGQSD------------------------AWLGECDQGCLALAEL 
hs1icia   INPDETPLTPIA--------------------DYSLRGKAGEVMDELVRH 
 
301      311       321        331      341 
query   LGWKKELEDLVRREHASIDAQSGAGVPNPSTSASPKKSPPPAKDEARTTE  
model_s10_1  LGWKK--------------------------------------------- 
hs1icia   VRKALS-------------------------------------------- 
 
351 
query   REKPQ 
model_s10_1  ----- 
hs1icia   ----- 
 
Joy Annotation: 
alpha helix red x 
beta strand blue x 
3 - 10 helix maroon x 
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8 SCREEN OF PSEUDOPEPTIDIC INHIBITORS OF HUMAN SIRTUINS 1-
3: TWO LEAD COMPOUNDS WITH ANTIPROLIFERATIVE EFFECTS IN 
CANCER CELLS 
QSAR MODELING IN THE DESIGN OF PSEUDOPEPTIDIC SIRT1 
INHIBITORS 
 
Abstract: In the past few years sirtuins have gained growing attention for their 
involvement in many biological processes such as cellular metabolism, apoptosis, 
aging and inflammation. In this paper, we report the synthesis of a library of 
thioacetylated pseudopeptides that were screened against human sirtuins 1-3 to 
reveal their in vitro inhibition activities. Molecular modeling studies were performed 
to acquire data about the binding modes of the inhibitors. Three sirtuin inhibitors 
were subjected to cellular studies and all of them showed an increase in acetylation 
of Lys382 of p53 after DNA damage. Furthermore, two of the compounds were able 
to inhibit both A549 lung carcinoma and MCF-7 breast carcinoma cell growth in 
micromolar concentration with the ability to arrest cancer cell cycle in the G1 phase.  
 
 
 
 
 
 
 
 
 
 
 
* Adapted with the permission from: Mellini, P.; Kokkola, T.; Suuronen, T.; Salo, H.;Tolvanen, L.; 
Mai, A.; Lahtela-Kakkonen, M.; Jarho, E.M. J Med Chem 2013, 56: 6681-6695. Copyright 2012 
American Chemical Society. 
* Adapted with the permission from: Kokkonen, P.; Mellini, P.; Nyrhilä, O.; Rahnasto-Rilla, M.;     
   Poso, A.; Lahtela-Kakkonen, M.; and Jarho, E.M.. Eur J Pharm Sci (manuscript in preparation). 
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8.1 Introduction 
The thioacetylated peptidic inhibitors have represented the first successful approach 
to develop potent competitive SIRT1/2 inhibitors.
125
 The inhibition mechanism 
(Figure 1), elucidated by Smith and Denu, shows that after a fast nicotinamide 
cleavage, the thioacetyl inhibitor is readily converted to a stalled intermediate 1′-S-
alkylamidate with a consequent  retardation of the overall turnover rate.
127
 
 
 
Figure 1. The mechanism of sirtuin inhibition of thioacetylated peptides.  
In the scenario in which the peptidic scaffold gave compounds with potent inhibition 
activity
129,133 
but negligible drug-like properties, Suzuki et al.
132
 and few years after, 
Huhtiniemi and co-workers,
134
 developed novel classes of pseudopeptides with an 
N
ε
-thioacetyl lysine residue   (Chart 1)  in order to improve the cell permeability.   
 
Chart 1. Reference compound A by Suzuki et al.
132
 and reference compound B by 
Huhtiniemi et al.
134
 
Pursuing the versatility of the peudopeptidic scaffold, we focused our efforts on the 
preparation and biological evaluation of a novel fragment based library (Chart 2, 
Tables 1-3). The library was generated considering our previously reported binding 
hypothesis that was developed with SIRT3 as the target structure.
134
  In this 
hypothesis, we suggested that a potential sirtuin inhibitor should create an H-bond 
network with Val292, Gly295, Glu296 and Glu325 (Figure 2). In addition, in the N-
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terminal area of a pseudopeptidic compound the binding affinity could be improved 
by formation of a hydrogen bond to Leu298 and filling the cavity surrounded by 
residues Pro297, Leu298, Phe302 and Leu303. On the other hand, in the C-terminal a 
compound with aromatic interactions with Phe294 or a hydrogen bond with Glu325 
might have good inhibition potency. 
 
 
Chart 2. The general structure and the compound collections of the pseudopeptide 
library. 
 
Figure 2. A scheme of the interaction pattern reported for a pseudopeptidic inhibitor 
in SIRT3 that fulfills the binding hypothesis. In cartoon, H-bonds and aromatic 
interactions are represented by dashed lines correspondingly in green and blue. 
 
To improve the knowledge of pseudopeptidic interactions in various sirtuins and to 
get structure-activity relationship (SAR) data, a set of novel pseudopeptides was 
designed. A small library of pdeudopeptides was synthesized (Chart 2, Tables 1-3) 
and screened in vitro against SIRT1-3 with the aim to understand how heterogeneous 
N- and C-terminal modifications might induce changes in the activity. Three 
compounds were selected for cellular studies. All three compounds were cell-
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permeable and non-toxic. Furthermore, two of the compounds showed 
antiproliferative effects on two different cancer cell lines (A549 and MCF-7) causing 
cell cycle arrest at the G1 phase. 
 
8.2 Chemistry 
The synthetic pathway to compounds 1-46 is depicted in Scheme 1. The N
ε
-
thioacetylated derivatives 1 and 24 were synthesized using ethyl dithioacetate and 
EtOH/10% (w/v) Na2CO3(aq) at rt for 12 h according to the literature.
125,134
 
Compounds 2-6 and 25-34 were obtained with a coupling reaction between the 
activated acid 1 or 24 and an appropriate amine using the coupling agent TBTU (O-
(benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium tetrafluoroborate) in 
dimethylformamide (DMF)/pyridine under argon flow. The hydrochlorides 7-11, 22, 
43, 44, 46 were gained via Boc (tert-butoxycarbonyl) deprotection
189
 performed at 60 
°C using 15 eq of HCl(aq)12 N, 2-propanol and 1,2-ethanedithiol as a scavenger for 
trapping the tert-butyl cation generated in situ. Initially, Boc deprotection was 
attempted in ethyl acetate under HCl-gas flow in the absence of a scavenger in order 
to precipitate the product as the HCl salt from the reaction mixture. However, the 
1
H-
spectrum revealed the disappearance of the thioacetyl methyl singlet (2.4 ppm in 
DMSO-d6) but showed instead a methyl singlet at 1.8 ppm, a shift characteristic to an 
acetyl methyl (unpublished data). Thus, the required amount of HCl was optimized; 
15 eq of HCl divided in three portions gave complete consumption of the starting 
material. This, together with the added scavenger, protected the thioacetyl group 
during the deprotection step. Compounds 12-23 and 35-46 were synthesized 
according to the above mentioned coupling procedure; in this case the appropriate 
acid was activated with TBTU to react with the corresponding unblocked amine. The 
hydrochloride release of the starting material 7 was a critical step that reduced the 
yields of the acetophenone (i.e. 2-oxo-2-phenyl ethyl) derivatives 12-18, 42. As a 
free amine, compound 7 underwent spontaneous side-reactions; most likely an 
intramolecular cyclization between the free amino group and the ketone function 
responsible for generating several byproducts during the coupling step. 
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a
Reagents and conditions: (a) Ethyl dithioacetate, EtOH/10% (w/v) Na2CO3(aq), rt, 12 
h; (b) appropriate amine or carboxylic acid, TBTU, DMF/Pyridine (1:1), argon flow, 
rt, 2-3 h; (c) 2-propanol, 1,2-ethanedithiol, HCl(aq) 12 N, 15 eq, 60°C, 2-3 h. 
8.3 Results and discussion 
Structure-Activity Relationship. A compound library of 30 pseudopeptides was 
synthesized. One collection explored modifications in the N-terminus (Table 1), the 
other collection explored the modifications in the C-terminus (Table 2) and, in the 
third collection miscellaneous modifications at both termini were studied (Table 3, 
4). All compounds were screened in vitro against SIRT1-3 at 50 µM concentration 
(Tables 1-4). However, the numbering of the target protein amino acids is adopted 
from SIRT3 in the structure-activity discussion unless otherwise noted. The main 
differences between SIRT1-3 substrate binding sites are labeled and the binding site 
overview can be seen  in Figure 3, 4.  The most representative docking poses for 
tested compounds can be find at the end of this paragraph (Structure-Activity 
Relationship). 
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Figure 3.  The overall structure of SIRT3 (PDB code: 3glr) is represented in blue 
ribbon (left).    The superimposition of the substrate binding sites (right) of SIRT1 
(green) and SIRT2 (orange) homology models and SIRT3 crystal structure (blue).  
The acetylated substrate is colored in black, the N- and C-terminal sides are 
represented by spheres V1 (pink) and V2 (yellow), respectively.  
The first set of compounds with modifications in the N-terminus shared a 2-oxo-2-
phenylethyl moiety in the C-terminus (2, 12-18 in Table 1). These compounds fulfill 
the hydrogen bonding network and the C-terminal π-π interaction requirements of the 
binding hypothesis (Figure 2). For SIRT1, the fulfillment of these requirements is 
enough to give highly potent compounds; despite the structural changes in the N-
terminus compounds 12-18 gave ≥ 95% inhibition. Compound 2 with the N-terminal 
Boc-group gave 91% SIRT1 inhibition, although weakest within this set it was still 
highly active.  For SIRT2 and SIRT3, more variation was seen in the inhibitory 
activities suggesting that the optimization of the N-terminus is more critical for these 
enzymes. However, the C-terminal 2-oxo-2-phenylethyl moiety seems to be very 
good also for SIRT2 and SIRT3 because ≥ 90% inhibition was achieved in several 
examples. Compounds 12-14 show the same trend for all the three enzymes; 
elongation of the chain improved inhibitory activity, the best compound being 14 
with five methylene groups between the phenyl and carbonyl functions. Based on the 
modeling studies, compound 14 seems to be better complementary with the 
hydrophobic cavity compared to compounds 12 and 13. Compound 2 with the N-
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terminal Boc-group gave SIRT2 inhibition comparable to compound 14 but against 
SIRT1 and SIRT3 it showed decreased activity. Introduction of the pyridyl group did 
not improve the inhibition of any of the enzymes (15 vs. 12). 
 
Figure 4. (A) SIRT1 homology model, (B) SIRT2 homology model and (C) SIRT3 
crystal structure (PDB: 3GLR). 
 
Compounds 16-18 were designed to improve the N-terminal interactions in the 
lipophilic cavity. Modeling studies also show that the hydroxyl moiety of the 4-
hydroxy-L-prolyl group in compound 16 can form an additional H-bond with Gly295 
(Figure 5d). Interestingly, compound 16 was the only compound within the whole 
compound library that achieved ≥ 90% inhibition of all three studied sirtuins and 
thus, seems to possess a well-optimized structure.  The second set of compounds 
with modifications in the N-terminus shared a phenyl moiety in the C-terminus (19-
23 in Table 1).  
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Table 1. Screening of the N-terminal modifications.  
No. R2 Inhibition-% @ 50 µM
a
 
SIRT1 SIRT2 SIRT3 
N
H
H
N
O
R2
O
HN S
 
2 
 
91 ± 0.6 87 ± 0.5 63 ± 1.2 
12 
 
96 ± 0.1 65 ± 1.5 68 ± 3.1 
13 
 
98 ± 0.1 76 ± 2.3 72  ± 0.2 
14 
 
98 ± 0.1 83 ± 0.4 82  ± 0.3 
15 
 
95 ± 0.3 58 ± 0.6 62  ± 1.3 
16 
 
99 ± 0.0 96 ± 0.3 90 ± 0.2 
17 
 
97 ± 0.4 95 ± 0.5 76 ± 1.2 
18 
 
96 ± 0.2 73 ± 1.2 61 ± 0.3 
N
H
H
N
O
R2
HN S
 
19 
 
82 ± 0.2 39 ± 2.6 44 ± 0.3 
20 
 
62 ± 2.2 18 ± 1.1 16 ± 1.1 
21 
 
80 ± 0.5 44 ± 0.5 45 ± 2.2 
22 
 
86 ± 0.1 13 ± 3.1 19 ± 0.8 
23 
 
90 ± 0.5 54 ± 1.4 69 ± 1.3 
a
Fluor de Lys assay, values are means  SD of at least three experiments. 
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Figure 5. Docking poses for 16 (green), 23 (blue), 35 (yellow) in A) SIRT1, B) 
SIRT2, C) SIRT3. On the protein surface the light green represents the hydrophilic 
and the light blue the lipophilic areas. D) Compound 16 docked in SIRT3 
highlighting the additional hydrogen bond between the hydroxyl group and Gly295.  
 
These compounds are missing one H-bond of the hydrogen bonding network due to 
the lack of the C-terminal H-bond acceptor. Furthermore, the phenyl ring is not in the 
optimal position for the C-terminal π-π interaction. It is obvious that the C-terminal 
phenyl is not as good a structure as the above studied 2-oxo-2-phenylethyl moiety 
(19, 21, 23 vs. 15, 17, 16, respectively). Again, the N-terminal Cbz-4-hydroxy-L-
prolyl moiety (23) gave the most potent compound (Figure 4). Boc-L-prolyl (21) 
instead, shows only comparable activity to the 3-(3-pyridyl)propanoyl fragment (19) 
in this series.  Boc deprotection of 21 gave compound 22 with an L-prolyl moiety and 
further simplification gave compound 20 with an N,N-dimethyl-glycine. Against 
SIRT1, compound 22 was able to maintain inhibition (86%), possibly due to an H-
bond from the NH-proton of the L-proline to Gly223 (SIRT1 numbering). Compound 
20 lacks this proton and shows decreased activity (62%).  However, against SIRT2 
and SIRT3 both 20 and 22 show only weak inhibition. This is in line with our 
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previous finding with peptidic inhibitors that SIRT1 can be inhibited with smaller 
compounds. Small pseudopeptides provide an approach to gain SIRT1 selectivity; 
compound 22 shows highest SIRT1 selectivity among the pseudopeptide library.  
The first set of compounds with modifications in the C-terminus shared a Cbz group 
in the N-terminus (25-34 in Table 2). Although the C-terminal 2-oxo-2-phenylethyl 
moiety had proven to be a very good structure (Table 1), it was causing side-
reactions during the synthesis reducing the yields. Thus, it was decided to explore 
whether a more stable group with similar activity could be found. The reduction (28) 
or deletion (25) of the carbonyl function (Figure 6) induced a uniform loss in 
potency, probably because of the lost H-bond to the carbonyl function. Compound 28 
was tested as a mixture of diastereomers but modeling did not suggest favorable 
interactions for one over the other. Next, the phenyl function was positioned closer to 
the thioacetylated lysine giving the benzyl derivative 26. For SIRT1 and SIRT3, this 
optimization of the C-terminal π-π interaction could compensate for the lost H-bond 
and high inhibition was observed. SIRT2 instead showed different behavior; the H-
bond seems to be more crucial for the SIRT2 inhibition. These results were verified 
also by another set of compounds (Figure 5, Table 2); compared to compound 16, 
compound 35 shows similar SIRT1 and SIRT3 inhibition but decreased SIRT2 
inhibition. However, both of these compounds show higher inhibition compared to 
compound 23 with the C-terminal phenyl group. Larger C-terminal aromatic groups 
were studied by compounds 27 and 29-31. The tryptamine moiety (29) does not 
show an optimal interaction with the Phe294. However, the tryptamine can have 
other hydrophobic interactions with surrounding hydrophobic residues. Also, in 
SIRT1 there is a possibility for the tryptamine nitrogen to form an additional 
hydrogen bond with Lys252 (SIRT1 numbering, compound 30 in Figure 6). Further 
bulkiness was gained by the methoxy (30) and benzyloxy (31) groups. These 
hydrophobic groups increase C-terminal hydrophobic interactions and improve 
potency. Also, the methoxy group in compound 27 can increase the hydrophobic 
interactions (Figure 6).  
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Table 2. Screening of the C-terminal modifications.  
No. R1 Inhibition-% @ 50 µM
a
 
SIRT1 SIRT2 SIRT3 
N
H
H
N
O
R1O
O
HN S
 
Ref.A 
 
83 ± 0.5 81 ± 1.1 62 ± 1.5 
Ref.B 
 
97 ± 0.3 94 ± 0.3 74 ± 0.9 
25 
 
72 ± 3.5 52 ± 1.6 41 ± 1.9 
26 
 
91 ± 0.1 67 ± 0.6 71 ± 2.8 
27 
 
97 ± 0.1 97 ± 0.2 82 ± 1.3 
28 
 
77 ± 0.2 54 ± 3.1 45 ± 2.7 
29 
 
85 ± 0.7 61 ± 2.3 46 ± 3.8 
30 
 
88 ± 0.3 66 ± 1.1 63 ± 1.2 
31 
 
87 ± 0.4 79 ± 0.6 68 ± 2.8 
32 
 
84 ± 1.0 70 ± 1.3 59 ± 1.7 
33 
 
91 ± 0.3 72 ± 0.5 77 ± 0.1 
34 
 
96 ± 0.2 86 ± 0.2 85 ± 0.9 
N
H
H
N
O
R1
O
N
HO
Cbz
HN S
 
16 
 
99 ± 0.0 96 ± 0.3 90 ± 0.2 
23 
 
90 ± 0.5 54 ± 1.4 69 ± 1.3 
35 
 
97 ± 0.2 87 ± 0.7 93 ± 0.1 
a
Fluor de Lys assay, values are means  SD of at least three experiments. 
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Three smaller, more polar C-terminal fragments were also studied. The pyridyl group 
in compound 32 can have a π-π interaction to the protein but surrounding water 
provides competing interactions to the polar moiety. Compounds 33 and 34 lack an 
aromatic ring and cannot form π-π interactions. However, these compounds are able 
to retain a good inhibition potency which may be due to an additional H-bond to the 
terminal amide nitrogen. The stereochemistry of the chiral compound 34 apparently 
orientates the hydrogen bonding more properly.  
 
Figure 6. Docking poses for 25 (yellow), 27 (green), 30 (blue) in A) SIRT1, B) 
SIRT2, C) SIRT3. On the protein surface the light green represents the hydrophilic 
and the light blue the lipophilic areas.  
 
A pyridyl group is often used to improve water solubility of compounds. Therefore, 
C-terminal pyridyl moieties were combined to miscellaneous N-terminal fragments 
(Table 3). Compounds 6 and 40 with the C-terminal 2-(3-pyridyl)ethyl fragment 
show weak to moderate sirtuin inhibition. Compounds 38 and 39 possess the C-
terminal 3-pyridyl moiety. In compound 38, the N-terminal Cbz group of compound 
32 was replaced by a phenylethyl group giving decreased SIRT2 and SIRT3 
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inhibition.  However, compound 39 with an ortho-fluoro substituent on the phenyl 
ring shows improved affinity towards all studied sirtuins compared to compounds 32 
and 38. The fluorine provides an H-bond acceptor that may form an additional H-
bond to the enzyme backbone (Leu298 in SIRT3) but the GlideScore scoring 
function does not reward fluorine as a hydrogen bond acceptor. Finally, two 
compounds with C-terminal benzyl groups were studied (36 and 37). These 
compounds have an N-terminal phenyl moiety at the end of a long, flexible chain. 
The length of these N-terminal moieties is similar to Cbz-4-hydroxy-L-prolyl group. 
The flexibility of the chains of 36 and 37 allows the phenyl groups be buried deep in 
the lipophilic cavity. This gives excellent SIRT1 inhibition and good SIRT2 and 
SIRT3 inhibition.  
 
Table 3. Screening of the miscellaneous modifications. 
Structure No. R2 R1 Inhibition-% @ 50 µM
a
 
SIRT1 SIRT2 SIRT3 
 
6 
  
41 ± 1.9 28 ± 3.8 24. ± 0.3 
36 
 
 
100 ± 0.1 71 ± 0.6 84 ± 0.2 
37 
 
 
99 ± 0.2 74 ± 1.2 87 ± 0.3 
38 
 
 
83 ± 1.0 21 ± 3.4 39 ± 1.2 
39 
 
 
94 ± 0.4 74 ± 0.2 72 ± 0.6 
40 
 
 
66 ± 0.5 49 ± 1.1 68 ± 3.0 
a
Fluor de Lys assay, values are means  SD of at least three experiments. 
 
In order to obtain preliminary SAR information a small series of proline derivatives 
41-46  was designed starting from the results obtained by compounds 16, 17, 21-23 
and 35. The shift from N-Cbz-4-trans-hydroxy-L-prolil 16, 35 (Table 2) to the 
corresponding N-Boc derivatives 41, 42 (Table 4) alter only partially the inhibition 
activity. Boc deprotection of compound 41 gave compound 43 with an  4-trans-
hydroxy-L-prolil moiety able to maintain the same SIRT1 inhibition but, slowly 
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reduced on SIRT2 and SIRT3. Interestingly Boc deprotection of 21 and 45 (Table 4) 
gave compounds 22 and 46 (Table 4) that retain a good SIRT1 inhibition but only 
weak against SIRT2 and SIRT3, confirming once again what proposed previously.  
 
Table 4. Screening of proline derivatives. 
No. R1 Inhibition-% @ 50 µM
a
 
SIRT1 SIRT2 SIRT3 
 
41 
 
83 ± 0.2 86 ± 0.3 92 ± 0.2 
42 
 
97 ± 0.1 96 ± 1.8 91 ± 0.1 
 
43 
 
89 ± 0.4 70 ± 0.9 78 ± 0.3 
44 
 
97 ± 0.1 Not available Not available 
 
17 
 
97 ± 0.4 95 ± 0.5 76 ± 1.2 
21 
 
80 ± 0.5 44 ± 0.5 45 ± 2.2 
45 
 
94 ± 0.1 84 ± 0.2 83 ± 1.0 
 
22 
 
86 ± 0.1 13 ± 3.1 19 ± 0.8 
46 
 
95 ± 0.0 58 ± 0.4 58 ± 1.2 
a
Fluor de Lys assay, values are means  SD of at least three experiments. 
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That SIRT1 can be inhibited by small C-terminal fragments, instead SIRT2 and 
SIRT3  require not only an improvement of H-bond interactions but, also the 
presence of bulky groups such as N-Cbz-4-trans-hydroxy-L-prolil (16, 35) able to fill 
the lipophilic cavity as we have discussed before in the binding hypothesis. 
Three compounds with slightly different inhibition profiles, 16, 27 and 30, were 
chosen for    IC50 profile evaluation and cellular studies. Compound 16 was chosen 
because it is the only compound giving ≥ 90% inhibition of all studied sirtuins. 
Compound 27 gives excellent SIRT1 and SIRT2 inhibition (97%) but slightly 
decreased SIRT3 inhibition (82%). Compound 30 has the highest selectivity towards 
SIRT1 among these three compounds; it shows 88% SIRT1 inhibition but 66% 
SIRT2 and 63% SIRT3 inhibition. Compounds 16 and 27 fulfill completely the 
binding hypothesis while compound 30 with its C-terminal tryptamine shows an 
alternative H-bond. The IC50 values of the three chosen compounds (Table 5, Figure 
7) follow nicely the preliminary screening results showing slightly different 
inhibition profiles. Also our previous experience with the thioacetylated compounds 
has indicated that the preliminary screening correlates well with the IC50 values. This 
may be due to the reaction mechanism and formation of the stable 1’-S-alkylamidate 
intermediate. 
 
Table 5. IC50 values, cLogP, PSA and MW for compounds 16, 27 and 30. 
 
No. 
IC50 µM  (95% confidence interval)
a
    
SIRT1 SIRT2 SIRT3 cLogP
b
 
PSA
c 
MW 
16 0.24 (0.22-0.25) 1.80 (1.44-2.26) 3.89 (3.47-4.37) 2.61 287.85 568.69 
27 0.89 (0.83-0.96) 2.53 (2.37-2.70) 8.35 (7.37-9.46) 3.66 262.74 485.60 
30 5.98 (5.25-6.81) 25.8 (22.7-29.3) 29.4 (23.1-37.4) 4.50 257.70 510.65 
 
a
Fluor de Lys assay, values are calculated from three independent determinations giving 
altogether 27 data points. 
b
Calculated logarithm of octanol/water partition coefficient, 
calculated with MOE 2011.10.
34  c
Total Polar Surface Area (Å
2
), calculated with MOE 
2011.10 (Molecular Operating Enviroment (MOE), 2011.10; Chemical Computing Group 
Inc., 1010 Sherbooke St. West, Suite #910, Montreal, QC, Canada, H3A 2R7). 
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Figure 7. The IC50 curves of compounds 16, 27 and 30 for A) SIRT1, B) SIRT2 and 
C) SIRT3. 
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Docking poses. 
 
Compounds  2 (green), 5 (blue), 6 (yellow) in SIRT1 (A), SIRT2 (B), SIRT3 (C) 
 
 
 
Compounds 12 (green), 15 (blue)  in SIRT1 (A), SIRT2 (B), SIRT3 (C) 
 
 
A B 
C 
A B 
C 
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Compounds 14 (green), 36 (blue) in SIRT2 (A) and SIRT3 (B) 
 
 
 
 
 
 
 
 
 
Compounds 17 (green), 18 (blue) in SIRT1 (A), SIRT2 (B) and SIRT3 (C) 
 
 
 
 
 
 
 
 
A B 
A B 
C 
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Compounds 19 (green), 21 (blue), 22 (yellow) in SIRT1 
 
 
 
 
 
 
 
 
Compounds 25 (green), 26 (blue), 28 (yellow) in SIRT1 (A), SIRT2 (B) and SIRT3 
(C) 
 
 
 
 
 
 
A B 
C 
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Compounds 29 (green), 31 (blue) in SIRT2 (A) and SIRT3 (B) 
 
 
 
 
 
 
 
 
Compounds 33 (green), 34 (blue) in SIRT1 (A), SIRT2 (B) and SIRT3 (C) 
 
 
 
 
 
 
A B 
A B 
C 
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Compounds 32 (green), 38 (blue), 39 (yellow) in SIRT1 (A), SIRT2 (B) and SIRT3 
(C) 
 
 
 
Compound 37  in SIRT1 
 
 
 
 
 
A B 
C 
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Compound 40 in SIRT1 (A), SIRT2 (B) and SIRT3 (C) 
 
  
 
 
The effects of compounds 16, 27 and 30 in human cell lines. To get the first 
glimpse of the cell-penetration of the compounds, they were studied in two different 
cell-lines that we have previously used for this purpose; ARPE-19 retinal pigment 
epithelium cells and SH-SY5Y neuroblastoma cells.
134 
In the literature, ARPE-19 
cells have been used to investigate age-related macular degeneration, where SIRT1 is 
expected to have a therapeutic role
190 
and in SH-SY5Y cells SIRT1 has been shown 
to have neuroprotective effects.
191
 Because SIRT1 is known to deacetylate Lys382 of 
p53,
132,119 
Western blot analysis was performed in order to detect changes in 
acetylation level of p53 after etoposide-induced DNA damage. Each of the 
compounds showed increased p53 acetylation in ARPE cells while the effect in SH-
SY5Y cells was not as evident (Figure 8A). The low levels of lactate dehydrogenase 
(LDH) leakage from the treated cells indicate that the tested compounds were not 
toxic to the cells at the used concentration (Figure 8B).  
A B 
C 
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Figure 8. Inhibition of SIRT1 activity increases p53 acetylation after DNA damage. 
(A) Effect of 20 μM compounds 16, 27, and 30 on p53 acetylation after 100 μM 
etoposide (eto) treatment for 5 h in ARPE-19 and SH-SY5Y cell lines. The results 
are shown as mean ± SEM of 2 independent experiments. The representative 
Western blots are shown below. (B) Effect of compounds 16, 27 and 30 on LDH 
leakage from ARPE-19 and SH-SY5Y cells.  
 
As sirtuin inhibition has been suggested as a potential therapy for breast and lung 
cancer,
64,141,192 
the effects of SIRT inhibitors 16, 27, and 30 on the proliferation of 
two tumor cell lines, A549 lung carcinoma and MCF-7 breast carcinoma, were 
measured with sulforhodamine B assay. Both A549 and MCF-7 cell growth was 
inhibited with ≥ 50 µM of 27 and 30 (Figure 9). The other tested SIRT inhibitor 16 
did not show any substantial inhibitory effect on A549 or MCF-7 cell growth with 
concentrations up to 200 µM (data not shown).  
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Figure 9. Effects of SIRT inhibitors on A549 and MCF-7 cell proliferation. The cells 
were treated with 0 to 100 μM of 27 (left) or 30 (right). Cell proliferation was 
determined by sulforhodamine B assay. The results are shown as mean ± SEM of 2-3 
independent experiments. 
In order to understand the different inhibitory behavior of the three tested inhibitors 
on cell proliferation, the cellular p53 acetylation levels in the MCF-7 cells were 
examined (Figure 10A) and physicochemical parameters for the inhibitors were 
calculated (Table 5). The study showed that all the three compounds were able to 
increase the acetylation level of p53 but compound 16 was less effective than 27 and 
30. Despite being a potent SIRT1-3 inhibitor, compound 16 did not inhibit MCF-7 or 
A549 cell proliferation. This could be explained by cell type specific differences in 
membrane permeability, together with different physico-chemical properties of the 
compounds (Table 5). As these compounds are rather large, it can be speculated that 
compound 16 with the lowest cLogP and the highest polar surface area and 
molecular weight may have difficulties in cell-permeation. The compounds did not 
show any toxic effect when tested with LDH assay (Figure 10B). 
 120 
 
 
Figure 10. Inhibition of SIRT1 activity increases p53 acetylation after DNA damage 
in MCF-7 cells. (A) Effect of 50 μM compounds 16, 27, and 30 on p53 acetylation in 
MCF-7 cells after 100 μM etoposide (eto) treatment for 5 h. The test was performed 
once for each compound. (B) Effect of compounds 16, 27, and 30 on LDH leakage 
from MCF-7 cells. 
 
Propidium iodide staining and flow cytometric DNA content analysis of MCF-7 and 
A549 cells treated with 27 and 30 was performed in order to detect the effect of these 
compounds on cell cycle progression. Cell cycle analysis revealed that both  27 and 
30 arrested cancer cells in the G1 phase, with > 50% reduction in DNA synthesis (S 
phase population), and no cell death was observed (Figure 11). 
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Figure 11. Effects of SIRT inhibitors on A549 and MCF-7 cell cycle. The cells were 
subjected to control treatment (0.5% DMSO) or treatment with 100 μM of 27 or 30 
for 18 h. Flow cytometric analysis of DNA content was done after propidium iodide 
staining. Percentage of cells in each phase of the cell cycle (G1, G2, and S) is 
indicated. Representative data from at least two independent experiments are shown. 
 
8.4 Conclusions 
A library of novel compounds around thioacetylated lysine scaffold was synthesized. 
The C-terminal 2-oxo-2-phenylethyl and benzyl moieties were found to be fragments 
that give excellent SIRT1 inhibitions (2, 12-18 and 26, 35-37). The N-terminal Cbz-, 
-Boc-4-hydroxy-L-prolyl or a long flexible chain attached to a phenyl group (16, 23, 
35 and 14, 36, 37, 41, 42) also gave a positive contribution to the binding hypothesis 
hinting that the H-bond with Gly295 and groups that can be buried deep in the 
lipophilic cavity can improve inhibition potency. Three compounds, 16, 27 and 30, 
with slightly different inhibition profiles were chosen for more detailed studies. Their 
effect on tumor cell proliferation was studied in A549 lung carcinoma and MCF-7 
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breast carcinoma cell lines. Interestingly, the in vitro inhibition potency did not 
correlate with the cellular effect; the most potent compound 16 did not show any 
antiproliferative effect while the two other compounds inhibited cell growth at ≥ 50 
µM concentration. The difference may arise from different cell permeation of the 
compounds. Due to the observed induction of p53 acetylation in ARPE-19 and MCF-
7 cells, SIRT1 is likely to be one of the cellular targets of compounds 27 and 30.  
Compounds 27 and 30 were shown to be cell-permeable and non-toxic sirtuin 
inhibitors. They both inhibited cell growth by the arrest at the G1 phase in two tumor 
cell-lines, although the effect of compound 30 was more pronounced. These two 
inhibitors are our new lead compounds that will be taken to further studies.  
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8.5 Experimental Section 
Chemistry. Chemical reagents and solvents used in this study were commercial high 
purity quality. Organic solutions were dried over anhydrous sodium sulfate. Pyridine 
and dimethylformamide (DMF) were dried over molecular sieves. Compounds 1, 24 
were prepared using the same amounts and following the procedure reported by 
Huhtiniemi and coworkers.
134 
Yields of all reactions refer to the purified products.  
NMR spectra were acquired on a Bruker Avance 500 AV (Bruker Biospin, 
Swizerland) spectrometer operating at 500.1 MHz for 
1
H and 125.8 MHz for 
13
C. 
 hemical shift values are reported as δ (ppm) relatively to TMS (tetramethylsilane) 
as an internal reference; coupling constant are given in Hz. Positive ion mass spectra 
were recorded with a quadrupole ion trap mass spectrometer (Finnigan MAT, San 
Jose, CA) equipped with an electrospray ionization source (ESI-MS). The purity of 
the compounds was derermined by Elemental analysis obtained by an Thermo Quest 
CE Instruments EA 1110 CHNS-O elemental analyzer and the Analytical results are 
within ± 0.40% of the theoretical values (see Supporting Information). Purity of 
tested compounds was ≥ 95%. The purity of compounds 27 and 28 was also 
determined by HPLC (Agilent 1100 series) on a C-18 column (Zorbax Eclipse XDB-
C18, 4.6*50 mm, 1.8 µm) using 45% acetate buffer (20 mM, pH 5) and 55% MeOH 
as eluent, flow rate 1 mL/min, column temperature 50°C and detection at 265 nm. 
 
(2S)-2-tert-Butyl 6-ethanethioamido-1-oxo-1-(2-oxo-2-phenylethylamino)hexan-
2-ylcarbamate (2). To a solution of 1 (1.17 g, 3.84 mmol) in DMF (17.0 mL) under 
Argon flow were added TBTU (1.36 g, 4.2 mmol), pyridine (17.0 mL) and 
maintained under stirring for 10min at rt . After this time 2-Aminoacetophenone 
hydrochloride (0.66 g, 3.84 mmol) was added and the solution mixed 2h 30min at rt 
under Argon flow. Solvents were evaporated and the obtained oil was dissolved in 
EtOAc (180 mL), washed with HCl 0.5M, brine (two times), satured NaHCO3 and 
finally dried with Na2SO4 and evaporated under vacuo. The crude product obtained 
was purified by column chromatography using silica Kieselgel for flash and EtOAc : 
MeOH (9.5 : 0.5 v/v) as eluent phase to give the pure product as a sticky solid (1.34 
g, 3.17 mmol, 83 %). 
1
H-NMR (DMSO-d6) : δ = 9.95 (s br, 1H), 8.13 (t, J = 5.36 Hz, 
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1H), 7.99 (d, J = 7.57 Hz, 2H), 7.67 (t, J = 7.57 Hz, 1H), 7.54 (t, J = 7.57 Hz, 2H), 
6.90 (d, J = 8.20 Hz, 1H), 4.70-4.54 (m, 2H), 4.01-3.97 (m, 1H), 3.50-3.39 (m, 2H), 
2.39 (s, 3H), 1.71-1.49 (m, 4H), 1.39-1.30 (m, 11H). 
13
C-NMR (CDCl3) : δ = 201.06, 
194.12, 172.33, 155.96, 134.43, 134.39, 129.13, 128.07, 54.11, 46.42, 46.12, 34.22, 
32.67, 29.82, 28.46, 27.16, 22.88. ESI-MS (m/z): 422.0 [M + H]
+
 , 444.20 [M + 
Na]
+
. Anal. (C21H31N3O4S) C, H, N. 
(2S)-2-tert-Butyl 6-ethanethioamido-1-oxo-1-(phenylamino)hexan-2-
ylcarbamate (3). Compound 3 was prepared using 1 (1.2 g, 4.00 mmol), DMF (17.0 
mL), TBTU (1.41 g, 4.4 mmol), pyridine (17.0 mL) and aniline (0.36 mL, 4.00 
mmol) following the same procedure described for 2. Purification by 
chromatography column using silica Kieselgel for flash and EtOAc : MeOH (9.5 : 
0.5 v/v)  to give the product as solid (1.11 g, 2.92 mmol, 73 %). 
1
H-NMR (DMSO-
d6) : δ = 9.94 (s br, 1H), 9.91 (s, 1H), 7.59 (d, J = 8.20 Hz, 2H), 7.30 (t, J = 8.20 Hz, 
2H), 7.04 (t, J = 8.20 Hz, 1H), 6.99 (d, J = 7.57Hz, 1H), 4.07-4.01 (m, 1H), 3.49-
3.42 (m, 2H), 2.36 (s, 3H), 1.68-1.49 (m, 4H), 1.38-1.30 (m, 11H). 
(2S)-2-tert-Butyl 6-ethanethioamido-1-oxo-1-(benzylamino)hexan-2-ylcarbamate 
(4). Compound 4 was prepared using 1 (1.22 g, 4.0 mmol), DMF (17.0 mL), TBTU 
(1.41 g, 4.40 mmol), pyridine (17.0 mL) and benzylamine (0.43 mL g, 4.0 mmol), 
following the same procedure described for 2. The product obtained as light-yellow 
solid  (1.42 g, 3.62 mmol, 90 %) was used without further purifications. 
1
H-NMR 
(DMSO-d6) : δ = 9.93 (s br, 1H), 8.29 (t, J = 5.99 Hz, 1H), 7.31-7.21 (-Ar, 5H), 6.86 
(d, J = 7.88 Hz, 1H), 4.32-4.23 (m, 2H), 3.94-3.89 (m, 1H), 3.45-3.41 (m, 2H), 2.37 
(s, 3H), 1.66-1.49 (m, 4H), 1.39-1.23 (m, 11H). 
2S)-2-tert-Butyl 6-ethanethioamido-1-oxo-1-(pyridin-3-ylamino)hexan-2-
ylcarbamate (5). Compound 5 was prepared using 1 (1.02 g, 3.37 mmol), in DMF 
(15.0 mL), TBTU (1.19 g, 3.70 mmol), pyridine (15.0 mL) and 3-Aminopyridine 
(0.32 g, 3.37 mmol), following the same procedure described for 2. The workup was 
made without HCl 0.5M and EtOAc was replaced by CH2Cl2. Purification by 
chromatography column using silica Kieselgel for flash and EtOAc : CH2Cl2 : MeOH 
(3.5 : 5.5 : 1) as eluent phase to give the pure product as solid (0.49 g, 1.28 mmol, 38 
%). 
1
H-NMR (DMSO-d6) : δ = 10.17 (s, 1H), 9.94 (s br, 1H), 8.73 (d, J = 1.40 Hz, 
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1H), 8.26 (dd, J = 1.40, 4.73 Hz,  1H), 8.03 (dt, J = 1.40, 8.20 Hz, 1H), 7.34 (dd, 
4.73, 8.20 Hz, 1H), 7.08 (d, J = 7.57 Hz, 1H), 4.07-4.02 (m, 1H), 3.50-3.41 (m, 2H), 
2.36 (s, 3H), 1.70-1.51 (m, 4H), 1.38-1.30 (m, 11H). 
 
2S)-2-tert-Butyl 6-ethanethioamido-1-oxo-1-[2-(pyridin-3-yl)ethylamino]hexan-
2-ylcarbamate (6). Compound 6 was prepared using 1 (1.02 g, 3.37 mmol), DMF 
(15.0 mL), TBTU (1.19 g, 3.70 mmol), pyridine (15.0 mL) and 3-(2-
Aminoethyl)pyridine dihydrobromide (0.96 g, 4.71 mmol), following the same 
procedure described for 2. The workup was made using only NaHCO3 5% and   
EtOAc was replaced by CH2Cl2 (300 mL). Purification by chromatography column 
using silica Kieselgel for flash and EtOAc : CH2Cl2 : MeOH (3 : 5.5 : 1.5) as eluent 
phase to give the pure product as solid (0.86 g, 2.11 mmol, 63 %). 
1
H-NMR (DMSO-
d6): δ = 9.93 (s br, 1H), 8.42 (m, 2H), 7.87 (t, J = 5.36 Hz, 1H), 7.62 (dt, J = 1.60, 
7.57 Hz, 1H), 7.30 (dd, J =  4.73, 7.57Hz, 1H), 6.75 (d, J = 8.20 Hz, 1H), 3.84-3.79 
(m, 1H), 3.44-3.24 (m, 4H), 2.74-2.71 (m, 2H), 2.37 (s, 3H), 1.52-1.34 (m, 13H), 
1.25-1.16 (m, 2H). 
13
C-NMR (DMSO-d6) : δ = 198.77, 172.10, 155.29, 149.59, 
147.09, 136.66, 135.07, 123.47, 77.98, 54.25, 45.28, 32.81, 32.07, 31.74, 28.21, 
26.93, 23.04, (-NH-CH2-CH2-pyr under DMSO- d6). ESI-MS (m/z): 409.15 [M + H]
+
 
. Anal. (C20H32N4O3S·0.03DMF·0.03hexane) C, H, N. 
(2S)-2-Amino-6-ethanethioylamino-N-(2-oxo-2-phenylethyl)hexanamide 
hydrochloride (7). To a solution of 2 (1.34 g, 3.18 mmol) in 2-propanol (45.0 mL), 
1,2-ethanedithiol (0.27 mL, 3.18 mmol) was added and after 1min under stirring at r.t 
HCl 12N (1.34 mL, 16.0 mmol) was added and the solution heated at 60°C; After 
20min and 40min other HCl 12N (1.34 mL) was added; when the total mmol of  HCl 
in the reaction flask were 48 mmol, the solution was maintained for 60 min at 60°C 
under stirring. After this time, 2-propanol was evaporated under reduced pressure 
and the yellow oil was washed with petroleum ether (2 x 20 mL), Et2O (3 x 15 mL) 
and finally washed with CH2Cl2 (7x 5 mL) provides the product as light-yellow solid 
(0.99 g, 2.77 mmol, 87 %). 
1
H-NMR (DMSO-d6) : δ = 10.10 (s br, 1H), 8.92 (t, J = 
5.36 Hz, 1H), 8.30 (s, 3H), 8.02 (d, J = 7.88 Hz, 2H), 7.69 (t, J = 7.88 Hz, 1H), 7.56 
(t, J = 7.57 Hz, 2H), 4.82-4.68 (m, 2H), 3.96-3.83 (m, 1H), 3.49-3.45 (m, 2H), 2.41 
(s, 3H), 1.82-1.78 (m, 2H), 1.61-1.56 (m, 2H), 1.48-1.39 (m, 2H). 
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(2S)-2-Amino-6-ethanethioylamino-N-phenylhexanamide hydrochloride (8). 
Compound 8 was preparaed using 3 (1.10 g, 2.89 mmol), 2-propanol (37.0 mL), 1,2-
ethanedithiol (0.24 mL, 2.89 mmol) and HCl 12N (1.10 mL, 13.1 mmol) added x 
three times, following the same procedure described for 7, provides the product as 
light-yellow solid (0.75 g, 2.36 mmol, 82 %).
1
H-NMR (DMSO-d6) : δ = 10.80 (s, 
1H), 10.12 (s br, 1H), 8.37 (s, 3H), 7.65 (d, J = 7.57 Hz, 2H), 7.35 (t, J = 7.57 Hz, 
2H), 7.11 (t, J = 7.57 Hz, 1H), 4.04-3.98 (m, 1H), 3.48-3.42 (m, 2H), 2.36 (s, 3H), 
1.88-1.79 (m, 2H), 1.62-1.57 (m, 2H), 1.43-1.37 (m,  2H). 
(2S)-2-Amino-6-ethanethioylamino-N-benzylhexanamide hydrochloride (9). 
Compound 9 was prepared using 4 (1.42 g, 3.61 mmol) in 2-propanol (44.0 mL), 1,2-
ethanedithiol (0.30 mL, 3.60 mmol) and HCl 12N (1.41 mL, 16.9 mmol) added x 
three times, following the same procedure described for 7, to furnish a yellow oil that 
was washed with petroleum ether (2 x 20 mL), Et2O (3 x 20 mL) and finally washed 
with CH2Cl2 (7x 5 mL) provides the product as white solid (1.12 g, 3.4 mmol, 94 %). 
1
H-NMR (DMSO-d6) : δ = 10.10 (s br, 1H), 9.03 (t, J = 5.80 Hz, 1H), 8.25 (s, 3H), 
7.36-7.25 (-Ar, 5H), 4.38-4.31 (m, 2H), 3.81-3.77 (m, 1H), 3.45-3.42 (m, 2H), 2.38 
(s, 3H), 1.81-1.71 (m, 2H), 1.59-1.53 (m, 2H), 1.39-1.25 (m, 2H). 
(2S)-2-Amino-6-ethanethioylamino-N-(pyridin-3-yl)hexanamide 
dihydrochloride (10). Compound 10 was prepared using 5 (1.04 g, 2.74 mmol), 2-
propanol (35.0 mL), 1,2-ethanedithiol (0.23 mL, 2.74 mmol) and HCl 12N (1.44 mL, 
17.28 mmol) added x three times, following the same procedure described for 7, to 
furnish a yellow oil that was washed with petroleum ether (2 x 20 mL) and CH2Cl2: 
petroleum ether (1:1) (4 x 4 mL) provides the product as white powder (0.71 g, 2.0 
mmol, 73 %). 
1
H-NMR (DMSO-d6) : δ = 12.17 (s, 1H), 10.14 (s br, 1H), 9.17 (d, J = 
2.21 Hz, 1H), 8.60 (d, J = 5.36 Hz, 1H), 8.56-8.53 (m, 4H), 7.90 (dd, J = 5.36, 8.51 
Hz, 1H), 4.18-4.14 (m, 1H), 3.50-3.40 (m, 2H), 2.36 (s, 3H), 1.97-1.86 (m, 2H), 
1.64-1.54 (m, 2H), 1.46-1.40 (m, 2H). 
(2S)-2-Amino-6-ethanethioylamino-N-[2-(pyridin-3-yl)ethyl]hexanamide 
dihydrochloride (11). Compound 11 was prepared using 6 (0.57 g, 1.41 mmol), 2-
propanol (19.5 mL), 1,2-ethanedithiol (0.12 mL, 1.42 mmol) and HCl 12N (0.74 mL, 
8.89 mmol) added x three times, following the same procedure described for 7,  to 
 127 
 
furnish a yellow oil that was washed with petroleum ether (10 mL), Et2O (4 x 15 mL) 
and finally washed with CH2Cl2 (3 x 5 mL) provides the product as light yellow 
powder (0.52 g, 1.36 mmol, 97 %). 
1
H-NMR (DMSO-d6) : δ = 10.19 (s br, 1H), 8.89 
(d, J = 1.26 Hz, 1H), 8.81-8.77 (m, 2H), 8.44 (d, J = 7.88 Hz, 1H), 8.27 (s, 3H), 7.95 
(dd, J = 5.36, 7.88 Hz, 1H), 3.70-3.65 (m, 1H), 3.56-3.36 (m, 4H), 3.02-2.93 (m, 
2H), 2.39 (s, 3H), 1.67-1.60 (m, 2H), 1.55-1.49 (m, 2H), 1.26-1.15 (m, 2H). 
(2S)-2-(3-Phenylpropanoylamino)-6-ethanethioylamino-N-(2-oxo-2 
phenylethyl)hexanamide (12). To a solution of 3-phenylpropanoic acid (0.13 g, 
0.87 mmol) in DMF (4.7 mL) under Argon flow were added TBTU (0.31 g, 0.97 
mmol), pyridine (4.7 mL) and maintained under stirring for 10min at rt . After this 
time 7 (0.32 g, 0.89 mmol) was added and the solution mixed 3h at rt under Argon 
flow. Solvents were evaporated and the obtained oil was dissolved in CH2Cl2 (100 
mL), washed with HCl 0.5M, brine (twice), NaHCO3 5%, finally dried with Na2SO4 
and evaporated under vacuo. The crude product obtained was purified with two 
columns chromatography, using Aluminum oxide and silica Kieselgel for flash with 
EtOAc : Hexane : MeOH (7: 2: 1) as eluent phase to give the pure product as white 
solid (0.052 g, 0.11 mmol, 13 %).  
1
H-NMR (DMSO-d6) : δ = 9.95 (s br, 1H), 8.24 (t, 
J = 5.36 Hz, 1H), 8.03 (d, J = 8.20 Hz,1H), 7.99 (d, J = 7.57 Hz, 2H), 7.67 (t, J = 
7.57 Hz, 1H), 7.54 (t, J = 7.57 Hz, 2H), 7.28-7.15 (-Ar, 5H), 4.65-4.55 (m, 2H), 4.37-
4.32 (m, 1H), 3.46-3.38 (m, 2H), 2.84-2.79 (m, 2H), 2.47-2.43 (m, 2H), 2.38 (s, 3H), 
1.70-1.62 (m, 1H), 1.55- 1.47 (m, 3H), 1.29-1.22 (m, 2H). 
13
C-NMR (DMSO-d6) : δ 
= 198.74, 195.13, 172.11, 171.35, 141.27, 134.95, 133.50, 128.77, 128.20, 128.17, 
127.79, 125.80, 52.16, 45.83, 45.33, 36.72, 32.78, 31.83, 31.04, 26.90, 22.82. ESI-
MS (m/z): 454.14 [M + H]
+
 . Anal. (C25H31N3O3S) C, H, N. 
(2S)-2-(4-Phenylbutyrylamino)-6-ethanethioylamino-N-(2-oxo-2-
phenylethyl)hexanamide (13). Compound 13 was prepared  using, 4-
phenylbutanoic acid (0.18 g, 1.1 mmol), DMF (5.5 mL), TBTU (0.39 g, 1.21 mmol), 
pyridine (5.5 mL) and 7 (0.4 g, 1.1 mmol) following the same procedure and 
purification described for 12; CH2Cl2 in the workup was replaced by EtOAc (200 
mL).  Compound 13 was obtained as white  solid (0.11 g, 0.23 mmol, 21 %).  
1
H-
NMR (DMSO-d6): δ = 9.93 (s br, 1H), 8.21 (t, J = 5.36 Hz, 1H), 7.98-7.96 (m, 3H), 
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7.65 (t, J = 7.25 Hz, 1H), 7.54 (t, J = 7.25 Hz, 2H), 7.29-7.16 (-Ar, 5H), 4.66-4.54 
(m, 2H), 4.37-4.32 (m, 1H), 3.47-3.42 (m, 2H), 2.58-2.52 (m, 2H), 2.37 (s, 3H), 
2.18-2.15 (m, 2H), 1.83-1.77 (m, 2H), 1.74-1.67 (m, 1H), 1.60-1.50 (m, 3H), 1.37-
1.28 (m, 2H). 
13
C-NMR (DMSO-d6): 198.69, 195.10, 172.17, 171.86, 141.82, 
134.95, 133.50, 128.76, 128.31, 128.23, 127.79, 125.69, 52.19, 45.85, 45.32, 34.66, 
34.66, 32.78, 31.72, 27.08, 26.89, 22.97. ESI-MS (m/z): 468.20 [M + H]
+
. Anal. 
(C26H33N3O3S) C, H, N. 
(2S)-2-(6-Phenyhexanoylamino)-6-ethanethioylamino-N-(2-oxo-2-
phenylethyl)hexanamide (14). Compound 14 was prepared using 6-phenyhexanoic 
acid (0.21 mL, 1.1 mmol), DMF (5.5 mL), TBTU (0.39 g, 1.21 mmol), pyridine (5.5 
mL) and 7 (0.4 g, 1.1 mmol) following the same procedure and purification 
described for 12; CH2Cl2 in the workup was replaced by EtOAc (200 mL). 
Compound 14 was obtained as white solid (0.12 g, 0.24 mmol, 22 %).  
1
H-NMR 
(DMSO-d6) : δ = 9.93 (s br, 1H), 8.20 (t, J = 5.67 Hz, 1H), 7.97 (d, J = 7.25 Hz, 2H), 
7.92 (d, J = 8.20 Hz, 1H), 7.66 (t, J = 7.25 Hz, 1H), 7.54 (t, J = 7.25 Hz, 2H), 7.27-
7.14 (-Ar, 5H), 4.65-4.54 (m, 2H), 4.36-4.31 (m, 1H), 3.46-3.42 (m, 2H), 2.57-2.54 
(m, 2H), 2.38 (s, 3H), 2.18-2.10 (m, 2H), 1.73-1.66 (m, 1H), 1.59-1.49 (m, 7H), 
1.36-1.24 (m, 4H). 
13
C-NMR (DMSO-d6) : 198.75, 195.13, 172.21, 172.15, 142.25, 
134.95, 133.51, 128.77, 128.22, 128.17, 127.79, 125.55, 52.10, 45.84, 45.33, 35.08, 
35.05, 32.78, 31.77, 30.75, 28.27, 26.89, 25.07, 22.92. ESI-MS (m/z): 496.22 [M + 
H]
+
. Anal. (C28H37N3O3S) C, H, N.  
(2S)-2-[3-(Pyridine-3-yl)propanoylamino]-6-ethanethioylamino-N-(2-oxo-2-
phenylethyl) hexanamide (15). Compound 15 was prepared using 3-(pyridin-3-
yl)propanoic acid (0.085 g, 0.56 mmol), DMF (3.0 mL), TBTU (0.20 g, 0.61 mmol), 
pyridine (3.0 mL) and 7 (0.20 g, 0.56 mmol), following the same procedure 
described for 12 with 2h as reaction time. After the  solvents evaporation the 
obtained oil was washed with EtOAc (3 x 7 mL), the residue solubilized with 
CH3CN and selectively precipitated by EtOAc, dried under vacuo and purified by 
chromatography using silica Kieselgel for flash with CH2Cl2: EtOAc: MeOH (6: 2.5: 
1.5) as eluent phase to give the pure product as white solid (0.050 g, 0.11 mmol, 20 
%). 
1
H-NMR (DMSO-d6) : δ = 9.97 (s br, 1H), 8.43 (s, 1H), 8.38 (d, J = 4.41 Hz, 
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1H), 8.27 (t, J = 5.36 Hz, 1H), 8.06 (d, J = 8.20 Hz, 1H), 7.99 (d, J = 7.57 Hz, 2H), 
7.67 (t, J = 7.57 Hz, 1H), 7.62 (d, J = 7.47 Hz, 1H), 7.54 (t, J = 7.57 Hz, 2H), 7.29 
(dd, J = 4.41, 7.47 Hz, 1H), 4.65-4.55 (m, 2H), 4.36-4.32 (m, 1H), 3.44-3.38 (m, 
2H), 2.85-2.82 (m, 2H), 2.55-2.42 (m, 2H), 2.38 (s, 3H), 1.69-1.62 (m, 1H), 1.55-
1.44 (m, 3H), 1.27-1.18 (m, 2H). 
13
C-NMR (DMSO-d6) : δ = 199.21, 195.61, 172.57, 
171.48, 150.03, 147.67, 137.09, 136.28, 135.40, 134.03, 129.27, 128.30, 123.81, 
52.61, 46.31, 45.81, 36.63, 33.27, 32.37, 28.58, 27.37, 23.29. ESI-MS (m/z): 455.19 
[M+ H]
+
. Anal. (C24H30N4O3S
.
 0.5 H2O) C, H, N. 
(2S,4R)-N-[(2S)-6-Ethanethioylamino-1-(2-oxo-2-phenylethylamino)-1-
oxohexan-2-yl]-4-hydroxypyrrolidine-1-benzyloxycarbonyl-2-carboxamide (16). 
Compound 16 was prepared using N-Cbz-Hydroxy-L-proline (0.29 g, 1.10 mmol), 
DMF (5.8 mL), TBTU (0.39 g, 1.21 mmol), pyridine (5.8 mL) and 7 (0.39 g, 1.10 
mmol) following the same procedure procedure and purification described for 12. 
Compound 16 was obtained as white solid (0.14 g, 0.25 mmol, 23 %). 
1
H-NMR 
(DMSO-d6): rotamers A+  δ = 9.91-9.88 (m br, 1H), 8.19-8.13 (m, 2H), 7.99 (t, J = 
7.57 Hz, 2H), 7.67 (t,  J = 7.57 Hz,1H), 7.54 (t, J = 7.57 Hz, 2H), 7.37-7.28 (-Ar, 
5H), 5.10-4.97 (m, 3H), 4.57-4.53 (m, 2H), 4.43-4.41 (m, 0.5H), 4.35-4.26 (m, 
2.5H), 3.52-3.44 (m, 2H), 3.39-3.35 (m, 2H), 2.38 ( s, 1.5H), 2.37 (s, 1.5H) 2.14-2.05 
(m, 1H), 1.90-1.86 (m, 1H), 1.78-1.72 (m, 0.5H), 1.65-1.52 (m, 1.5H), 1.48-1.34 (m, 
2.5H), 1.29-1.19 (m, 1.5H).
13
C-NMR (DMSO-d6): rotamers A+( )  δ = 198.72, 
195.11, 172.01 (171.90), 171.85 (171.71), 154.29 (154.01), 136.90, 134.92, 133.54, 
128.78, 128.37 (128.17), 127.80, 127.46, 126.89, 68.48 (67.77), 65.93 (65.79), 58.80 
(58.09), 55.34 (54.87), 52.39 (52.24), 45.85, 45.39 (45.29), 38.51, 32.77, 31.77 
(31.57), 26.90 (26.82), 22.78.  ESI-MS (m/z): 569.15 [M + H]
+
. Anal. (C29H36N4O6S) 
C, H, N. 
(2S)-N-[(2S)-6-Ethanethioylamino-1-(2-oxo-2-phenylethylamino)-1-oxohexan-2-
yl]-pyrrolidine-1-tert-butoxycarbonyl-2-carboxamide (17). Compound 17 was 
prepared using N-Boc-L-proline (0.18 g, 0.84 mmol), DMF (4.5 mL), TBTU (0.30 g, 
0.93 mmol), pyridine (4.5 mL) and 7 (0.30 g, 0.84 mmol), following the same 
procedure described for 12, the used amount of CH2Cl2 was 150 mL. Purification by 
two columns chromatography, using Aluminum oxide EtOAc : Hexane : MeOH (7: 
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1.5: 1.5) as eluent phase and silica Kieselgel for flash with EtOAc : Hexane : MeOH 
(7: 2: 1) to give the pure product as white solid (0.10 g, 0.19 mmol, 23 %).  
1
H-NMR 
(DMSO-d6) : rotamers A+B δ = 9.91 (s br, 1H), 8.27 (t, J = 5.36 Hz, 0.6H), 8.15 (t, J 
= 5.36 Hz, 0.4H), 7.98-7.92 (m, 3H), 7.66 (t, J = 7.25 Hz, 1H), 7.54 (t, J = 7.25 Hz, 
2H), 4.69-4.55 (m, 2H), 4.39-4.32 (m, 1H), 4.17-4.15 (m, 1H), 3.47-3.37 (m, 3H), 
3.28-3.25 (m, 1H), 2.38 (s, 3H), 2.14-2.00 (m, 1H), 1.86-1.67 (m, 4H), 1.62-1.52 (m, 
3H), 1.41-1.30 (m, 11H). 
13
C-NMR (DMSO-d6) : rotamers A+( ) δ = 198.77, 195.11 
(195.03), 172.33, 171.97 (171.93), 153.76 (153.26), 134.92, 133.53, 128.78, 127.80, 
78.64 (78.29), 59.28, 52.15, 46.74 (46.49), 45.85, 45.30, 32.77, 32.05 (31.80), 31.00 
(29.58), 28.11 (28.00), 26.91, 23.98 (23.02), 22.85 (22.75). ESI-MS (m/z): 519.03 [M 
+ H]
+
. Anal. (C26H38N4O5S) C, H, N. 
(S)-2-(2-((2S,5S)-5-Benzyl-3,6-dioxopiperazin-2-yl)acetamido)-6-
ethanethioamido-N-(2-oxo-2-phenylethyl)hexanamide (18). Compound 18 was 
prepared using [(2S,5S)-5-benzyl-3,6-dioxopiperazin-2-yl]acetic acid (0.20 g, 0.76 
mmol), DMF (4.0 mL), TBTU (0.27 g, 0.87 mmol), pyridine (4.0 mL) and 7 (0.27 g, 
0.75 mmol) following the same procedure described for 12  the used amount of 
CH2Cl2 was 160 mL. Purification by two columns chromatography, using silica 
Kieselgel for flash EtOAc : Hexane : MeOH (7: 1.5: 1.5) and CH2Cl2 : Hexane : 
MeOH (7: 1.5: 1.5)  as eluent phase to give the pure product as white solid (0.050 g, 
0.088 mmol, 12 %). 
1
H-NMR (DMSO-d6) : δ = 9.94 (s br, 1H), 8.28 (t, J = 5.67 Hz, 
1H), 8.20 (s, 1H), 8.02 (d, J = 7.88 Hz, 1H), 7.97 (d, J = 7.57 Hz, 2H), 7.69-7.64 (m, 
2H), 7.53 (t, J = 7.57 Hz, 2H), 7.29-7.19 (-Ar, 5H), 4.63-4.50 (m, 2H), 4.25-4.21 (m, 
2H), 4.13-4.10 (m, 1H), 3.49-3.45 (m, 2H), 3.10 (m, 1H), 2.94 (m, 1H), 2.38-2.35 
(m, 4H), 1.77-1.71 (m, 1H), 1.63-1.52 (m, 4H), 1.37-1.29 (m, 2H).
13
C-NMR 
(DMSO-d6) : δ = 198.91, 195.09, 172.02, 169.43, 167.19, 166.51, 136.47, 134.81, 
133.39, 130.21, 128.71, 128.01, 127.63, 126.75, 54.87, 52.73, 51.50, 45.72, 45.52, 
38.57, 37.67, 32.97, 31.41, 26.75, 22.81. ESI-MS (m/z): 566.14 [M + H]
+
, 588.23 
[M+ Na]
+
. Anal. (C29H35N5O5S) C, H, N. 
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(2S)-6-(Ethanethioylamino)-N-phenyl-2-[3-(pyridin-3-
yl)propanoylamino]hexanamide (19). Compound 19 was prepared using 3-
(pyridin-3-yl)propanoic acid (0.15 g, 1.0 mmol), DMF (4.7 mL), TBTU (0.35 g, 1.1 
mmol), pyridine (4.7 mL) and 8 (0.32 g, 1.0 mmol) following the same procedure 
described for 12, the used amount of CH2Cl2 was 170 mL and the workup was made 
without HCl 0.5M. Purification by two columns chromatography using Aluminum 
oxide and silica Kieselgel for flash, with EtOAc : Hexane : MeOH (7: 1: 2) as eluent 
phase to give the pure product as white solid (0.19 g, 0.46 mmol, 46 %). 
1
H-NMR 
(DMSO-d6): δ = 10.04 (s, 1H), 9.97 (s br, 1H), 8.44 (s, 1H), 8.38 (d, J = 4.88 Hz, 
1H), 8.17 (d, J = 7.93 Hz, 1H), 7.63-7.58 (m, 3H), 7.32-7.27 (m, 3H), 7.05 (m, 1H), 
4.40-4.36 (m, 1H), 3.44-3.41 (m, 2H), 2.85-2.82 (m, 2H), 2.54-2.46 (m, 2H), 2.36 (s, 
3H), 1.69-1.62 (m, 1H), 1.57-1.48 (m, 3H), 1.32-1.18 (m, 2H). 
13
C-NMR (DMSO-
d6): δ = 198.80, 171.19, 170.76, 149.56, 147.18, 138.89, 136.57, 135.77, 128.68, 
128.68, 123.29, 119.28, 53.22, 45.24, 36.07, 32.79, 31.81, 28.13, 26.92, 22.96. ESI-
MS (m/z): 413.22 [M + H]
+
. Anal. (C22H28N4O2S) C, H, N. 
(2S)-6-(Ethanethioylamino)-N-phenyl-2-[(dimethylamino)acetylamino]-
hexanamide (20). Compound 20 was prepared using a suspension of N,N-
Dimethylglycine hydrochloride (0.13 g, 0.93 mmol), DMF (5.0 mL), TBTU (0.34 g, 
1.05 mmol), pyridine (5.0 mL) and 8 (0.30 g, 0.96 mmol) following the same 
procedure described for 12. Reaction time  2h, 30min, the used amount of CH2Cl2 
was 130 mL and the workup was made without HCl 0.5M. Purification by column 
chromatography using silica Kieselgel for flash with CH2Cl2 : MeOH (6.5: 3.5) as 
eluent phase to give the pure product as white solid (0.074 g, 0.20 mmol, 21 %). 
 1
H-
NMR (DMSO-d6): δ = 10.08 (s, 1H), 9.94 (s br, 1H) 7.82 (d, J = 8.20 Hz, 1H), 7.58 
(d, J = 7.88 Hz, 2H), 7.30 (t, J = 7.88 Hz, 2H), 7.05 (t, J = 7.88 Hz, 1H), 4.50-4.45 
(m, 1H), 3.46-3.43 (m, 2H),  2.95 (d, J = 15.26 Hz, 1H) 2.92 (d, J = 15.26 Hz, 1H), 
2.35 (s, 3H), 2.24 (s, 6H), 1.78-1.52 (m, 4H), 1.39-1.23 (m, 2H). 
13
C-NMR (DMSO-
d6): δ = 199.28, 170.93, 169.90, 139.22, 129.20, 123.91, 119.77, 62.94, 53.12, 45.89, 
45.65, 33.24, 32.62, 27.38, 23.37. ESI-MS (m/z): 365.19 [M + H]
+
. Anal. 
(C18H28N4O2S) C, H, N. 
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(2S)-N-[(2S)-6-Ethanethioylamino-1-phenylamino-1-oxohexan-2-yl]-pyrrolidine-
1-tert-butoxycarbonyl-2-carboxamide (21). Compound 21 was prepared using N-
Boc-L-proline (0.28 g, 1.30 mmol), DMF (6.0 mL), TBTU (0.46 g, 1.43 mmol), 
pyridine (6.0 mL) and 8 (0.41 g, 1.29 mmol) following the same procedure described 
for 12, the used amount of CH2Cl2 was 180 mL. Purification by column 
chromatography using silica Kieselgel for flash with EtOAc : MeOH (9.5: 0.5) as 
eluent phase to give the pure product as light yellow solid (0.30 g, 0.63 mmol, 49 %). 
1
H-NMR (DMSO-d6) : rotamers A+  δ = 10.06 (s, 0.6H), 9.93 (s br, 1H), 9.84 (s, 
0.4H), 8.04 (d, J = 7.88 Hz, 1H), 7.59 (d, J = 7.57 Hz, 2H), 7.30 (t, J = 7.57 Hz,  
2H), 7.04 (t, J = 7.57 Hz, 1H), 4.43-4.33 (m, 1H), 4.19-4.15 (m, 1H), 3.45-3.36 (m, 
3H), 3.29-3.24 (m, 1H), 2.36 (s, 3H), 2.15-2.04 (m, 1H), 1.83-1.52 (m, 7H), 1.45-
1.23 (m, 11H). 
13
C-NMR (DMSO-d6) : rotamers A+( ) δ = 198.79, 172.55 (172.18), 
170.58, 153.88 (153.29), 138.89 (138.81), 128.67, 123.27, 119.21 (119.14), 78.76 
(78.34), 59.36 (59.31), 53.21, 46.72 (46.50), 45.22 (45.16), 32.75, 31.83 (31.49), 
30.99 (29.77), 28.11 (27.98), 26.90, 23.91, 23.05 (23.02). ESI-MS (m/z): 477.03 [M 
+ H]
+
, 499.19 [M + Na]
+
. Anal. (C24H36N4O4S) C, H, N. 
(2S)-N-[(2S)-6-Ethanethioylamino-1-(phenylamino)-1-oxohexan-2-yl]-
pyrrolidine-2-carboxamide hydrochloride (22). To a solution of 21 (0.10 g, 0.21 
mmol) in 2-propanol (3.6 mL), 1,2-ethanedithiol (0.018 mL, 0.21 mmol) was added 
and after 1 min under stirring at r.t HCl 12N (0.11 mL, 1.32 mmol) was added and 
the solution heated at 60°C; After 20min and 40min other HCl 12N (0.11 mL) was 
added; when the total mmol of  HCl in the reaction flask were 3.96 mmol, the 
solution was maintained for 60 min at 60°C under stirring. After this time, 2-
propanol was evaporated under reduced pressure and the yellow oil was washed with 
petroleum ether (4 x 10 mL) and CH2Cl2: petroleum ether (1:1) (4 x 4 mL) provides 
the product as white solid (0.077 g, 0.18 mmol, 85 %). 
1
H-NMR (DMSO-d6) : δ = 
10.23 (s, 1H), 10.11 (s br, 1H), 9.72 (s br, 1H), 8.85 (d, J = 7.57 Hz, 1H), 8.49 (s br, 
1H), 7.61 (d, J = 7.25 Hz, 2H), 7.30 (t, J = 7.25 Hz, 2H), 7.05 (t, J = 7.25 Hz, 1H), 
4.46-4.42 (m, 1H), 4.28-4.23 (m, 1H), 3.49-3.45 (m, 2H), 3.24-3.16 (m, 2H), 2.38-
2.33 (m, 4H), 1.89-1.55 (m, 7H), 1.48-1.31 (m, 2H). 
13
C-NMR (DMSO-d6) : δ = 
198.77, 170.01, 168.22, 138.86, 128.69, 123.36, 119.21, 58.62, 53.95, 45.58, 45.03, 
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32.74, 31.58, 29.62, 26.81, 23.46, 23.07. ESI-MS (m/z): 377.20 [M + H]
+
. Anal. 
(C19H29ClN4O2S·0.3H2O) C, H, N. 
(2S,4R)-N-[(2S)-6-Ethanethioylamino-1-phenylamino-1-oxohexan-2-yl]-4-
hydroxypyrrolidine-1-benzyloxycarbonyl-2-carboxamide (23). Compound 23 was 
prepared using N-Cbz-Hydroxy-L-proline (0.36 g, 1.35 mmol), DMF (6.3 mL), 
TBTU (0.47 g, 1.46 mmol), pyridine (6.3 mL) and 8 (0.42 g, 1.33 mmol) following 
the same procedure described for 12, the used amount of CH2Cl2 was 200 mL. 
Purification by two columns chromatography using silica Kieselgel for flash with 
EtOAc : Hexane : MeOH (7: 1.5: 1.5) and EtOAc : Hexane : MeOH (7: 2: 1) as 
eluent phase to give the pure product as white solid (0.17 g, 0.32 mmol, 24 %). 
1
H-
NMR (DMSO-d6): rotamers A+  δ = 10.04 (s, 0.55H), 9.93-9.90 (m br, 1H), 9.82 (s, 
0.45H), 8.26 (m, 1H), 7.63-7.59 (m, 2H), 7.37-7.30 (m, 7H), 7.08-7.03 (m, 1H), 
5.13-4.97 (m, 3H), 4.44-4.41 (m, 0.5H), 4.38-4.34 (m, 1.5H), 4.28-4.23 (m, 1H), 
3.53-3.47 (m, 2H), 3.39-3.35 (m, 2H), 2.36 (s, 1.45H), 2.35 (s, 1.55H) 2.14-2.07 (m, 
1H), 1.90-1.84 (m, 1H), 1.79-1.73 (m, 0.5H), 1.67-1.20 (m, 5.5H).  
13
C-NMR 
(DMSO-d6): rotamers A+(B)  δ = 198.77, 172.14 (171.83), 170.54, 154.43 (154.01), 
138.88 (138.83), 136.86 (136.82), 128.68, 128.38 (128.16), 127.78 (127.49), 127.42 
(126.94), 123.32 (123.28), 119.19 (119.11), 68.40 (67.60), 65.92 (65.87), 58.90 
(57.90), 55.40 (54.80), 53.38 (53.30), 45.26  (45.20), 38.63, 32.75, 31.80 (31.38), 
26.92 (26.72), 22.85 (22.80).  ESI-MS (m/z): 527.11 [M + H]
+
. Anal. (C27H34N4O5S) 
C, H, N. 
(2S)- 2-Benzyl 6-ethanethioamido-1-oxo-1-(2-phenylethylamino)hexan-2-
ylcarbamate (25). To a solution of 24 (0.23 g, 0.68 mmol) in DMF (3.5 mL) under 
Argon flow were added TBTU (0.24 g, 0.75 mmol), pyridine (3.5 mL) and 
maintained under stirring for 10min at rt . After this time 2-phenylethanamine (0.087 
mL, 0.69 mmol) was added and the solution mixed 2h, 30 min at rt under Argon 
flow. Solvents were evaporated and the obtained oil was dissolved in EtOAc (200 
mL), washed with HCl 0.5M, brine, NaHCO3 5% (twice), finally dried with Na2SO4 
and evaporated under vacuo. The crude product obtained was purified by column 
chromatography using silica Kieselgel for flash and EtOAc : CH2Cl2 : MeOH (4.5 : 4 
: 1.5) as eluent phase to give the pure product as white solid (0.19 g, 0.44 mmol, 63 
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%). 
1
H-NMR (CDCl3) : δ = 7.77 (s br, 1H), 7.39-7.29 (m, 7H), 7.25-7.22 (m, 1H), 
7.18 (m, 2H), 6.12 (s br, 1H), 5.45 (d, J = 7.57 Hz, 1H), 5.09 (s, 2H), 4.12-4.07 (m, 
1H), 3.65-3.46 (m, 4H), 2.82-2.80 (m, 2H), 2.54 (s, 3H), 1.81-1.74 (m, 1H), 1.68-
1.59 (m, 3H), 1.40-1.33 (m, 2H). 
13
C-NMR (DMSO-d6) : δ = 198.75, 171.57, 155.81, 
139.31, 136.98, 128.54, 128.21, 128.15, 127.64, 127.55, 125.94, 65.31, 54.63, 45.19, 
40.02, 34.99, 32.74, 31.65, 26.83, 22.93. ESI-MS (m/z): 442.20 [M + H]
+
. Anal. 
(C24H31N3O3S) C, H, N. 
(2S)- 2-Benzyl 6-ethanethioamido-1-oxo-1-(benzylamino)hexan-2-ylcarbamate 
(26). Compound 26 was prepared using 24 (0.23 g, 0.68 mmol), DMF (3.5 mL), 
TBTU (0.24 g, 0.75 mmol), pyridine (3.5 mL) and benzylamine (0.075 mL, 0.69 
mmol), following the same procedure and purification described for 25. Compound 
26 was obtained as white solid (0.19 g, 0.45 mmol, 66 %). 
1
H-NMR (CDCl3) : δ = 
7.69 (s br, 1H), 7.38-7.29 (m, 8H), 7.26-7.24 (m, 2H), 6.41 (s br, 1H), 5.45 (d, J = 
7.57 Hz, 1H), 5.09 (s, 2H), 4.48-4.40 (m, 2H), 4.23-4.19 (m, 1H), 3.68-3.60 (m, 2H), 
2.53 (s, 3H), 1.91-1.86 (m, 1H), 1.75-1.68 (m, 3H), 1.45-1.39 (m, 2H). 
13
C-NMR 
(DMSO-d6) : δ = 198.74, 171.80, 155.90, 139.28, 136.97, 128.21, 128.11, 127.64, 
127.55, 126.98, 126.58, 65.32, 54.67, 45.18, 41.97, 32.73, 31.56, 26.79, 23.01. ESI-
MS (m/z): 428.18 [M + H]
+ 
, 450.19 [M + Na]
+
. Anal. (C23H29N3O3S) C, H, N. 
(2S)- 2-Benzyl 6-ethanethioamido-1-oxo-1-[2-oxo-2-(4-
methoxyphenyl)ethylamino]hexan-2-ylcarbamate (27). Compound 27 was 
prepared using 24 (0.33 g, 0.97 mmol), DMF (4.8 mL), TBTU (0.34 g, 1.06 mmol), 
pyridine (4.8 mL) and 2-amino-1-(4-methoxyphenyl)ethanone hydrochloride  (0.19 
g, 0.94 mmol) following the same procedure described for 25. Purification by 
column chromatography using silica Kieselgel for flash and EtOAc : Hexane : MeOH 
(7 : 2 : 1) as eluent phase to give the pure product as white solid (0.27 g, 0.55 mmol, 
57 %). 
1
H-NMR (DMSO-d6) : δ = 9.93 (s br, 1H), 8.17 (t, J = 5.36 Hz, 1H), 7.97 (d, 
J = 8.83 Hz, 2H), 7.45 (d, J = 8.20 Hz, 1H), 7.37-7.30 (m, 5H), 7.05 (d, J = 8.83 Hz, 
2H), 5.06-5.01 (m, 2H), 4.64-4.49 (m, 2H), 4.09-4.05 (m, 1H), 3.84 (s, 3H), 3.48-
3.40 (m, 2H), 2.37 (s, 3H), 1.74-1.67 (m, 1H), 1.60-1.50 (m, 3H), 1.41-1.30 (m, 2H).  
13
C-NMR (DMSO-d6) : δ = 198.75, 193.35, 172.26, 163.34, 155.96, 137.03, 130.12, 
128.31, 127.81, 127.78, 127.64, 113.98, 65.37, 55.54, 54.58, 45.47, 45.30, 32.80, 
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31.71, 26.88, 23.05. ESI-MS (m/z): 486.14 [M + H]
+
. HPLC : Rt. 2.64 min, area 
percent 98.87 % 265nm. Anal. (C25H31N3O5S ·0.02hexane) C, H, N. 
(2S)- 2-Benzyl 6-ethanethioamido-1-oxo-1-(2-hydroxy-2-
phenylethylamino)hexan-2-ylcarbamate (28). Compound 28 was prepared using 
24 (0.33 g, 0.97 mmol), DMF (4.8 mL), TBTU (0.34 g, 1.06 mmol), pyridine (4.8 
mL) and (R,S)-2-amino-1-phenylethanol (0.13 g, 0.95 mmol), following the same 
procedure described for 25. Purification  by column chromatography using silica 
Kieselgel for flash and EtOAc : Hexane : MeOH (7 : 2 : 1) as eluent phase to give the 
pure product as white solid (0.22 g, 0.48 mmol, 49 %). 
1
H-NMR (DMSO-d6) : 
diastereoisomer A+   δ = 9.93 (s br, 1H), 7.87-7.83 (m, 1H), 7.40-7.23 (m, 11H), 
5.46-5.44 (m, 1H), 5.06-5.00 (m, 2H), 4.63-4.58 (m, 1H), 3.99-3.93 (m, 1H), 3.47-
3.39 (m, 2H), 3.36-3.31 (m, 0.4H), 3.26-3.24 (m, 1H), 3.16-3.11 (m, 0.6H), 2.38 (s, 
3H), 1.58-1.43 (m, 4H), 1.32-1.18 (m, 2H). 
13
C-NMR (CDCl3) : diastereoisomer 
A+( )  δ = 200.89 (200.86), 172.75, 156.49, 141.32, 135.92, 128.57, 128.57, 128.31, 
128.00, 127.96, 125.75, 73.08 (72.99), 67.19, 54.63, 47.16, 45.79, 33.87, 32.22, 
27.04 (27.00), 22.60. ESI-MS (m/z): 458.14 [M + H]
+ 
HPLC : Rt. 1.92 min, area 
percent 98.91 % 265nm.
 
Anal.  (C24H31N3O4S·0.1hexane·0.01EtOAc) C, H, N.  
(2S)- 2-Benzyl 6-ethanethioamido-1-oxo-1-[2-(1H-indol-3yl)ethylamino]hexan-2-
ylcarbamate (29). Compound 29 was prepared using 24 (0.33 g, 0.97 mmol), DMF 
(4.8 mL), TBTU (0.34 g, 1.06 mmol), pyridine (4.8 mL) and tryptamine (0.15 g, 0.94 
mmol) following the same procedure described for 25, the workup was made without 
HCl 0.5M. Purification by column chromatography using silica Kieselgel for flash 
and EtOAc : Hexane : MeOH (7 : 2 : 1) as eluent phase to give the pure product as 
white solid (0.32 g, 0.66 mmol, 68 %). 
1
H-NMR (DMSO-d6): δ = 10.79 (s, 1H), 9.92 
(s br, 1H), 7.97 (t, J = 5.67 Hz, 1H), 7.54 (d, J = 7.88 Hz, 1H), 7.37-7.32 (m, 7H), 
7.13 (s, 1H), 7.05 (t, J = 7.57 Hz, 1H), 6.97 (t, J = 7.57 Hz, 1H), 5.06-4.99 (m, 2H), 
3.95-3.91 (m, 1H), 3.45-3.40 (m, 2H), 3.38-3.26 (m, 2H), 2.82-2.79 (m, 2H), 2.36 (s, 
3H), 1.64-1.46 (m, 4H), 1.35-1.22 (m, 2H).  
13
C-NMR (DMSO-d6): δ = 198.75, 
171.65, 155.93, 137.05, 136.21, 128.30, 127.75, 127.67, 127.16, 122.64, 120.87, 
118.22, 118.18, 111.68, 111.32, 65.36, 54.69, 45.25, 39.47, 32.79, 31.70, 26.89, 
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25.13, 23.09. ESI-MS (m/z): 481.17 [M + H]
+ 
, 503.23 [M + Na]
+
. Anal. 
(C26H32N4O3S) C, H, N. 
(2S)- 2-Benzyl 6-ethanethioamido-1-oxo-1-[2-(5-methoxy-1H-indol-
3yl)ethylamino]hexan-2-ylcarbamate (30). Compound 30 was prepared using 24 
(0.34 g, 1.00 mmol), DMF (4.5 mL), TBTU (0.36 g, 1.12 mmol), pyridine (4.5 mL) 
and 5-methoxytryptamine (0.19 g, 1.00 mmol) following the same procedure used 
for 25, the workup was made without HCl 0.5M. Purification by column 
chromatography using silica Kieselgel for flash and EtOAc : Hexane : MeOH (7.5 : 2 
: 0.5) as eluent phase to give the pure product as white solid (0.33 g, 0.65 mmol, 65 
%). 
1
H-NMR (DMSO-d6): δ = 10.63 (s, 1H), 9.93 (s br, 1H), 7.97 (t, J = 5.36 Hz, 
1H), 7.37-7.22 (m, 7H), 7.10 (s, 1H), 7.03 (s, 1H), 6.71 (d, J = 8.83 Hz, 1H), 5.07-
5.00 (m, 2H), 3.97-3.90 (m, 1H), 3.76 (s, 3H), 3.46-3.29 (m, 4H), 2.79 (t, J = 7.25 
Hz, 2H), 2.37 (s, 3H), 1.64-1.49 (m, 4H), 1.32-1.24 (m, 2H). 
13
C-NMR (DMSO-d6): 
δ = 198.75, 171.67, 155.95, 152.96, 137.06, 131.36, 128.32, 127.76, 127.69, 127.47, 
123.32, 111.97, 111.43, 111.02, 100.11, 65.37, 55.34, 54.72, 45.26, 39.34, 32.80, 
31.72, 26.91, 25.18, 23.12. ESI-MS (m/z): 511.19 [M + H]
+
. Anal. (C27H34N4O4S) C, 
H, N. 
(2S)- 2-Benzyl 6-ethanethioamido-1-oxo-1-[2-(5-benzyloxy-1H-indol-
3yl)ethylamino]hexan-2-ylcarbamate (31). Compound 31 was prepared using 24 
(0.34 g, 1.00 mmol), DMF (4.5 mL), TBTU (0.36 g, 1.12 mmol), pyridine (4.5 mL) 
and 5-benzyloxytryptamine hydrochloride  (0.30 g, 1.00 mmol), following the same 
procedure used for 25, the workup was made without HCl 0.5M. Purification by 
column chromatography using silica Kieselgel for flash and EtOAc : Hexane : MeOH 
(7.5 : 2 : 0.5) as eluent phase to give the pure product as white solid (0.22 g, 0.37 
mmol, 37 %). 
1
H-NMR (DMSO-d6): δ = 10.66 (s, 1H), 9.93 (s br, 1H), 7.97 (t, J = 
5.36 Hz, 1H), 7.50-7.23 (m, 12H), 7.16 (s, 1H), 7.11 (s, 1H), 6.81 (d, J = 10.40 Hz, 
1H), 5.10-5.00 (m, 4H), 3.98-3.93 (m, 1H), 3.48-3.27 (m, 4H), 2.79 (t, J = 7.25 Hz, 
2H), 2.37 (s, 3H), 1.61-1.46 (m, 4H), 1.36-1.23 (m, 2H). 
13
C-NMR (DMSO-d6): δ = 
198.76, 171.68, 155.96, 151.98, 137.81, 137.06, 131.56, 128.32,128.32, 127.76, 
127.69, 127.69, 127.59, 127.48, 123.44, 111.97, 111.59, 111.45, 101.83, 69.86, 
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65.37, 54.72, 45.26, 39.31, 32.80, 31.72, 26.91, 25.17, 23.12. ESI-MS (m/z): 587.22 
[M + H]
+
. Anal. (C33H38N4O4S) C, H, N. 
(2S)-2-Benzyl 6-ethanethioamido-1-oxo-1-(pyridin-3-ylamino)hexan-2-
ylcarbamate (32). Compound 32 was prepared using 24 (0.50 g, 1.47 mmol), DMF 
(7.0 mL), TBTU (0.52 g, 1.62 mmol), pyridine (7.0 mL) and 3-aminopyridine (0.14 
g, 1.48 mmol), following the same procedure described for 25, the workup was made 
without HCl 0.5M. Purification by two columns chromatography using Aluminum 
oxide and silica Kieselgel for flash, with CH2Cl2: EtOAc: MeOH (5.5: 3: 1.5) as 
eluent phase to give the pure product as white solid (0.12 g, 0.29 mmol, 20 %). 
1
H-
NMR (DMSO-d6) : δ = 10.25 (s, 1H), 9.95 (s br, 1H), 8.76 (d, J = 2.21 Hz, 1H), 8.27 
(dd, J = 1.58, 6.31 Hz, 1H), 8.05-8.03 (m, 1H), 7.63 (d, J = 7.57 Hz, 1H), 7.37-7.30 
(m, 6H), 5.07-5.01 (m, 2H), 4.17-4.13 (m, 1H), 3.49-3.42 (m, 2H), 2.36 (s, 3H), 
1.75-1.50 (m, 4H), 1.46-1.29 (m, 2H). 
13
C-NMR (DMSO-d6) : δ = 198.79, 171.67, 
156.12, 144.23, 140.81, 136.95, 135.56, 128.33, 127.80, 127.72, 126.24, 123.63, 
65.47, 55.54, 45.16, 32.80, 31.36, 26.91, 23.19. ESI-MS (m/z): 415.19 [M + H]
+
. 
Anal. (C21H26N4O3S) C, H, N. 
(2S)-2-Benzyl 6-ethanethioamido-1-oxo-1-(2-amino-2-oxoethylamino)hexan-2-
ylcarbamate (33). Compound 33 was prepared using 24 (0.50 g, 1.47 mmol), DMF 
(7.0 mL), TBTU (0.52 g, 1.62 mmol), pyridine (7.0 mL) and glycinamide 
hydrochloride  (0.16 g, 1.45 mmol), following the same procedure used for 25, 
CH2Cl2 was replaced by CH2Cl2 : MeOH (9: 2) (250 mL). Purification by column 
chromatography using silica Kieselgel for flash, with CH2Cl2: MeOH (8.5: 1.5) as 
eluent phase to give the pure product as white solid (0.21 g, 0.53 mmol, 37 %). 
1
H-
NMR (DMSO-d6) : δ = 9.92 (s br, 1H), 8.10 (t, J = 5.67 Hz, 1H), 7.49 (d, J = 7.57 
Hz, 1H), 7.39-7.32 (m, 5H), 7.19 (s, 1H), 7.07 (s, 1H), 5.06-4.99 (m, 2H), 3.99-3.94 
(m, 1H), 3.67-3.59 (m, 2H), 3.47-3.41 (m, 2H), 2.37 (s, 3H), 1.70-1.63 (m, 1H), 
1.57-1.48 (m, 3H), 1.39-1.23 (m, 2H). 
13
C-NMR (DMSO-d6) : δ = 198.75, 172.04, 
170.77, 156.12, 136.91, 128.32, 127.78, 127.69, 65.46, 54.72, 45.26, 41.86, 32.79, 
31.27, 26.85, 23.01. ESI-MS (m/z): 395.19 [M + H]
+
. Anal. (C18H26N4O4S) C, H, N. 
(2S)-2-Benzyl 6-ethanethioamido-1-oxo-1-[((2S)-1-amino-1-oxopropan-
2yl)amino]hexan-2-ylcarbamate (34). Compound 34 was prepared using 24 (0.50 
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g, 1.47 mmol), DMF (7.0 mL), TBTU (0.52 g, 1.62 mmol), pyridine (7.0 mL) and L-
alaninamide hydrochloride  (0.18 g, 1.44 mmol), following the same procedure 
described for 25, CH2Cl2 was replaced by CH2Cl2: MeOH (9: 2) (250 mL). 
Purification by column chromatography using silica Kieselgel for flash, with CH2Cl2: 
MeOH (8.5: 1.5) as eluent phase to give the pure product as white solid (0.34 g, 0.83 
mmol, 58 %). 
1
H-NMR (DMSO-d6) : δ = 9.91 (s br, 1H), 7.87 (d, J = 7.25 Hz, 1H), 
7.43 (d, J = 8.20 Hz, 1H), 7.38-7.29 (m, 6H), 6.99 (s, 1H), 5.04-4.99 (m, 2H), 4.22-
4.16 (m(5), J = 7.25 Hz, 1H), 3.98-3.94 (m, 1H), 3.47-3.37 (m, 2H), 2.36 (s, 3H), 
1.68-1.61 (m, 1H), 1.57-1.47 (m, 3H), 1.37-1.27 (m, 2H), 1.20 (d, J = 7.25 Hz, 3H). 
13
C-NMR (DMSO-d6) : δ = 198.78, 174.12, 171.40, 156.01, 137.02, 128.34, 127.76, 
127.62, 65.39, 54.61, 47.87, 45.30, 32.82, 31.52, 26.88, 23.04, 18.44. ESI-MS (m/z): 
409.19 [M + H]
+
. Anal. (C19H28N4O4S) C, H, N. 
(2S,4R)-N-[(2S)-6-Ethanethioylamino-1-benzylamino-1-oxohexan-2-yl]-4-
hydroxypyrrolidine-1-benzyloxycarbonyl-2-carboxamide (35). Compound 35 was 
prepared using N-Cbz-Hydroxy-L-proline (0.30 g, 1.13 mmol), DMF (5.5 mL), 
TBTU (0.40 g, 1.24 mmol), pyridine (5.5 mL) and 9 (0.37 g, 1.12 mmol) following 
the same procedure described for 12, CH2Cl2 was replaced by EtOAc (200 mL). 
Purification by two columns chromatography using silica Kieselgel for flash with 
EtOAc : Hexane : MeOH (7: 1.5: 1.5) and CH2Cl2 : MeOH (9.5 : 0.5) as eluent phase 
to give the pure product as white solid (0.53 g, 0.98 mmol, 87 %). 
1
H-NMR (DMSO-
d6): rotamers A+  δ = 9.91-9.88 (m br, 1H), 8.37 (t, J = 5.99 Hz, 0.51H), 8.25 (t, J = 
5.99 Hz, 0.49H), 8.15-8.13 (m, 1H), 7.38-7.20 (-Ar, 10H), 5.06-4.93 (m, 3H), 4.41-
4.38 (m, 0.5H), 4.31-4.21 (m, 4.5H), 3.53-3.42 (m, 2H), 3.37-3.33 (m, 2H), 2.37 (s, 
1.49H), 2.36 (s, 1.51H), 2.12-2.04 (m, 1H), 1.86-1.83 (m, 1H), 1.78-1.71 (m, 0.5H), 
1.62-1.13 (m, 5.5H). 
13
C-NMR (DMSO-d6): rotamers A + ( ) δ = 198.74, 171.96 
(171.71), 171.45, 154.44 (154.00), 139.29, 136.86 (136.81), 128.37, 128.20 (128.17), 
127.78, 127.47 (127.44), 127.02 (126.98), 126.88 (126.69), 68.43 (67.76), 65.96 
(65.79), 59.00 (58.09), 55.33 (54.88), 52.61 (52.49), 45.33 (45.24), 41.96 (41.92), 
38.54, 32.77, 31.71 (31.27), 26.88 (26.80), 22.93 (22.88). ESI-MS (m/z): 541.21  [M 
+ H]
+
. Anal. (C28H36N4O5S·0.03hexane) C, H, N. 
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(2S)-2-(6-Phenyhexanoylamino)-6-ethanethioylamino-N-benzylhexanamide (36). 
Compound 36 was prepared using 6-phenyhexanoic acid (0.22 mL, 1.17 mmol), 
DMF (5.5 mL), TBTU (0.40 g, 1.24 mmol), pyridine (5.5 mL) and 9 (0.37 g, 1.12 
mmol) following the same procedure described for 12,  CH2Cl2 was replaced by  
EtOAc (200 mL). Purification by two columns chromatography using silica 
Kieselgel for flash with EtOAc : Hexane : MeOH (7: 2: 1) as eluent phase to give the 
pure product as white solid (0.22 g, 0.47 mmol, 42 %).  
1
H-NMR (DMSO-d6) : 9.92 
(s br, 1H), 8.37 (t, J = 5.99 Hz, 1H), 7.90 (d, J = 7.88 Hz, 1H), 7.32-7.14 (-Ar, 10H), 
4.27-4.24 (m, 3H), 3.48-3.39 (m, 2H), 2.56-2.53 (m, 2H), 2.37 (s, 3H), 2.18-2.08 (m, 
2H), 1.70-1.63 (m, 1H), 1.58-1.49 (m, 7H), 1.34-1.23 (m, 4H). 
13
C-NMR (DMSO-d6) 
: δ = 198.75, 172.17, 171.83, 142.24, 139.40, 128.22, 128.18, 128.17, 127.00, 
126.66, 125.55, 52.35, 45.28, 41.91, 35.08, 35.05, 32.78, 31.72, 30.74, 28.26, 26.87, 
25.08, 23.02. ESI-MS (m/z): 468.25  [M + H]
+
. Anal. (C27H37N3O2S) C, H, N. 
(2S)-2-(7-Phenyheptanoylamino)-6-ethanethioylamino-N-benzylhexanamide 
(37). Compound 37 was prepared using 7-phenyheptanoic acid (0.24 mL, 1.12 
mmol), DMF (5.5 mL), TBTU (0.40 g, 1.24 mmol), pyridine (5.5 mL) and 9 (0.37 g, 
1.12 mmol) following the same procedure described for 12, CH2Cl2 was replaced by 
EtOAc (200 mL). Purification by two columns chromatography using silica 
Kieselgel for flash with EtOAc : Hexane : MeOH (7: 2.5: 0.5) as eluent phase to give 
the pure product as white solid (0.10 g, 0.21 mmol, 18 %).  
1
H-NMR (DMSO-d6): 
9.92 (s br, 1H), 8.37 (t, J = 6.30 Hz, 1H), 7.91 (d, J = 7.88 Hz, 1H), 7.31-7.14 (-Ar, 
10H), 4.30-4.24 (m, 3H), 3.46-3.39 (m, 2H), 2.56-2.53 (m, 2H), 2.36 (s, 3H), 2.17-
2.07 (m, 2H), 1.70-1.63 (m, 1H), 1.57-1.46 (m, 7H), 1.34-1.24 (m, 6H). 
13
C-NMR 
(DMSO-d6): δ = 198.77, 172.24, 171.87, 142.28, 139.41, 128.22, 128.19, 128.19, 
127.00, 126.67, 125.56, 52.37, 45.29, 41.92, 35.17, 35.11, 32.79, 31.69, 30.91, 28.45, 
28.43, 26.87, 25.23, 23.03. ESI-MS (m/z): 482.24  [M + H]
+
. Anal. (C28H39N3O2S) C, 
H, N. 
(2S)-2-(3-Phenylpropanoylamino)-6-ethanethioylamino-N-(pyridin-3-
ylamino)hexanamide (38). Compound 38 was prepared using 3-phenylpropionic 
acid (0.17 g, 1.13 mmol), DMF (2.8 mL), TBTU (0.40 g, 1.24 mmol), pyridine (2.8 
mL) and 10 (0.40 g, 1.13 mmol) following the same procedure described for 12, the 
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amount of CH2Cl2 was 140 mL and the workup was made without HCl 0.5M. 
Purification by column chromatography using silica Kieselgel for flash with EtOAc: 
CH2Cl2: Hexane: MeOH  (5.5: 1.5: 1.5: 1.5) as eluent phase to give the pure product 
as white solid (0.18 g, 0.43 mmol, 38 %). 
1
H-NMR (DMSO-d6): δ = 10.26 (s, 1H), 
9.94 (s br, 1H), 8.76 (d, J = 2.21 Hz, 1H), 8.27 (dd, J = 1.58, 4.73 Hz, 1H), 8.17 (d, J 
= 7.88 Hz, 1H), 8.03 (dt, J = 1.58, 8.20 Hz, 1H), 7.35 (dd, J = 4.73, 8.20 Hz, 1H), 
7.27-7.15 (m, 5H), 4.42-4.38 (m, 1H), 3.47-3.40 (m, 2H), 2.84-2.81 (m, 2H), 2.53-
2.42 (m, 2H), 2.36 (s, 3H), 1.73-1.66 (m, 1H), 1.63-1.49 (m, 3H), 1.37-1.20 (m, 2H). 
13
C-NMR (DMSO-d6): δ = 198.77, 171.70, 171.37, 144.12, 141.11, 140.69, 135.50, 
128.19, 128.19, 126.46, 125.94, 123.72, 53.13, 45.10, 36.45, 32.88, 31.67, 30.93, 
27.05, 22.85. 
ESI-MS (m/z): 413.18 [M + H]
+
 Anal. (C22H28N4O2S) C, H, N. 
(2S)-2-[3-(2-Fluorophenyl)propanoylamino]-6-ethanethioylamino-N-(pyridin-3-
ylamino)hexanamide (39). Compound 39 was prepared using 3-(2-
fluorophenyl)propionic acid (0.15 g, 0.89 mmol), DMF (4.6 mL), TBTU (0.34 g, 
1.06 mmol), pyridine (4.6 mL) and 10 (0.31 g, 0.87 mmol), following the same 
procedure described for 12, the amount of CH2Cl2 was 140 mL and the workup was 
made without HCl 0.5M and brine. Purification by column chromatography using 
silica Kieselgel for flash with CH2Cl2: EtOAc: MeOH  (5.5: 3.5: 1) as eluent phase to 
give the pure product as white solid (0.11 g, 0.25 mmol, 29 %). 
1
H-NMR (DMSO-
d6): δ = 10.25 (s, 1H), 9.93 (s br, 1H), 8.75 (d, J = 2.21 Hz, 1H), 8.27 (dd, J = 1.58, 
4.73 Hz, 1H), 8.20 (d, J = 7.88 Hz, 1H), 8.03 ( dt, J = 1.58, 8.20 Hz, 1H), 7.34 (dd, 
4.73, 8.20 Hz, 1H), 7.28 (m, 1H), 7.23 (m, 1H), 7.14-7.07 (m, 2H), 4.41-4.36 (m, 
1H), 3.46-3.41 (m, 2H), 2.86-2.83 (m, 2H), 2.53-2.42 (m, 2H), 2.36 (s, 3H), 1.74-
1.66 (m, 1H), 1.62-1.49 (m, 3H), 1.36-1.22 (m, 2H). 
13
C-NMR (DMSO-d6) : δ = 
198.79, 171.40, 171.26, 160.53 (d, J = 242.29 Hz), 144.29, 140.90, 135.53, 130.60 
(d, J = 4.62 Hz), 127.98 (d, J = 8.32 Hz), 127.71 (d, J = 15.72 Hz), 126.20, 124.23 (d, 
J = 3.70 Hz), 123.60, 114.92 (d, J = 21.27 Hz), 53.24, 45.19, 34.99, 32.77, 31.57, 
26.91, 24.16, 22.98. ESI-MS (m/z): 431.21 [M + H]
+ 
. Anal. (C22H27FN4O2S) C, H, 
N. 
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(2S)-N-{(2S)-6-Ethanethioylamino-1-[2-(pyridin-3-yl)ethylamino]-1-oxohexan-2-
yl}-pyrrolidine-1-tert-butoxycarbonyl-2-carboxamide (40). Compound 40 was 
prepared using N-Boc-L-proline (0.27 g, 1.26 mmol), DMF (7.2 mL), TBTU (0.49 g, 
1.53 mmol), pyridine (7.2 mL) and 11 (0.48 g, 1.26 mmol), following the same 
procedure described for 12, the amount of CH2Cl2 was 150 mL and the workup was 
made without HCl 0.5M and brine. Purification by column chromatography silica 
Kieselgel for flash with CH2Cl2: EtOAc: MeOH (5.5: 3: 1.5) as eluent phase to give 
the pure product as white solid (0.31 g, 0.61 mmol, 48 %). 
1
H-NMR (DMSO-d6)  
rotamers A+ : δ = 9.91 (s br, 1H), 8.41 (s, 2H), 8.02 (s br, 0.54H), 7.87-7.82 (m, 
1.46H), 7.62 (m, 1H), 7.30-7.28 (m, 1H), 4.20-4.11 (m, 2H), 3.42-3.37 (m, 3H), 
3.28-3.24 (m, 2H), 2.73 (t, J = 6.94 Hz, 2H), 2.36 (s, 3H), 2.10-2.02 (m, 1H), 1.77-
1.70 (m, 3H), 1.61-1.13 (m, 16H). 
13
C-NMR (DMSO-d6):  rotamers A + ( ) δ = 
198.76, 172.18 (171.88), 171.36, 153.95 (153.29), 149.84, 147.37, 136.17, 134.75, 
123.30, 78.79 (78.34), 59.50 (59.31), 52.25, 46.71 (46.47), 45.22, 32.75, 32.09 
(31.97), 31.52, 30.99, 29.68, 28.10 (27.97), 26.88, 23.94, 23.04 (22.80).ESI-MS 
(m/z): 506.22 [M + H]
+
. Anal. (C25H39N5O4S) C, H, N. 
(2S,4R)-N-[(2S)-6-Ethanethioylamino-1-(benzylamino)-1-oxohexan-2-yl]-4 
hydroxypyrrolidine-1-tert-butoxycarbonyl-2-carboxamide (41). To a solution of 
N-Boc-Hydroxy-L-proline (0.72 g, 3.1 mmol) in DMF (30 mL) under Argon flow 
were added TBTU (1.10 g, 3.4 mmol), pyridine (30 mL) and maintained under 
stirring for 10min at rt . After this time 9 (1.02 g, 3.1 mmol) was added and the 
solution mixed 3h at rt under Argon flow. Solvents were evaporated and the obtained 
oil was dissolved in EtOAc (300 mL), washed with HCl 0.5M, brine (twice), 
NaHCO3 5%, finally dried with Na2SO4 and evaporated under vacuum. The crude 
product obtained was purified by columns chromatography, using silica Kieselgel for 
flash with EtOAc : Hexane : MeOH (7: 2: 1) as eluent phase to give the pure product 
as white solid (0.55 g, 1.10 mmol, 35 %).
 1
H-NMR (DMSO-d6) : rotamers A+  δ = 
9.90 (s br, 1H), 8.43 (t, J =  5.67 Hz, 0.6H), 8.25 (t, J = 5.67 Hz, 0.4H), 8.02 (d, J =  
7.88 Hz, 0.4H), 7.96 (d, J = 7.88 Hz, 0.6H), 7.30-7.23 (m, 5H), 4.99-4.96 (m, 1H), 
4.28-4.20 (m, 5H), 3.44-3.37 (m, 3H), 3.26-3.24 (m, 1H), 2.37 (s, 3H), 2.06-1.99 (m, 
1H), 1.87-1.51 (m, 5H), 1.36-1.25 (m, 11H). 
13
C-NMR (DMSO-d6 ): rotamers A+(B)  
δ  = 198.79 (198.75), 172.35 (171.98), 171.54 (171.49), 154.18 (153.53), 139.28, 
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128.20, 127.03 (126.94), 126.71 (126.67), 78.87 (78.45), 68.38 (67.71), 58.69 
(58.51), 55.02 (54.69), 52.50, 45.31 (45.23), 41.95, 38.41, 32.77, 31.88 (31.30), 
28.10 (27.96), 26.90 (26.82), 22.96 (22.91).
 
ESI-MS (m/z): 507.09 [M + H]
+ 
Anal. 
(C25H38N4O5S) C, H, N.  
(2S,4R)-N-[(2S)-6-Ethanethioylamino-1-(2-oxo-2-phenylethylamino)-1-
oxohexan-2-yl]-4-hydroxypyrrolidine-1-tert-butoxycarbonyl-2-carboxamide 
(42). To a solution of N-Boc-Hydroxy-L-proline (0.69 g, 3.0 mmol) in DMF (30 mL) 
under Argon flow were added TBTU (1.06 g, 3.3 mmol), pyridine (30 mL) and 
maintained under stirring for 10min at rt. After this time 7 (1.07 g, 3.0 mmol) was 
added and the solution mixed 3h at rt under Argon flow. Solvents were evaporated 
and the obtained oil was dissolved in EtOAc (300 mL), washed with HCl 0.5M, brine 
(twice), NaHCO3 5%, finally dried with Na2SO4 and evaporated under vacuum. The 
crude product obtained was purified with two columns chromatography, using 
Aluminum oxide and silica Kieselgel for flash with EtOAc : Hexane : MeOH (7: 2: 
1) as eluent phase to give the pure product as white solid (0.24 g, 0.45 mmol, 15 %). 
1
H-NMR (DMSO-d6) : rotamers A+  δ = 9.91 (s br, 1H), 8.24 (t, J = 5.26 Hz, 0.6H), 
8.12 (t, J = 5.26 Hz, 0.4H), 8.04-7.97 (m, 3H), 7.66 (t, J = 7.25 Hz, 1H), 7.55 (t, J =  
7.25Hz, 2H), 4.99-4.96 (m, 1H), 4.68-4.54 (m, 2H), 4.37-4.29 (m, 1H), 4.26-4.21 (m, 
2H), 3.47-3.36 (m, 3H), 3.27-3.23 (m, 1H), 2.38 (s, 3H), 2.09-1.99 (m, 1H), 1.91-
1.81 (m, 1H), 1.78-1.66 (m, 1H), 1.62-1.50 (m, 3H), 1.41-1.29 (m, 11H). 
13
C-NMR 
(DMSO-d6 ): rotamers A+( )  δ  = 198.77 (198.72), 195.12 (195.02), 172.36, 
171.91, 154.05 (153.52), 134.92, 133.54, 128.78, 127.80, 78.78 (78.45), 68.42, 
67.73, 58.48 (58.42), 54.99 (54.70), 52.31 (52.19), 45.85 (45.30), 38.36, 32.78, 31.96 
(31.58), 28.12 (27.99), 26.94 (26.82), 22.88 (22.71). ESI-MS (m/z): 535.06 [M + H]
+
 
Anal. (C26H38N4O6S·0.01 H2O) C, H, N.  
(2S,4R)-N-[(2S)-6-Ethanethioylamino-1-(benzylamino)-1-oxohexan-2-yl]-4-
hydroxypyrrolidine-2-carboxamide hydrochloride (43). Compound 43 was 
synthesized using 41 (0.28 g, 0.55 mmol) in 2-propanol (8.6 mL), 1,2-ethanedithiol 
(0.058 mL, 0.55 mmol) and HCl 12N (0.28 mL, 3.36 mmol) added x three times, 
following the same procedure described for 22. The yellow oil as residue was 
washed with petroleum ether (4 x 10 mL) and CH2Cl2: petroleum ether (1:1) (4 x 4 
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mL) provides the product as white solid (0.22 g, 0.49 mmol, 90 %). 
1
H-NMR 
(DMSO-d6) : δ = 10.08 (s br, 1H), 9.87 (s br, 1H), 8.79 (d, J = 7.57 Hz, 1H), 8.68-
8.57 (m, 2H), 7.33-7.22 (m, 5H), 5.51 (s, 1H), 4.42-4.37 (m, 2H), 4.33-4.23 (m, 3H), 
3.46-3.42 (m, 2H), 3.07 (d, J = 11.98 Hz, 1H), 2.38 (s, 3H), 2.32-2.28 (m, 1H), 1.89-
1.83 (m, 1H), 1.75-1.52 (m, 4H), 1.40-1.30 (m, 2H). ESI-MS (m/z):407.28 [M + H]
+
 
Anal. (C20H31ClN4O3S) C, H, N.  
(2S,4R)-N-((S)-6-ethanethioamido-1-oxo-1-((2-oxo-2-phenylethyl)amino)hexan-
2-yl)-4-hydroxypyrrolidine-2-carboxamide hydrochloride (44). Compound 44 
was synthesized using 42 (0.15 g, 0.33 mmol) in 2-propanol (4.7 ml), 1,2-
ethanedithiol (0.030 mL, 0.33 mmol) and HCl 12N (0.15 ml, 1.8 mmol) added x 
three times following the same procedure described for 22. The yellow oil residue 
was washed with petroleum ether (4 x 10 ml) and CH2Cl2: petroleum ether (1:1) (4 x 
4 ml) providing the product as white solid (0.12 g, 0.25 mmol, 77%). 
1
H-NMR 
(DMSO-d6): δ = 10.07 (s br, 1H), 9.84 (s br 1H), 8.78 (d, J = 8.24 Hz, 1H), 8.66 (s 
br, 1H), 8.39 (t, J = 5.49 Hz, 1H), 7.98 (d, J = 7.32 Hz, 2H), 7.68 (t, J = 7.32 Hz, 
1H), 7.55 (t, J = 7.32 Hz, 2H), 5.47 (s, 1H), 4.70-4.56 (m, 2H), 4.43-4.45 (m, 3H), 
3.49-3.45 (m, 2H), 3.09-3.07 (m, 1H), 2.39 (s, 3H), 2.32-2.28 (m, 1H), 1.91-1.85 (m, 
1H), 1.79-1.72 (m, 1H), 1.65-1.54 (m, 3H), 1.43-1.34 (m, 2H). 
13
C-NMR (DMSO-d6 
): δ  = 198.78, 195.08, 171.29, 167.85, 134.89, 133.58, 128.80, 127.80, 68.98, 57.75, 
53.42, 52.89, 45.85, 45.25, 32.78, 31.83, 30.67, 26.90, 22.86. ESI-MS (m/z): 435.22 
[M + H]
+
. Anal. (C21H31ClN4O4S·0.04hexane·0.02 CH2Cl2) C, H, N. 
2S)-N-[(2S)-6-Ethanethioylamino-1-(benzylamino)-1-oxohexan-2-yl]-
pyrrolidine-1-tert-butoxycarbonyl-2-carboxamide (45). To a solution of Boc-L-
proline (0.38 g, 1.75 mmol) in DMF (8.5 mL) under Argon flow were added TBTU 
(0.61 g, 1.9 mmol), pyridine (6.5 mL) and maintained under stirring for 10min at rt. 
After this time 9 (0.58 g, 1.75 mmol) was added and the solution mixed 3h at rt 
under Argon flow. Solvents were evaporated and the obtained oil was dissolved in 
EtOAc (200 mL), washed with HCl 0.5M, brine (twice), NaHCO3 5%, finally dried 
with Na2SO4 and evaporated under vacuum. The crude product obtained was purified 
by columns chromatography, using silica Kieselgel for flash with EtOAc : Hexane : 
MeOH (7: 2.5: 0.5) as eluent phase to give the pure product as white solid (0.58 g, 
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1.18 mmol, 67 %). 
1
H-NMR (DMSO-d6) : rotamers A+  δ = 9.92 (s br, 1H), 8.43 (t, 
J = 5.36 Hz, 0.6H), 8.28 (t, J = 5.36 Hz, 0.4H), 7.95-7.92 (m, 1H), 7.33-7.24 (m, 
5H), 4.31-4.23 (m, 3H), 4.15-4.13 (m, 1H), 3.46-3.37 (m, 3H), 3.28-3.23 (m, 1H), 
2.38 (s, 3H), 2.12-2.03 (m, 1H), 1.82-1.60 (m, 7H), 1.37-1.24 (m, 11H).  
13
C-NMR 
(DMSO-d6): rotamers A+ (B) δ = 198.78, 172.34 (172.05), 171.53, 153.94 (153.32), 
139.27, 128.19, 127.01, 126.96 (126.71), 78.79 (78.36), 59.51 (59.34), 52.40, 46.71 
(46.49), 45.23, 41.94, 32.77, 31.92 (31.43), 30.99 (29.71), 28.10 (27.98), 26.85, 
23.91 (23.01), 22.92. ESI-MS (m/z): 491.13 [M + H]
+
 Anal. (C25H38N4O4S)  C, H, N.  
(2S)-N-[(2S)-6-Ethanethioylamino-1-(benzylamino)-1-oxohexan-2-yl]-
pyrrolidine-2-carboxamide  hydrochloride (46) Compound 46 was synthesized 
using 45 (0.53 g, 1.1 mmol) in 2-propanol (16 mL), 1,2-ethanedithiol (0.091 mL, 1.1 
mmol) and HCl 12N (0.55 mL, 6.6 mmol) added x three times, following the same 
procedure described for 22 , to furnish the product as white solid (0.35 g, 0.81 mmol, 
75 %). 
1
H-NMR (DMSO-d6) : δ = 10.09 (s br, 1H), 9.78 (s br, 1H), 8.74 (d, J = 7.88 
Hz, 1H), 8.61-8.47 (m, 2H), 7.31-7.22 (m, 5H), 4.33-4.21 (m, 4H), 3.46-3.42 (m, 
2H), 3.23-3.17 (m, 2H), 2.38 (s, 3H), 2.34-2.26 (m, 1H), 1.92-1.82 (m, 3H), 1.76-
1.52 (m, 4H), 1.42-1.27 (m, 2H). ESI-MS (m/z): 391.28 [M + H]
+
 Anal. 
(C20H31ClN4O2S) C, H, N.   
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Elemental analysis data. 
Compound Formula 
Calculated  % Found  % 
C H N C H N 
2 C21H31N3O4S 59.83 7.41 9.97 60.09 7.42 9.59 
6 C20H32N4O3S·0.03DMF·0.03Hexane 58.12 7.80 13.55 58.25 7.67 13.17 
12 C25H31N3O3S 66.20 6.89 9.26 66.53 6.58 9.24 
13 C26H33N3O3S 66.78 7.11 8.99 66.90 6.96 8.74 
14 C28H37N3O3S 67.85 7.52 8.48 68.07 7.45 8.23 
15 C24H30N4O3S·0.5 H2O 62.17 6.74 12.08 62.14 6.39 11.94 
16 C29H36N4O6S 61.25 6.38 9.85 61.50 6.21 9.67 
17 C26H38N4O5S 60.21 7.38 10.80 60.28 7.17 10.93 
18 C29H35N5O5S 61.57 6.24 12.38 61.31 6.09 12.08 
19 C22H28N4O2S 64.05 6.84 13.58 63.66 6.71 13.56 
20 C18H28N4O2S 59.31 7.74 15.37 59.44 7.54 15.05 
21 
C24H36N4O4S 60.48 7.61 11.75 60.70 7.39 11.54 
22 C19H29ClN4O2S·0.3H2O 54.55 7.13 13.39 54.30 6.82 13.06 
23 C27H34N4O5S 61.58 6.51 10.64 61.72 6.16 10.51 
25 C24H31N3O3S 65.28 7.08 9.52 65.61 6.87 9.43 
26 C23H29N3O3S 64.61 6.84 9.83 64.98 6.70 9.84 
27 C25H31N3O5S·0.02hexane 61.91 6.47 8.62 62.28 6.26 8.64 
28 C24H31N3O4S·0.1hexane·0.01 EtOAc 63.36 7.00 8.99 63.61 6.62 9.16 
29 C26H32N4O3S 64.97 6.71 11.66 65.03 6.50 11.45 
30 C27H34N4O4S 63.51 6.71 10.97 63.49 6.51 10.85 
31 C33H38N4O4S 67.55 6.53 9.55 67.31 6.33 9.47 
32 C21H26N4O3S 60.85 6.32 13.52 60.82 6.15 13.39 
33 C18H26N4O4S 54.80 6.64 14.20 54.76 6.49 13.98 
34 C19H28N4O4S 55.86 6.91 13.71 56.00 6.65 13.65 
35 C28H36N4O5S·0.03hexane 62.30 6.76 10.31 62.68 6.91 10.21 
36 C27H37N3O2S 69.34 7.97 8.99 69.67 7.85 8.63 
37 C28H39N3O2S 69.82 8.16 8.72 69.78 8.02 8.50 
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38 C22H28N4O2S 64.05 6.84 13.58 63.81 6.64 13.32 
39 C22H27FN4O2S 61.37 6.32 13.01 61.05 6.28 12.84 
40 C25H39N5O4S 59.38 7.77 13.85 59.47 7.46 13.74 
41 C25H38N4O5S 59.26 7.56 11.06 59.17 7.25 10.94 
42 C26H38N4O6S·0.01 H2O 58.38 7.16 10.47 57.99 6.86 10.29 
43 C20H31ClN4O3S 54.22 7.05 12.65 54.11 6.74 12.53 
44 
C21H31ClN4O4S·0.04hexane·0.02 
CH2Cl2 
53.62 6.68 11.76 53.97 6.64 11.44 
45 C25H38N4O4S 61.20 7.81 11.42 60.81 7.44 11.32 
46 C20H31ClN4O2S 56.26 7.32 13.12 55.93 7.00 13.01 
 
SIRT1-3 in Vitro Assay. The Fluor de Lys fluorescence assays were based on the 
method described in the BIOMOL product sheet (Enzo Life Sciences) using the 
BIOMOL KI177 substrate for SIRT1 and the KI179 substrate for SIRT2 and SIRT3. 
The determined Km value of SIRT1 for KI177 was 58 µM and the Km of SIRT2 for 
KI179 was 198 µM.
29
 The Km of SIRT3 for KI179 was reported by BIOMOL to be 
32 µM. The Km values of SIRT1, SIRT2 and SIRT3 for NAD
+
 were reported by 
BioMol to be 558 µM, 547µM and 2 mM, respectively. 
Briefly, assays were carried out using the Fluor de Lys acetylated peptide substrate at 
0.7 Km and NAD
+
 (Sigma N6522 or BIOMOL KI282) at 0.9 Km, recombinant GST-
SIRT1/2-enzyme or recombinant His-SIRT3 and SIRT assay buffer (KI286). GST-
SIRT1 and GST-SIRT2 were produced as described previously.
193,194
 His-SIRT3 
(BML-SE270) was purchased from Enzo Life Sciences. The buffer, Fluor de Lys 
acetylated peptide substrate, NAD
+
 and DMSO/compounds in DMSO (2.5 µL in 50 
µL total reaction volume; DMSO from Sigma, D2650) were preincubated for 5 min 
at room temperature. The reaction was started by adding the enzyme. The reaction 
mixture was incubated for one hour at 37 °C. After that, Fluor de Lys developer 
(KI176) and 2 mM nicotinamide (KI283) in SIRT assay buffer (total volume 50 µL) 
were added and the incubation was continued for 45 min at 37 °C. Fluorescence 
readings were obtained using EnVision 2104 Multilabel Reader (PerkinElmer) with 
excitation wavelength 370 nm and emission 460 nm. 
The IC50 values were determined as three independent determinations giving 
altogether 27 data-points. All the data-points were included in the calculation of the 
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best-fit value for non-linear curve fitting with GraphPad Prism5 (GraphPad Software, 
Inc.). 
 
Cell Culture. Human retinal pigment epithelial cells (ARPE-19, obtained from 
ATCC, American Type Culture Collection) and SH-SY5Y neuroblastomas (DSMZ) 
were grown as described earlier in Huhtiniemi et al. 2011.
 134
 A549 lung carcinoma 
and MCF-7 breast carcinoma cells (both  from ATCC) were maintained in 
Dulbecco’s modified  agle’s medium (DM M   ibco) containing 10% fetal calf 
serum, 100 U/ml penicillin and 100 μg/ml streptomycin at +37°  in humidified 
atmosphere of 5% CO2 / 95% air. 
 Western Blotting. Western blot analysis was done as described in Huhtiniemi et al. 
2011.
 134
 The cells were plated to 12-well plates (Nunc) at a density of 10
5
 cells/well, 
and the experiments were initiated after 24 h. Test compounds and etoposide (Sigma) 
were added at the same time and incubated for 5 h before harvesting. 
Lactate Dehydrogenase Assay. Lactate dehydrogenase (LDH) leakage from the 
cells to medium was used as a marker for cytotoxicity. LDH was measured from cell 
culture medium with CytoTox assay (Promega #G1780). 
Cell proliferation and cell cycle analysis. For cell proliferation assays with 
sulforhodamine B, A549 and MCF-7 cells were plated to 96-well plates (Nunc) 24 h 
before the start of the treatments (3000 cells / well). The cells were treated with 
vehicle (0.5% DMSO) or test compounds for 48 h (A549 cells) or 72 h (MCF-7 
cells). Sulforhodamine B staining was performed as previously described.
195
 After 
treatments, 50 μl of 50% trichloroacetic acid (Sigma) was added to each well and 
incubated for 1 h at +4°C. The plates were then washed with water and air dried. The 
fixed cells were incubated with 100 μl of 0.4% sulforhodamine   solution (Sigma) at 
room temperature for 1 h. The plates were again washed with water and air dried, 
followed by solubilization of the bound dye with 200 μl of 10 mM Tris base solution. 
The results were measured with EnVision plate reader (PerkinElmer) at a wavelength 
of 565 nm. Cell cycle analysis of A549 and MCF-7 cells was done by propidium 
iodide staining as previously described.
196
 The cells were plated to 6-well plates 
(Nunc) 6 h before the start of the treatments (0.6 × 10
5
 cells / well). The cells were 
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treated with vehicle (0.5% DMSO) or test compounds for 18 h. Both adherent and 
floating cells were harvested and fixed with ice-cold 70% ethanol. After overnight 
incubation at +4°C, the cells were collected by centrifugation and incubated with 
150 μg/ml DNase free RNase (Thermo Scientific) for 1 h at +50°C. Propidium iodide 
(Sigma) was added to the final concentration of 8 μg/ml and incubation was 
continued for 2 h at +37°C. FACScanto II flow cytometer with FACSDiva software 
(Becton Dickinson) was used to analyze cellular DNA content and cell cycle. 
Molecular Modeling. Homology models for SIRT1 and SIRT2 were built in 
bioactive conformation using the crystal structure of SIRT3 (PDB code 3glr)
30
 in 
which is co-crystallized AceCS2-K
Ac
 peptide (
639
RSGK
Ac
VMR) sequence, 
containing acetylated lysine 642 that has been identified to be deacetylated by 
SIRT3. The amino acid sequence of Homo Sapiens SIRT1 and SIRT2 was obtained 
from the NCBI (National Center for Biotechnology Information). The sequences of 
SIRT1 and SIRT2 were manually aligned with SIRT3 based on sequence similarity, 
(40% and 52.9% respectively, for alignments see below)
30
 Homology models for the 
catalytic deacetylase core of SIRT1 (555 residues) and a full-length, homology 
modeled SIRT2 (352 residues) was constructed using ORCHESTRA in SYBYL 1.3 
(following the same procedure described for Rotili et al 2012).
143
  The geometry of 
the side chains was manually optimized to obtain a crude model. The models were 
polished with Protein Preparation Wizards available in the Schrödinger Suite 2009 
(Schrödinger Suite 2009 Protein Preparation Wizard; Schrödinger, LLC: New York, 
NY, 2009). In that process, the bond orders were assigned and hydrogens were 
added. In addition, the exhaustive sampling method was used to optimize the 
hydrogen bonding, and determine the orientations of hydroxyl groups, amide groups 
of Asn and Gln amino acids, and the proper state and orientations of the histidine 
imidazole rings. To relax the structure of the initial SIRT1 and SIRT2 models, the 
models were subjected to a restrained minimization using OPLS2001 force field, 
with a 0.3 Å rmsd atom displacement limit. The protein geometry was evaluated by 
Ramachandran plot and Verify 3D (Verify3D Structure Evaluation Server: 
nihserver.mbi.ucla.edu/Verify_3D). SIRT1 outliers: Val293, Asp237; SIRT2 
outliers: Ser63, Arg164, Asp213 and Gly224. The pseudopeptidic database was 
prepared using Ligprep (LigPrep, version 2.3; Schrödinger, LLC: New York, NY, 
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2009), the geometric optimization was carried out using OLPS2005 force field, and 
all possible ionization and tautomeric form were created at pH 8.0 ± 0.2 using EPIK 
(Epik, version 2.2, Schrödinger, LLC, New York, NY, 2011). The chiralities 
specified in the input structures were retained. Dockings were performed using Glide 
(Glide, version 5.5; Schrödinger, LLC: New York, NY, 2009). For the grid file and 
docking parameters were applied settings previously published by Huhtiniemi et 
al.
134
 The figures were prepared using MOE (Molecular Operating Environment 
(MOE), 2011.10; Chemical Computing Group Inc., 1010 Sherbooke St. West, Suite 
#910, Montreal, QC, Canada, H3A 2R7). 
 
Alignment SIRT1_SIRT3
30
 
SIRT1 Homo Sapiens sequence 555aa, was downloaded from NCBI (National Center 
for Biotechnology Information) AAH12499.1, and aligned with SIRT3 (PDB code: 
3glr). 
Alignment SIRT1 model using SIRT3 as template (ORCHESTRA, SYBYL) 
 
 
           1         11        21        31        41         
SIRT1 555aa      MIGTDPRTILKDLLPETIPPPELDDMTLWQIVINILSEPPKRKKRKDINT 
Hom.model        ------------------------------------------------NT 
3GLR             ----------------------------------------------GKLS 
 
                 51        61        71        81        91         
SIRT1 555aa      IEDAVKLL--QECKKIIVLTGAGVSVSCGIPDFRSR-DGIYARLAVDFPD 
Hom.model        IEDAVKLL--QECKKIIVLTGAGVSVSCGIPDFRSR-DGIYARLAVDFPD 
3GLR             LQDVAELIRARACQRVVVMVGAGISTPSGIPDFRSPGSGLYSNLQQ--YD 
 
                 101       111       121       131       141        
SIRT1 555aa      LPDPQAMFDIEYFRKDPRPFFKFAKEIYPGQFQPSLCHKFIALSDKEGKL 
Hom.model        LPDPQAMFDIEYFRKDPRPFFKFAKEIYPGQFQPSLCHKFIALSDKEGKL 
3GLR             LPYPEAIFELPFFFHNPKPFFTLAKELYPGNYKPNVTHYFLRLLHDKGLL 
 
                 151       161       171       181       191        
SIRT1 555aa      LRNYTQNIDTLEQVAGIQ--RIIQCHGSFATASCLICKYKVDCEAVRGAL 
Hom.model        LRNYTQNIDTLEQVAGIQ--RIIQCHGSFATASCLICKYKVDCEAVRGAL 
3GLR             LRLYTQNIDGLERVSGIPASKLVEAHGTFASATCTVCQRPFPGEDIRADV 
 
                 201       211       221       231       241        
SIRT1 555aa      FSQVVPRCPRCPADEPLAIMKPEIVFFGENLPEQFHRAMKYDKDEVDLLI 
Hom.model        FSQVVPRCPRCPADEPLAIMKPEIVFFGENLPEQFHRAMKYDKDEVDLLI 
3GLR             MADRVPRCPVCT-----GVVKPDIVFFGEPLPQRFLLHV-VDFPMADLLL 
 
                 251       261       271       281       291        
SIRT1 555aa      VIGSSLKVRPVALIPSSIPHEVPQILINREPLPHL-----HFDVELLGDC 
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Hom.model        VIGSSLKVRPVALIPSSIPHEVPQILINREPLPHL-----HFDVELLGDC 
3GLR             ILGTSLEVEPFASLTEAVRSSVPRLLINRDLVGPLAWHPRSRDVAQLGDV 
 
                 301       311       321       331       341        
SIRT1 555aa      DVIINELCHRLGGEYAKLCCNPVKLSEITEKPPRTQKELAYLSELPPTPL 
Hom.model        DVIINELCHRLGGEYAK---------------PRTQKELAY--------- 
3GLR             VHGVESLVELLGWTEEM--------------RDLVQRETGKL-RSG-VMR 
 
                 351       361       371       381       391        
SIRT1 555aa      HVSEDSSSPERTSPPDSSVIVTLLDQAAKSNDDLDVSESKGCMEEKPQEV 
Hom.model        -------------------------------------------------- 
3GLR             -------------------------------------------------- 
 
                 401       411       421       431       441        
SIRT1 555aa      QTSRNVESIAEQMENPDLKNVGSSTGEKNERTSVAGTVRKCWPNRVAKEQ 
Hom.model        -------------------------------------------------- 
3GLR             -------------------------------------------------- 
 
                 451       461       471       481       491        
SIRT1 555aa      ISRRLDGNQYLFLPPNRYIFHGAEVYSDSEDDVLSSSSCGSNSDSGTCQS 
Hom.model        -------------------------------------------------- 
3GLR             -------------------------------------------------- 
 
                 501       511       521       531       541        
SIRT1 555aa      PSLEEPMEDESEIEEFYNGLEDEPDVPERAGGAGFGTDGDDQEAINEAIS 
Hom.model        -------------------------------------------------- 
3GLR             -------------------------------------------------- 
 
                 551       561   
SIRT1 55aa       VKQEVTDMNYPSNKS 
Hom.model        --------------- 
3GLR             --------------- 
 
Key 
Joy Annotation: 
 alpha helix                           red         x 
 beta strand                           blue        x 
 3 - 10 helix                          maroon      x 
 
Alignment SIRT2_SIRT3
30
 
SIRT2 Homo Sapiens sequence 352aa, was downloaded from NCBI (National Center 
for Biotechnology Information) AAK51133.1, and aligned with SIRT3 (PDB code: 
3glr). 
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Alignment SIRT2 model using SIRT3 as template (ORCHESTRA, SYBYL) 
 
 
                 1         11        21        31        41         
SIRT2 352aa      MDFLRNLFSQTLSLGSQKERLLDELTLEGVARYMQSERCRRVICLVGAGI 
Hom.model        ------------------------LTLEGVARYMQSERCRRVICLVGAGI 
3GLR             ----------------------GKLSLQDVAELIRARACQRVVVMVGAGI 
 
                 51        61        71        81        91         
SIRT2 352aa      STSAGIPDFRSPSTGLYDNLEKYHLPYPEAIFEISYFKKHPEPFFALAKE 
Hom.model        STSAGIPDFRSPSTGLYDNLEKYHLPYPEAIFEISYFKKHPEPFFALAKE 
3GLR             STPSGIPDFRSPGSGLYSNLQQYDLPYPEAIFELPFFFHNPKPFFTLAKE 
 
                 101       111       121       131       141        
SIRT2 352aa      LYPGQFKPTICHYFMRLLKDKGLLLRCYTQNIDTLERIAGLEQEDLVEAH 
Hom.model        LYPGQFKPTICHYFMRLLKDKGLLLRCYTQNIDTLERIAGLEQEDLVEAH 
3GLR             LYPGNYKPNVTHYFLRLLHDKGLLLRLYTQNIDGLERVSGIPASKLVEAH 
 
                 151       161       171       181       191        
SIRT2 352aa      GTFYTSHCVSASCRHEYPLSWMKEKIFSEVTPKCEDCQSLVKPDIVFFGE 
Hom.model        GTFYTSHCVSASCRHEYPLSWMKEKIFSEVTPKCEDCQSLVKPDIVFFGE 
3GLR             GTFASATCTV--CQRPFPGEDIRADVMADRVPRCPVCTGVVKPDIVFFGE 
 
                 201       211       221       231       241        
SIRT2 352aa      SLPARFFSCMQSDFLKVDLLLVMGTSLQVQPFASLISKAPLSTPRLLINK 
Hom.model        SLPARFFSCMQSDFLKVDLLLVMGTSLQVQPFASLISKAPLSTPRLLINK 
3GLR             PLPQRFLLHV-VDFPMADLLLILGTSLEVEPFASLTEAVRSSVPRLLINR 
 
                 251       261       271       281       291        
SIRT2 352aa      EKAGQSDPFLGMIMGLGGGMDFDSKKAYRDVAWLGECDQGCLALAELLGW 
Hom.model        EKAGQSDPFLGMIMGLGGGMDFDSKKAYRDVAWLGECDQGCLALAELLGW 
3GLR             DLVGPLAW----------------HPRSRDVAQLGDVVHGVESLVELLGW 
 
                 301       311       321       331       341        
SIRT2 352aa      KKELEDLVRREHASIDAQSGAGVPNPSTSASPKKSPPPAKDEARTTEREK 
Hom.model        KKELEDLVRREHASI----------------------------------- 
3GLR             TEEMRDLVQRETGKL--RSG-VMR-------------------------- 
 
                 351 
SIRT2 352aa      PQ 
Hom.model        -- 
3GLR             -- 
 
 
Key 
Joy Annotation: 
 alpha helix                           red         x 
 beta strand                           blue        x 
 3 - 10 helix                          maroon      x 
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9 DESIGN AND SYNTHESIS OF PSEUDOPEPTIDIC AND PEPTIDIC 
ACTIVITY-BASED PROBES AS SIRT1-3 INHIBITORS. USEFUL TOOLS IN 
UNDERSTANDING THEIR SUBCELLULAR LOCALIZATION AND 
SPECIFICITY. 
 
Abstract: The seven sirtuin isoforms SIRT1-7 show different cellular localization. 
SIRT1, SIRT6, and SIRT7 being nuclear, SIRT2 cytoplasmic and SIRT3-5 
mitochondrial. Due to this, the development of specific inhibitors with enzymatic 
efficacy must face the difficulty to reach the cellular target. Here we propose the 
design and synthesis of potential pseudopeptidic and peptidic inhibitors of human 
SIRT1-3 labeled with Thiazole orange for live cellular imaging. Furthermore, we aim 
to develop the first SIRT3 peptidic inhibitor based on AceCS2 sequence containing a 
peptidic shuttle for mitochondrial delivery. 
 
 
 
 
 
 
 
 
 
 
 
* Adapted with the permission from: Mellini, P.; Kokkola, T.; Suuronen, T.; Nyrhilä, O.; Leppänen, 
J.; Mai, A.; Lahtela-Kakkonen, M.; and Jarho, E.M. 
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9.1 Introduction  
The seven sirtuin isoforms SIRT1-7 show different cellular localization, SIRT1, 
SIRT6, and SIRT7 being nuclear, SIRT2 cytoplasmic and SIRT3-5 mitochondrial. 
Due to this, develop specific inhibitors with enzymatic efficacy must face the 
difficulty to reach the cellular target. Recently we have developed pan SIRT1-3 
pseudopeptidic inhibitors in which N-terminal Cbz- or Boc-L-prolyl moiety gave the 
most potent compounds of the series (Chart 1).
197
 Activity-based probes for SIRTs 
enable to allow subcellular localization/specificity of inhibitor might be valuable 
tools in understanding the sirtuin biology. Pursuing the results from our previous 
fragment based library, we designed and synthesized two selected pseudopeptidic 
inhibitors with 4-trans-hydroxy- and L-prolil moiety. The inhibitors were conjugated 
with an appropriate fluorophore (Thiazole orange) for confocal microscopy, in order 
to detect their subcellular localization. Furthermore in this study following a rational 
selection of side chains, based on sequence of AceCS2 a known SIRT3 substrate
128
 
and our previous reported prolyl scaffold, we designed also potential SIRT3 
inhibitors linked with a molecular shuttle for mitochondrial delivery, and Thiazole 
orange for cellular imaging.  
Chart 1. L-proline derivatives 
 
9.2 Chemistry 
The Thiazole orange (to) was obtained following the procedure according to the 
literature
198
 (Scheme 1). The N
ε
-thioacetylated compound 4 was synthesized using 
ethyl dithioacetate and EtOH/10% (w/v) Na2CO3(aq) at rt for 12h according to the 
literature.
125,134
 Compounds 5 (Scheme 2) was obtained with a coupling reaction 
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between the activated acid 4  and benzylamine using the coupling agent TBTU (O-
(benzotriazol-1-yl)-N,N,N′,N′/tetramethyluronium tetrafluoroborate) in 
dimethylformamide (DMF)/pyridine under argon flow following the procedure 
reported previously.
197
 
Scheme 1
a
 Synthesis of Thiazole orange (to) 
 
a
Reagents and conditions: (a) CH3I, 45°C, 4h; (b) neat 125°C, 4h; (c) Et3N, CH2Cl2, 
rt, 24h. 
 
The hydrochloride 6, 9, 10 (Scheme 2) were gained via Boc (tert-butoxycarbonyl) 
deprotection performed at 60 °C using 15 equiv of HCl(aq) 12N, 2-propanol and 1,2-
ethanedithiol as a scavenger for trapping the tert-butyl cation generated in situ.
197
 
Compounds 7, 8 (Scheme 2) were synthesized according to the above mentioned 
coupling reaction, in this case N-Boc-L-proline and N-Boc-4-trans-hydroxy-L-
proline were activated with TBTU to react with the corresponding unblocked amine 
6. Compounds 11 and 12 were synthesized (Scheme 3) simply by a coupling reaction 
between the pseudopeptidic inhibitors 9, 10 and compound 3 (to) using the coupling 
agent COMU ((1-Cyano-2-ethoxy-2-oxoethylidenaminooxy)dimethylamino-
morpholino-carbenium hexafluoro-phosphate) in dimethylformamide (DMF) and 
N,N-diisopropylethylamine (DIPEA). To obtain compounds 13-15 (Figure 4), H-
Arg(Pbf) N-terminal protected with a 9-fluorenylmethoxycarbonyl (Fmoc) preloaded 
in 2-ClTrt resin was used and a solid phase peptide synthesis (SPPS) protocol was 
utilized. Compounds 13-15 were synthesized using the appropriate aminoacids 
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following the Fmoc strategy in which COMU, DIPEA and DMF were used for 
coupling reaction and piperidine 20% for the deprotection.  
Scheme 2
a
  Synthesis of pseudopeptidic inhibitors 
 
a
Reagents and conditions: (a) Ethyl dithioacetate, EtOH/10% (w/v) Na2CO3(aq), rt, 
12h; (b) appropriate amine or carboxylic acid, TBTU, DMF/Pyridine (1:1), argon 
flow, rt, 2-3h; (c) 2-propanol, 1,2-ethanedithiol, HCl(aq) 12N, 15 eq, 60°C, 2-3 h. 
 
Scheme 3
a
  Preparation of Probes 11, 12 
 
a
Reagents and conditions: (a) COMU, DIPEA (10eq), DMF, argon flow, rt, 2-3h. 
Cleavage from the resin with TFA 92.5: TIS 2.5: H2O 2.5 (v/v/v) gave a free 
carboxylic acid. Initially the purification of 11-15 by RP-HPLC (reverse phase) was 
carried out using 0.1 % of TFA that allowed the best separation of peaks. However 
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1
H-NMR and LC-MS analysis revealed the presence of an impurity generated during 
the purification and corresponding to the N
ε
-acetyl methyl (compound 12 Figure 1A 
1
H-NMR, Figure 2 LC-MS) analogue. Using AcOH 0.05 % this side effect that 
reduced the final purity of compounds could be reduced but not completely 
eliminated (compound 12, Figure 1B 
1
H-NMR, Figure 3 LC-MS). 
 
Figure 1. 
1
H-NMR window of compound 12 (2.5-1.0 ppm). (A) After purification 
using 0.1 % TFA; (B) after purification using 0.05 % AcOH (HPLC purity 96 %).  
 
 
A 
B 
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Figure 2. LC-MS of compound 12 after purification with 0.1 % of TFA. (A) Signal 
corresponding to Acetylated byproduct, Rt: 18 min, M
+
 761.35. (B) Signal 
corresponding to Thioacetylated product, Rt 19.71 min, M
+  
777.32. 
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Figure 3. LC-MS of compound 12 after purification with 0.05 % of AcOH. Signal 
corresponding to Thioacetylated product, Rt: 19.81 min, M
+  
777.54. 
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Compound 13. 
 
Compound 14. 
 
Compound 15. 
Figure 4. Structure of compounds 13-15. 
9.3 Results and discussion  
Compounds 11 and 12 were designed simply by the idea to detect the subcellular 
localization of the potential SIRT1-3 inhibitor. The fluorophore Thiazole orange (to) 
was chosen considering that in the past few years has gained growing attention not 
only for its high molar extinction coefficient that allows to use it at low 
concentrations but, mainly for its cell permeability that make it an ideal cellular 
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fluorophore. As lipophilic cation Thiazole orange rapidly enters in living cells in 
which can be excited at 511 nm (ʎmax Abs) and directly observed with an emission at 
525 nm (ʎmax Em).
198-203 
 N
ε
-Thioacetylated Lys peptide are known substrate 
competitive inhibitors
126
 of sirtuins, and differently to the smaller pseudopeptidic 
derivatives the potential binding mode cannot be predicted easily because of too 
rotatable bonds. In designing 11 and 12, we had to consider not only the binding 
mode of pseudopeptidic fragment but also the correct place in which Thiazole orange 
could be bound to the inhibitor and more importantly, its geometric isomerism. In 
contrast with the above cited literature
198-203
 (Figure 5 left) more specific information 
regarding the geometric isomerism of Thiazole orange (Figure 5 right) were 
proposed by Seits
204, O’ eary205, Armitage206 and co-workers.  
 
Figure 5. Two potential geometric isomers of Thiazole orange. 
From computational to NMR studies they proved that the only isomer detected of 
Thiazole orange was the (Z). As showed in Figure 6 also in our hands through a 
simple NOESY spectrum was evident that geometric isomer of Thiazole orange was 
(Z). Once confirmed the structural isomer, we started to consider in which portion of 
the pseudopeptidic inhibitor this bulky fluorophore could be bound. The analysis of 
protein surface close to the substrate binding region of SIRT1-3, together to our 
previous results
197
 suggested that in the N-terminal position of pseudopeptidic 
inhibitors bulky group might be well tolerated. Again, in Figure 7 the structures of 
SIRT1-3 reveal a small lipophilic cavity close to the N-terminal site of bound 
substrate that might accommodate the bulky Thiazole orange. Indeed 4-trans-
hydroxy-L-prolyl and L-prolyl moieties that well fit in the substrate binding region 
were chosen and linked to Thiazole orange using a flexible spacer 6-bromohexanoic 
acid. 
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Figure 6. A window of NOESY spectrum of Thiazole orange (3). Spectrum 
processed with ACD/NMR Processor Academic Edition. 
  
Figure 7. (A) SIRT1 homology model, (B) SIRT2 homology model and (C) SIRT3 
crystal structure (PDB: 3GLR).The N-terminal lipophilic cavity is evidenced in red. 
197
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After this first approach in which we aimed to develop light-up pseudopeptidic 
inhibitors to detect their cellular localization, we considered the difficulty to reach 
the desired target. As introduced previously the seven isoforms SIRT1-7 are 
differently located within the cellular compartments and it depends upon cell type, 
stress conditions and interaction with other proteins.
31
 SIRT1 being nuclear but can 
be also found in cytoplasm in  which SIRT2 is predominantly located
32
. SIRT3 is 
localized to the mitochondria
33
 and that make it a difficult target to reach. As 
reviewed by Murphy and co-workers
207
 various strategies have been used to target 
small molecules to mitochondria, particularly conjugation to lipophilic cations and 
peptides that let them  pass easily through phospholipid bilayers, enabling their 
accumulation into the mitochondrial matrix in response to the membrane potential. 
Close to these well-established features, in particular for mitochondrial penetrating 
peptides (MPP) in which peptides have to incorporate positive charges and lipophilic 
sidechains, in our case also the potential binding mode of inhibitor must be 
considered. Compounds 13-15 were designed based on sequence of AceCS2 a 
known SIRT3 substrate and N-terminal coupled with Thiazole orange. The C-
terminal residues from lys642 to 646 of AceCS2 sequence have two positive charges 
from arginine and lipophilic aminoacids that should respect not only the binding 
requirements for enzymatic inhibition activity but also the feature for the correct 
mitochondrial delivery. Compound 13 was designed considering the amino acids 
beyond positions -1 and +4 (calculating from the N-acetyl-lysine K642), compound 
14 considered the amino acids -3 and +4 and finally compound 15 was designed with 
an N-terminal pseudopeptidic fragment and C-terminal +4 residues of AceCS2 
sequence. Biological assays for the above mentioned probes 11-15 are ongoing.  
 
9.4 Conclusion 
A new approach in designing sirtuin inhibitors has been carried out. Enzymatic and 
cellular assays will be performed in order to check the inhibitor subcellular 
localization and the possibility of a specific mitochondrial delivery. The design of 
more specific and “intelligent” sirtuin inhibitors could be a new valuable tool for 
better understands the sirtuin inhibitors. 
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9.5 Experimental Section 
 
Chemistry. Chemical reagents and solvents used in this study were commercial high 
purity quality. Organic solutions were dried over anhydrous sodium sulfate. Pyridine 
and dimethylformamide (DMF) were dried over molecular sieves. The Thiazole 
orange (to) 3 was obtained following the procedure according to the literature
198
. 
Compounds 4-6 were synthesized following the same procedure previously reported 
by us. 
197
 Yields of all reactions refer to the purified products.  NMR spectra were 
acquired on a Bruker Avance 500 AV (Bruker Biospin, Swizerland) spectrometer 
operating at 500.1 MHz for 1H and 125.8 MHz for 13C. Chemical shift values are 
reported as δ (ppm) relatively to TMS (tetramethylsilane) as an internal reference  
coupling constant are given in Hz. Positive ion mass spectra were recorded with a 
quadrupole ion trap mass spectrometer (Finnigan MAT, San Jose, CA) equipped with 
an electrospray ionization source (ESI-MS). The purity of the compounds 7-10 was 
determined by Elemental analysis obtained by a Thermo Quest CE Instruments EA 
1110 CHNS-O elemental analyzer and the Analytical results are within ± 0.40% of 
the theoretical values. The purity of compound 11-15 was determined using 
Shimadzu LC-10Avp (Shimadzu, Kyoto, Japan) with a reverse phase column 
(Phenomenex  emini NX  18, 150 x 4.60mm,  5μm) detection at 215mn and 512nm 
using as solvent A H2O x 0.05% AcOH and B (CH3CN/MeOH) x 0.05% AcOH; 
Flow rate : 1.0 mL/min. 
 
 
 
(2S,4R)-N-[(2S)-6-Ethanethioylamino-1-(benzylamino)-1-oxohexan-2-yl]-4 
hydroxypyrrolidine-1-tert-butoxycarbonyl-2-carboxamide (7). To a solution of 
N-Boc-Hydroxy-L-proline (0.72 g, 3.1 mmol) in DMF (30 mL) under Argon flow 
were added TBTU (1.10 g, 3.4 mmol), pyridine (30 mL) and maintained under 
stirring for 10min at rt. After this time 6 (1.02 g, 3.1 mmol) was added and the 
solution mixed 3h at rt under Argon flow. Solvents were evaporated and the obtained 
oil was dissolved in EtoAc (300 mL), washed with HCl 0.5M, brine (twice), 
NaHCO3 5%, finally dried with Na2SO4 and evaporated under vacuo. The crude 
product obtained was purified by columns chromatography, using silica Kieselgel for 
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flash with EtOAc : Hexane : MeOH (7: 2: 1) as eluent phase to give the pure product 
as white solid (0.55 g, 1.10 mmol, 35 %).
 1
H-NMR (DMSO-d6) : rotamers A+  δ = 
9.90 (s br, 1H), 8.43 (t, J =  5.67 Hz, 0.6H), 8.25 (t, J = 5.67 Hz, 0.4H), 8.02 (d, J =  
7.88 Hz, 0.4H), 7.96 (d, J = 7.88 Hz, 0.6H), 7.30-7.23 (m, 5H), 4.99-4.96 (m, 1H), 
4.28-4.20 (m, 5H), 3.44-3.37 (m, 3H), 3.26-3.24 (m, 1H), 2.37 (s, 3H), 2.06-1.99 (m, 
1H), 1.87-1.51 (m, 5H), 1.36-1.25 (m, 11H). 
13
C-NMR (DMSO-d6 ): rotamers A+(B)  
δ  = 198.79 (198.75), 172.35 (171.98), 171.54 (171.49), 154.18 (153.53), 139.28, 
128.20, 127.03 (126.94), 126.71 (126.67), 78.87 (78.45), 68.38 (67.71), 58.69 
(58.51), 55.02 (54.69), 52.50, 45.31 (45.23), 41.95, 38.41, 32.77, 31.88 (31.30), 
28.10 (27.96), 26.90 (26.82), 22.96 (22.91).
 
ESI-MS (m/z): 507.09 [M + H]
+
. Anal. 
(C25H38N4O5S) C, H, N. Calculated:  C 59.26, H 7.56, N 11.06; Found:  C 59.17, H 
7.25, N 10.94. 
 
2S)-N-[(2S)-6-Ethanethioylamino-1-(benzylamino)-1-oxohexan-2-yl]-
pyrrolidine-1-tert-butoxycarbonyl-2-carboxamide (8). To a solution of Boc-L-
proline (0.38 g, 1.75 mmol) in DMF (8.5 mL) under Argon flow were added TBTU 
(0.61 g, 1.9 mmol), pyridine (6.5 mL) and maintained under stirring for 10min at rt. 
After this time 6 (0.58 g, 1.75 mmol) was added and the solution mixed 3h at rt 
under Argon flow. Solvents were evaporated and the obtained oil was dissolved in 
EtoAc (200 mL), washed with HCl 0.5M, brine (twice), NaHCO3 5%, finally dried 
with Na2SO4 and evaporated under vacuo. The crude product obtained was purified 
by columns chromatography, using silica Kieselgel for flash with EtOAc : Hexane : 
MeOH (7: 2.5: 0.5) as eluent phase to give the pure product as white solid (0.58 g, 
1.18 mmol, 67 %). 
1
H-NMR (DMSO-d6) : rotamers A+  δ = 9.92 (s br, 1H), 8.43 (t, 
J = 5.36 Hz, 0.6H), 8.28 (t, J = 5.36 Hz, 0.4H), 7.95-7.92 (m, 1H), 7.33-7.24 (m, 
5H), 4.31-4.23 (m, 3H), 4.15-4.13 (m, 1H), 3.46-3.37 (m, 3H), 3.28-3.23 (m, 1H), 
2.38 (s, 3H), 2.12-2.03 (m, 1H), 1.82-1.60 (m, 7H), 1.37-1.24 (m, 11H).  
13
C-NMR 
(DMSO-d6): rotamers A+ (B) δ = 198.78, 172.34 (172.05), 171.53, 153.94 (153.32), 
139.27, 128.19, 127.01, 126.96 (126.71), 78.79 (78.36), 59.51 (59.34), 52.40, 46.71 
(46.49), 45.23, 41.94, 32.77, 31.92 (31.43), 30.99 (29.71), 28.10 (27.98), 26.85, 
23.91 (23.01), 22.92. ESI-MS (m/z): 491.13 [M + H]
+
. Anal. (C25H38N4O4S) C, H, N. 
Calculated: C 61.20, H 7.81, N 11.42; Found: C 60.81, H 7.44, N 11.32. 
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(2S,4R)-N-[(2S)-6-Ethanethioylamino-1-(benzylamino)-1-oxohexan-2-yl]-4-
hydroxypyrrolidine-2-carboxamide hydrochloride (9). To a solution of 7 (0.28 g, 
0.55 mmol) in 2-propanol (8.6 mL), 1,2-ethanedithiol (0.058 mL, 0.55 mmol) was 
added and after 1 min under stirring at r.t HCl 12N (0.28 mL, 3.36 mmol) was added 
and the solution heated at 60°C; After 20min and 40min other HCl 12N (0.28 mL) 
was added; when the total mmol of  HCl in the reaction flask were 10.1 mmol, the 
solution was maintained for 60 min at 60°C under stirring. After this time, 2-
propanol was evaporated under reduced pressure and the yellow oil was washed with 
petroleum ether (4 x 10 mL) and CH2Cl2: petroleum ether (1:1) (4 x 4 mL) provides 
the product as white solid (0.22 g, 0.49 mmol, 90 %). 
1
H-NMR (DMSO-d6) : δ = 
10.08 (s br, 1H), 9.87 (s br, 1H), 8.79 (d, J = 7.57 Hz, 1H), 8.68-8.57 (m, 2H), 7.33-
7.22 (m, 5H), 5.51 (s, 1H), 4.42-4.37 (m, 2H), 4.33-4.23 (m, 3H), 3.46-3.42 (m, 2H), 
3.07 (d, J = 11.98 Hz, 1H), 2.38 (s, 3H), 2.32-2.28 (m, 1H), 1.89-1.83 (m, 1H), 1.75-
1.52 (m, 4H), 1.40-1.30 (m, 2H). ESI-MS (m/z): 407.28 [M + H]
+
. Anal. 
(C20H31ClN4O3S) C, H, N. Calculated: C 54.22, H 7.05, N 12.65; Found: C 54.11, H 
6.74, N 12.52. 
(2S)-N-[(2S)-6-Ethanethioylamino-1-(benzylamino)-1-oxohexan-2-yl]-
pyrrolidine-2-carboxamide  hydrochloride (10). Compound 10 was synthesized 
using 8 (0.53 g, 1.1 mmol) in 2-propanol (16 mL), 1,2-ethanedithiol (0.091 mL, 1.1 
mmol) and HCl 12N (0.55 mL, 6.6 mmol) added x three times, following the same 
procedure described for 9 , to furnish the product as white solid (0.35 g, 0.81 mmol, 
75 %). 
1
H-NMR (DMSO-d6) : δ = 10.09 (s br, 1H), 9.78 (s br, 1H), 8.74 (d, J = 7.88 
Hz, 1H), 8.61-8.47 (m, 2H), 7.31-7.22 (m, 5H), 4.33-4.21 (m, 4H), 3.46-3.42 (m, 
2H), 3.23-3.17 (m, 2H), 2.38 (s, 3H), 2.34-2.26 (m, 1H), 1.92-1.82 (m, 3H), 1.76-
1.52 (m, 4H), 1.42-1.27 (m, 2H). ESI-MS (m/z): 391.28 [M + H]
+
 Anal. 
(C20H31ClN4O2S) C, H, N.  Calculated: C 56.26, H 7.32, N 13.12; Found C 55.93, H 
7.00, N 13.01. 
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to-(2S,4R)-N-[(2S)-6-Ethanethioylamino-1-(benzylamino)-1-oxohexan-2-yl]-4-
hydroxypyrrolidine-2-carboxamide (11).  
To a solution of 3 (0.18 g, 0.36 mmol) in DMF (10 mL) under Argon flow were 
added COMU (0.17 g, 0.40 mmol), DIPEA (0.74 mL) and maintained under stirring 
for 2 min at rt. After this time 9 (0.16 g, 0.36 mmol) was added and the solution 
mixed 2h at rt under Argon flow. Solvents were evaporated and the obtained oil was 
dissolved in CH2Cl2 (300 mL), washed with HCl 0.5M, brine (twice), dried with 
Na2SO4, evaporated under vacuo and finally washed with Et2O (2 x 15 mL). Of the 
crude product obtained (0.25g) only 0.05 g were purified by preparative RP-HPLC 
on a C18 column using two steps with preparative column: Phenomenex Gemini NX 
5µm C18 150 x 21,2mm to furnish 0.02 g (0.025 mmol) of 11. 
Conditions used for purification:  
1. 50mg dissolved in 3.3mL of 45% B (B= (CH3CN/MeOH)x 0,1% TFA)), Flow : 
18mL/min; Gradient : B 45%, 5.00min 52%, 20.00min 100%, 25.00min 100%.  
2. 26mg (from the preliminary prep.) dissolved in 2.5mL 40%B, (B=  
(CH3CN/MeOH)x 0,05% AcOH), Flow : 16mL/min; Gradient : B 30%, 7.00min 
35%, 14.00min 45%, 32.00min 100% STOP. 
1
H-NMR (DMSO-d6): rotamers A+  δ = 9.92 (s br, 1H), 8.81-8.78 (m, 1H), 8.61 (d, 
J = 7.25 Hz, 1H), 8.45 (t, J = 5.99 Hz, 0.3H), 8.32 (d, J = 8.20 Hz, 0.3 H), 8.20 (t, J = 
5.99 Hz, 0.7H), 8.13-8.10 (m, 1H), 8.06-8.04 (m, 1H), 8.01-7.95 (m, 1.7H), 7.81-
7.75 (m, 2H), 7.62 (dt, J = 8.51, 1 Hz, 1H), 7.42 (dt, J = 8.51, 1 Hz, 1H), 7.38-7.36 
(m, 1H), 7.29-7.15 (m, 5H), 6.94 (pseudo d, 1H), 4.58-4.55 (m, 2H), 4.50-4.47 (m, 
0.3H), 4.34-4.17 (m, 4.7H), 4.03 (pseudo d, 3H), 3.64-3.61 (m, 1H), 3.46-3.33 (m, 
3H), 2.35 (pseudo d, 3H), 2.26-2.14 (m, 2H), 2.03-1.99 (m, 1H), 1.97-1.72 (m, 5H), 
1.66-1.44 (m, 5H), 1.41-1.23 (m, 4H). ESI-MS (m/z): 793.34 [M]
+
, 794.31 [M
 
+ H]
+
, 
397.40 [M + H]
2+
. RP-HPLC: Rt. 19.15 min, area percent 92.81% 215 nm. 
Quality control:  
Sample conc.400µg/mL dissolved in 30% B   B = (CH3CN/MeOH) x 0.05% AcOH 
Column: Phenomenex Gemini NX 5µm C18 150x 4.60 mm    
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Flow: 1mL/min 
Gradient: B 30%, 7.00 min 35%, 14.00 min 45%, 30.00 min 100% STOP 
Detection: 215/512 nm (reported here 215nm). 
 
Detector A - 1 (215nm)      
Pk # Retention Time Area Area % Height Height % 
1 16,808 1331928 4,991 31228 4,485 
2 17,450 584972 2,192 19254 2,765 
3 19,158 24770657 92,817 645774 92,750 
Totals  26687557 100,000 696256 100,000 
 
 
to-(2S)-N-[(2S)-6-Ethanethioylamino-1-(benzylamino)-1-oxohexan-2-yl]-
pyrrolidine-2-carboxamide (12). To a solution of 3 (0.30 g, 0.62 mmol) in DMF 
(12 mL) under Argon flow were added COMU (0.30 g, 0.7 mmol), DIPEA (1.1 mL) 
and maintained under stirring for 2 min at rt. After this time 10 (0.27 g, 0.63 mmol) 
was added and the solution mixed 2h at rt under Argon flow. Solvents were 
evaporated and the obtained oil was dissolved in CH2Cl2 (300 mL), washed with HCl 
0.5M, brine (twice), dried with Na2SO4. evaporated under vacuo. The red gum 
obtained was solubilized in CH2Cl2 and precipitated with cold ether to furnish a red 
solid (0.40 g). Of the crude product obtained 0.045 g were purified by preparative 
RP-HPLC using preparative column: Phenomenex Gemini NX 5µm C18 150 x 
21,2mm to yield 0.021 g (0.027 mmol) of pure product 12. 
Conditions used for purification:  
Solvent A H2O x 0.05% AcOH and B (CH3CN/MeOH) x 0.05% AcOH; Flow rate : 
18 mL/min Gradient 30% B, 7 min 35%, 14 min 45%, 32 min 100%, Rt: 18.50 min, 
Area percent 96.0 % 215 nm / 512 nm. 
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1
H-NMR (DMSO-d6) : rotamers A+  δ = 9.92 (s br, 1H), 8.82-8.78 (m, 1H), 8.61 (d, 
J = 7.19 Hz, 1H), 8.44 (t, J = 6.19 Hz, 0.3H), 8.22-8.18 (m, 1H), 8.14 (t, J =  8.70 
Hz, 1H), 8.06-8.04 (m, 1H), 7.99-7.95 (m, 1H), 7.89 (d, J =  8.20 Hz, 0.7H), 7.81-
7.74 (m, 2H), 7.62 (td, J = 7.53, 1.0 Hz, 1H), 7.43 (td, J = 7.53, 1.0 Hz, 1H), 7.37 (m, 
1H), 7.29-7.16 (m, 5H), 6.94 (pseudo d, 1H), 4.57 (t, J =  7.36 Hz, 2H), 4.41-4.39 
(m, 0.4H), 4.32-4.19 (m, 3.6H), 4.03 (pseudo d, 3H), 3.58-3.46 (m, 0.8 H), 3.46-3.35 
(m, 3.2H), 2.35 (pseudo d, 3H), 2.29 (m, 1.3H), 2.20-2.14 (m, 0.7H), 2.04-1.98 (m, 
1H), 1.92-1.72 (m, 5.8H), 1.68-1.46 (m, 5.2H), 1.40-1.24 (m, 4H). ESI-MS (m/z): 
777.51 [M]
+
, 778.22 [M
 
+ H]
+
, 389.65 [M + H]
2+
. RP-HPLC: Rt. 18.50 min, area 
percent 96.01% 215 nm. 
Quality control:  
Sample conc: 350µg/mL dissolved in 40% B   B = (CH3CN/MeOH) x 0.05% AcOH 
Column: Phenomenex Gemini NX 5µm C18 150x 4.60 mm    
Flow: 1mL/min 
Gradient: B 30%, 7.00 min 35%, 14.00 min 45%, 32.00 min 100% STOP 
Detection: 215/512 nm (reported here 215nm). 
 
 
Detector A - 1 (215nm)      
Pk # Retention Time Area Area % Height Height % 
1 16,617 1029197 3,989 15051 2,062 
2 18,508 24774417 96,011 714984 97,938 
Totals  25803614 100,000 730035 100,000 
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General procedure for the synthesis of 13-15.  
 
H-Arg(Pbf)-2-ClTrt resin (Loading 0.6 mmol/g) was used as solid support for the 
synthesis of compounds 13-15. The synthesis was performed in a 10 mL syringe 
equipped with a frit. H-Arg(Pbf)-2-ClTrt resin was swelled for 2h with 4 mL of 
DMF. In the coupling phase the selected N
α
-Fmoc amino acid (5 equiv) was 
preactivated (4 min) with the coupling agent COMU (5 equiv) and DIPEA (10 equiv) 
in 3.5 mL of DMF under argon flow. The obtained solution was added on the resin 
and shaked for 60 min (the coupling reaction of Arginine and ThioAc-lysine to the 
resin was repeated two times). After this time, the resin was washed 5 times with 
DMF (5 x 6 mL). In the deprotection phase, N
α
-Fmoc protection was removed with 4 
mL of 20% (V/V) piperidine in DMF for 17 min. Then the resin was washed 5 times 
with DMF (5 x 6 mL). The cycle coupling followed by Fmoc deprotection was 
repeated until the desired resin-bound peptide was completed. In the last step before 
to remove the probe from the resin, after the deprotection phase, Thiazole orange (5 
equiv) was activated with COMU and coupled using the same condition as well as 
Fmoc aminoacids (reaction time 1h 30 min). After this step, the resin was washed 5 
times with DMF (5 x 6 mL), DCM (5 x 6 mL) and MeOH (5 x 6 mL) and dried 
overnight under vacuum. The dried resin was shacked in a cleavage cocktail 9.7 mL 
of TFA: TIS: H2O V/V/V (92.5: 2.5: 2.5) for 2h the filtered off and washed with 
other 9.7 mL of cocktail. The light yellow solution obtained contained in a flask is 
evaporated of 1/4 under vacuum, then placed in ice bed in which Et2O was added 
until complete precipitation of product as orange-red solid.  
 
to-Gly-Lys-(ThioAc)-Val-Met-Arg-Arg-COOH (13) 
Crude product 0.154 g (using 0.096 mmol, 0.150 g of resin).  
Purification:  
0.035 g of crude product were dissolved in 3,5 mL 10% B (B =  (CH3CN/MeOH)x 
0,05% AcOH); Flow : 8mL/min; Gradient : B 10%, 20.00min 45%, 26.00min 60%, 
35.00min 60% STOP. Preparative column used: Supelcogel ODP-50 5µm C18 250 x 
21,2mm. 0.015 g (0.012 mmol) of pure compound 13 were obtained. ESI-MS (m/z): 
1190.51 [M]
+
, 596.04 [M + H]
2+
, 397.95 [M + 2H]
3+
. RP-HPLC Rt. 15.57 min, area 
percent 96.74% 215 nm. 
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Quality control:  
Sample conc: 600µg/mL dissolved in 20% CH3CN    
Column: Phenomenex Gemini NX 5µm C18 150x 4.60 mm    
Flow: 1mL/min 
Gradient: B 10%, 20.00 min 45%, 30.00 min 60% STOP (B= CH3CN/MeOH) x 
0.05% AcOH 
Detection: 215/512 nm (reported here 215nm). 
 
Detector A - 1 (215nm)      
Pk # Retention Time Area Area % Height Height % 
1 14,525 358566 2,493 21768 2,329 
2 15,575 13917091 96,746 900973 96,396 
3 16,583 109592 0,762 11916 1,275 
Totals  14385249 100,000 934657 100,000 
 
 
to-Arg-Ser-Gly-Lys-(ThioAc)-Val-Met-Arg-Arg-COOH (14) 
Crude product 0.136 g (using 0.096 mmol, 0.150 g of resin). 
Purification:  
0.025 g of crude product were dissolved in 3,0 mL 10% B, (B =  (CH3CN/MeOH)x 
0,05% AcOH), Flow : 8mL/min; Gradient : B 10%, 20.00 min 45%, 26.00 min 60%, 
30.00 min 60% STOP. Preparative column used: Supelcogel ODP-50 5µm C18 250 
x 21,2mm. 0.018 g (0.012 mmol) of 14 as red solid were obtained. ESI-MS (m/z): 
717.62 [M + H]
2+
, 478.99 [M + 2H]
3+
, 359.52 [M + 3H]
4+
. RP-HPLC Rt: 11.33 min, 
area percent 86.64% 215 nm. 
Quality control:  
Sample conc: 600µg/mL dissolved in 20% CH3CN 
Column: Phenomenex Gemini NX 5µm C18 150x 4.60 mm    
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Flow: 1mL/min 
Gradient: B 10%, 20.00 min 45%, 26.00 min 60% STOP (B = CH3CN/MeOH) x 
0.05% AcOH) 
Detection: 215/512 nm (reported here 215nm). 
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Detector A - 1 (215nm)      
Pk # Retention 
Time 
Area Area % Height Height % 
1 9,642 20011 0,340 1849 0,528 
2 9,967 26563 0,452 2704 0,772 
3 10,583 268182 4,559 22513 6,429 
4 11,333 5096476 86,640 281078 80,273 
5 12,592 37804 0,643 3705 1,058 
6 13,658 81887 1,392 9014 2,574 
7 14,675 351415 5,974 29289 8,365 
Totals  5882338 100,000 350152 100,000 
 
                               
 
to-Pro(OH)-Lys-(ThioAc)-Val-Met-Arg-Arg-COOH (15) 
Crude product: 0.128 g (using 0.096 mmol, 0.150 g of resin). 
Purification:  
0.041 g of crude product were dissolved in 4,0 mL 10% B, (B =  (CH3CN/MeOH)x 
0,05% AcOH), Flow : 8mL/min; Gradient : B 10%, 20.00 min 45%, 26.00 min 60%, 
40.00 min 60% STOP. Preparative column used: Supelcogel ODP-50 5µm C18 250 
x 21,2mm. 0.019 g (0.015 mmol) of 15 as red solid were obtained. ESI-MS (m/z): 
1246.42 [M]
+
, 624.05 [M + H]
2+
, 416.60 [M + 2H]
3+
. RP-HPLC Rt. 16.10 min, area 
percent 96.77% 215 nm (this is a preliminary result that has to be confirmed the final 
data is not available yet). 
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10 DESIGN AND SYNTHESIS OF PYRIDINIUM SALTS AS INHIBITORS 
OF HUMAN SIRTUINS  
 
Abstract: Starting from the chemical structure of nicotinamide and NAD
+
 a small 
array of pyridinium salts was synthesized and screened against SIRT1. Compound 6 
that that showed the best SIRT1 inhibition was assayed also against SIRT2. 
Compound 6 slightly increased acetyl p53 and acetyl-a-tubulin levels, without 
affect cell viability of U937 cells. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Adapted with the permission from Mellini, P.; Carafa, V.; Altucci, L.; Mai A.  
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10.1 Introduction 
From yeast to human sirtuins the NAD
+
 binding site has been found highly 
conserved. NAD
+
 binds in a cleft adjacent to the acetyl lysine side chain that is 
formed by three pockets: A, B, C.  The adenine-ribose binding site (pocket A) is an 
exposed surface area in which adenine has  H bonds with backbone amides Leu215, 
Val232 and side chains Asp231 and Thr26 (Sirt2Tm numbering PDB code: 2H4F). 
The ribose moiety has H bond with Gly216
26
, the phosphate groups binds between A 
and B pockets and show several H bonds with Ala22, Phe33, Arg34, Ser189, Ser190 
and with a conserved water molecule.
26
 Conserved residues His116 and Phe33 
located in the B pocket makes H bonds and van der Waals interactions with the 
nicotinamide ribose ring. Finally the nicotinamide moiety is positioned in 
hydrophobic cavity the so called C pocked and forms H bonds interactions with 
Ile100, Asp101 and a conserved water molecule.
26
 The design of NAD
+
 mimetic 
compounds represents one of the first approaches used to develop sirtuin inhibitors 
(Chart 1).
121-124
 Unfortunately due to their poor cellular permeability, stability and 
negligible drug-like properties NAD
+
 mimetics are considered only useful molecular 
probes. In 2006 Suzuki et al.
110
 reported the screening of a homemade library of 
compounds comprised also by pyridinium salts of nicotinamide (1, 2 Chart 1) that at 
300 µM showed only a weak or null inhibition against SIRT1.  In this work, we aim 
to start the first step in order to move from NAD
+
 structure to drug-like molecules 
inhibitors of human sirtuins. Considering both the structural features of nicotinamide 
and NAD+ (Chart 1), we designed a small array of simple pyridinium salts (3-6) as 
potential nicotinamide/ NAD
+
 mimetic compounds (Scheme 1).  
Chart 1. Structure of NAD
+
, nicotinamide and their derivatives. 
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The compounds were screened at 50 µM in vitro against SIRT1. One compound was 
selected for be tested also on SIRT2 and for cellular studies. 
 
10.2 Chemistry 
The synthetic pathway followed for the preparation of 3-6 is depicted in Scheme 1. 
Compounds 3-6 were synthesized simply by reacting of substituted pyridine with the 
appropriate alkylating agent in CH3CN or DMA at reflux for 4-24h.  
 
Scheme 1
a 
 
 
a
Reagents and conditions: 3-5 CH3CN reflux 4-24h; 6 N,N-Dimethylacetamide 
(DMA) reflux 14h. 
 
10.3 Results and discussion 
Compounds 3-6 were designed considering how described above, or else the fact that 
NAD
+
 binding site offers the possibility of several H-bonds interactions. The 
pyridine ring has been functionalized with an acetophenon moiety and hydroxyl 
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groups that allow not only an appreciable flexibility (Figure 1) of the scaffold but 
also the possibility of H-bond interactions. 
 
 
Figure 1. Two rotamers of the minimized structure (left) of compound 6 generated 
by rotation around the  α carbon of acetophenon moiety. Maestro 9.2 Schrödinger, 
LLC, New York, NY, 2011. 
 
Compounds 3-6 screened at 50 µM against SIRT1 show an appreciable inhibition 
activity that range from 20-42 % of inhibition (Figure 2). Little differences can be 
seen and let us speculate that the best inhibition showed by compound 6 is due to the 
additional carbamoyl function, but this has to be confirmed with an exhaustive SAR 
investigation. Compound 6 that can be considered our new starting point for develop 
more potent compounds, has been also tested against SIRT2 (Figure 2) for which 
shows the same trend of inhibition seen for SIRT1.  
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Figure 2. Inhibitory activity of compounds 3-6 at 50 µM against SIRT1 (blue) and 
SIRT2 (red). The data represent the mean of two experiment (standard deviation is 
not reported). 
 
SIRT1/2 inhibition by compound 6 was confirmed by Western blot analyses (Figure 
3). The acetylation levels of α-tubulin and p53 (MCF-7 cells) were determined after 
the treatment with 50 µM of 6. EX-527, etoposide (10 µM) and SAHA (5 µM) were 
used as reference compounds. 
 
 
Figure 3. Western blot analyses of compound 6 (50 µM). A) α-tubulin acetylation; 
B) p53 acetylation in MCF-7 cells. EX-527, etoposide (10 µM) and SAHA (5 µM) 
were used as reference compounds. 
 
Compound 6 showed a little but significant increase of α-tubulin and p53 acetylation 
these evidences let us speculate that at the condition used compound 6 is cell 
permeable. The effect of 6 on cell cycle progression was evaluated and at 50 µM for 
30 h in the human U937 leukemia cell line. As shown in Figure 4 differently to 
SAHA and MS275 compound 6 does not cause any detectable effect under the tested 
conditions. 
 
A 
B 
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Figure 4. Cell cycle effect in a given phase of cell cycle and apoptosis induction of 
compound 6 in U937 cells (50 µM, 30h). SAHA and MS275 (5 µM) were used as 
reference compounds. 
 
10.4 Conclusions 
A small array of pyridinium salts has been synthesized and screened against SIRT1. 
One of them, compound 6 was found the first pyridinium salt reported to date with 
SIRT1/2 inhibition properties. Compound 6 might be a new starting point for a SAR 
investigation in order to find more potent derivatives. 
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10.5 Experimental Section 
Chemistry. Chemical reagents including carprofen and solvent used in this study 
were purchased from Sigma-Aldrich Chemical Co. (Milano, Italy) and were of 
analytical grade. Melting points were determined on a Tottoli apparatus (Buchi) and 
are uncorrected. Infrared spectra were recorded on neat compounds on a Perkin-
Elmer Spectrum-One spectrophotometer equipped with an ATR detector; band 
frequencies are reported in wave number (cm
-1
). 
1
H NMR spectra were acquired on a 
Broker Avance 400 spectrometer operating at 400 MHz Chemical shift values, unless 
otherwise stated, are reported as δ (ppm) relatively to TMS (tetramethylsilane) as 
internal reference; coupling constant are given in Hz. Yields of all reactions refer to 
the purified products. Mass spectra were recorded on: API-TOF Mariner by 
Perspective Biosystem (Stratford, Texas, USA), samples were injected by an Harvard 
pump using a flow rate of 5-10 µl/min, infused in the Electrospray system. Elemental 
analyses were obtained by a PE 2400 (Perkin- Elmer) analyser and have been used to 
determine purity of the described compounds, that is >95%. Analytical results are 
within ± 0.40% of the theoretical values. 
 
3-carbamoyl-1-(2-(2,4-dihydroxyphenyl)-2-oxoethyl)pyridin-1-ium bromide (3). 
To a warm solution of 2-bromo-1-(2,4-dihydroxyphenyl)ethanone (0.286 g, 1.2 
mmol) in CH3CN (4 mL) a solution of nicotinamide (0.151 g, 1.2 mmol) in CH3CN 
(4 mL) in  was added and refluxed for 4h. After this time the obtained precipitate was 
filtered off and washed with CH3CN (3 x 10 mL), Et2O (3 x 10 mL) and dried under 
reduced pressure to furnish 3 (0.28 g, 0.78 mmol, 65.47 %). 
1
H-NMR (DMSO-d6): δ 
= 11.23 (s br, 1H), 10.65 (s br, 1H), 9.45 (s, 1H), 9.10 (d, J = 6.11 Hz, 1H), 9.03 (d, J 
= 6.11 Hz, 1H), 8.57 (s, 1H), 8.35-8.32 (m, 1H), 8.17 (s, 1H), 7.73 (d, J = 8.80 Hz, 
1H), 6.46-6.43 (m, 2H), 6.23 (s, 2H). ESI-MS (m/z): 273.10 [M]
+
. Anal. 
(C14H13BrN2O4) Calculated: C 47.61, H 3.71, N 7.93; Found: C 47.41, H 3.53, N 
7.77. 
 
3-carbamoyl-1-(2-(3,4-dihydroxyphenyl)-2-oxoethyl)pyridin-1-ium chloride (4).  
To a warm solution of 2-chloro-1-(3,4-dihydroxyphenyl)ethanone (1.23 g, 6.6 mmol) 
in CH3CN (20 mL) a solution of nicotinamide (0.40 g, 3.3 mmol) in CH3CN (7 mL) 
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in was added and refluxed for 24h. After this time the obtained precipitate was 
filtered off and washed with EtOAc (3 x 10 mL), Et2O (3 x 10 mL) and dried under 
reduced pressure to furnish 4 (0.62 g, 2.0 mmol, 60.85 %). 
1
H-NMR (DMSO-d6): δ = 
9.52 (s, 1H), 9.13-9.11 (m, 2H), 8.74 (s br, 1H), 8.37-8.34 (m, 1H), 8.17 (s br, 1H), 
7.48-7.44 (m, 2H), 6.99 (d, J = 8.31 Hz, 1H), 6.42 (s, 2H). ESI-MS (m/z): 273.14 
[M]
+
. Anal. (C14H13ClN2O4) Calculated: C 54.47, H 4.24, N 9.07; Found: C 54.80, H 
4.35, N 9.15. 
 
4-carbamoyl-1-(2-(3,4-dihydroxyphenyl)-2-oxoethyl)pyridin-1-ium chloride (5). 
To a warm solution of 2-chloro-1-(3,4-dihydroxyphenyl)ethanone (1.21 g, 6.5 mmol) 
in CH3CN (10 mL) a solution of nicotinamide (0.40 g, 3.3 mmol) CH3CN (15 mL) in 
was added and refluxed for 12h. After this time the obtained precipitate was filtered 
off and washed with CH3CN (3 x 10 mL), EtOAc (3 x 10 mL) and dried under 
reduced pressure to furnish 5 (0.48 g, 1.55 mmol, 47.11 %). 
1
H-NMR (DMSO-d6): δ 
= 10.01 (s br, 2H), 9.14 (d, J = 6.36 Hz, 2H), 8.82 (s br, 1H), 8.54 (d, J = 6.36 Hz, 
2H), 8.29 (s br, 1H), 7.49-7.45 (m, 2H), 6.99 (d, J = 8.31 Hz, 1H), 6.42 (s, 2H). ESI-
MS (m/z): 273.11 [M]
+
. Anal. (C14H13ClN2O4) Calculated: C 54.47, H 4.24, N 9.07; 
Found: C 54.52, H 4.50, N 9.21. 
 
3,4-dicarbamoyl-1-(2-(3,4-dihydroxyphenyl)-2-oxoethyl)pyridin-1-ium chloride 
(6). To a warm solution of 2-chloro-1-(3,4-dihydroxyphenyl)ethanone (1.13 g, 6.0 
mmol) in DMA (3 mL) a solution of pyridine-3,4-dicarboxamide (0.50 g, 3.0 mmol)  
was added and refluxed for 14h. After this time EtOAc was added until the 
precipitation of compound was completed, then the precipitate was filtered off and 
washed with EtOAc (3 x 15 mL) and MeOH (3 x 15 mL). The solid obtained was 
dissolved under reflux in a mixture MeOH/CH3CN 1:1 (V/V) and after cooling was 
slowly precipitated with cold Et2O dried under reduced pressure to furnish 6 (0.25 g, 
0.71 mmol, 23.6 %). 
1
H-NMR (DMSO-d6): δ = 10.05 (s br, 2H), 9.28 (s, 1H), 9.10 
(d, J = 6.36 Hz, 1H), 8.50 (s, 1H), 8.31-8.27 (m, 2H), 8.16 (s, 1H), 8.04 (s, 1H), 7.48-
7.43 (m, 2H), 6.98 (d, J = 8.07 Hz, 1H), 6.36 (s, 2H). ESI-MS (m/z): 316.13 [M]
+
. 
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Anal. (C15H14ClN3O5) Calculated: C 51.22, H 4.01, N 11.95; Found: C 51.60, H 
4.13, N 11.72. 
 
SIRT1/2 Inhibition Assay. The SIRT activity assay was performed using human 
recombinant SIRT1 and SIRT2 produced in E. coli. Compounds were tested using a 
modified Fluor de Lys fluorescence-based assay kit (AK-555, AK-556 BIOMOL). 
The assay procedure has two steps: in the first part the SIRT1/2 substrate, an 
acetylated Lys side chain comprising amino acids 379-382 (Arg-His-Lys-Lys (Ac)) 
(for SIRT1 assay) or 317-320 (Gln-Pro-Lys-Lys(Ac)) (for SIRT2 assay) of human 
p53 conjugated with aminomethylcoumarin is deacetylated during incubation at 37 
°C for 1 h by SIRT1 or SIRT2 in the presence of NAD
+
 and the tested compounds. 
The second stage is initiated by the addition of the Developer II, including 
nicotinamide (NAM), a sirtuin inhibitor that stops the SIRT1/2 activity, and the 
fluorescent signal is produced. The fluorescence was measured on a fluorometric 
reader (Inphinite 200 TECAN) with excitation set at 360 nm and emission detection 
set at 460 nm. Experiments on the SIRT1 and 2 inhibitions have been performed in 
triplicate. IC50 data were analyzed using GraphPad Prism Software. 
 
Cell lines. Human leukemia cell lines (U937) was grown in RPMI 1640 medium 
(EuroClone) supplemented with 10% heat-inactivated FBS (Sigma Aldrich), 1% 
glutamine (EuroClone), 1% penicillin/streptomycin (EuroClone) and 0.1% 
gentamycin (EuroClone), and kept at 37°C in air and 5% CO2. Conversely, adherent 
MCF7 (human breast cancer) cells were grown in D-MEM medium (EuroClone) 
supplemented with the same components described above and in the same incubation 
settings. 
 
Western Blot analyses of p53 and α–tubulin acetylation. To detect acetylation of 
p53 (K373/382) and -tubulin, 50 and 20  of total protein extracts (MCF7 cells), 
respectively, were separated on a 10% polyacrylamide gels and blotted for 2 h at 
70V. Western blots were shown for acetylated p53 (K373/382) (Upstate, dilution 
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1:500) and -tubulin (Sigma, dilution 1:1000). Total ERKs (Santa Cruz, 
dilution1:1000) represent equal loading. 
 
Cell Cycle and Cell death Analysis on U937 cells. Cells were collected and 
resuspended in L of hypotonic buffer (0.1% Triton X-100, 0.1% sodium citrate, 
50 g/mL propidium iodide (PI)). Then the cells were incubated in the dark for 30 
min. Samples were acquired on a FACS-Calibur flow cytometer using the Cell Quest 
software (Becton Dickinson). Analyses were performed with standard procedures 
using ModFit LT version3 software (Verity). All experiment were performed in 
triplicate. 
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